



76TH ANNUAL MEETING
**PORTLAND
OREGON**
APRIL 26-29, 2017
OREGON CONVENTION CENTER

SOCIETY FOR
INVESTIGATIVE
DERMATOLOGY

**MEETING
PROGRAM**

FUTURE ANNUAL MEETINGS

IID 2018

May 16-19, 2018

Rosen Shingle Creek
Orlando, Florida



Permission was granted by Rosen Shingle Creek to use this photo

77th Annual Meeting

May 8-11, 2019

Hilton Chicago
Chicago, Illinois



78th Annual Meeting

May 13-16, 2020

Westin Kierland Resort
& Spa
Scottsdale, Arizona



**CONNECT WITH
THE SID!**



#SID17PORTLAND
www.sidnet.org



On behalf of the Society for Investigative Dermatology (SID), welcome to the 2017 Annual Meeting in Portland. Portland is a city that's known for being a little bit "different". In fact, one of the unofficial mottos, displayed on a large mural near the famous 24-hour Voodoo Doughnut, is "Keep Portland Weird". Known for being environmentally conscious, we're confident you'll be delighted by what sets this "Green" city apart.

Portland is home to the nation's favorite airport, an efficient light rail system and pedestrian-friendly city blocks – uncommon qualities that are easy to get used to. You'll find retailers large and small, international and indie within easy reach of downtown hotels. With no sales tax, it is a haven for shoppers. There is also a staggering selection of food and drink options in Portland from hundreds of inexpensive food carts all over town to nationally acclaimed chef-driven restaurants. Thirsty? Portland has more craft breweries than any other city on earth as well as more than a dozen urban wineries and a myriad of coffee roasters.

To counteract all those delicious meals, Portlanders love to burn calories in the great outdoors. Hit the pavement on more than 100 miles of trails and paths, see Portland by bicycle or take a hike in one of the country's largest urban forests. Within two hours of downtown you can visit the Oregon Coast beaches, Mount Hood ski resorts or Columbia River Gorge waterfalls. We hope you will find time to sample all that Oregon has to offer and we are confident you will enjoy your stay.

As always, we are grateful to the Committee on Scientific Programs which has once again planned an exciting and enlightening program for us.

Since its founding in 1937, the SID has been committed to facilitating the careers of young investigators by providing a dynamic forum in which a diverse group of scientists can interact. We remain fully committed to this goal and to offer programming that reaches all members of the dermatology and cutaneous biology research communities.

We have scheduled a variety of activities to highlight scientific advances made by our community, and social events that will celebrate our international scientific community and the culture and beauty of Portland.

Welcome to what promises to be another truly outstanding SID Annual Meeting!





PRESIDENT
Angela Christiano, PhD




SECRETARY-TREASURER
Alice P. Pentland, MD




SECRETARY-TREASURER
Richard L. Gallo, MD/PhD

SID Governance

GOVERNANCE

Officers and Directors

President

Angela Christiano, PhD

Vice President

Martin Weinstock, MD/PhD

President-Elect

Russell Hall, MD

Vice President-Elect

Lisa Beck, MD

Secretary-Treasurer

Alice P. Pentland, MD

Secretary-Treasurer

Richard L. Gallo, MD/PhD

Immediate Past President

Mark C. Udey, MD/PhD

JID Editor

Barbara A. Gilchrest, MD

Directors

Cheng-Ming Chuong, MD/PhD
 Mitchell Denning, PhD
 James T. Elder, MD/PhD
 Valentina Greco, PhD
 Ryan Hobbs, PhD*
 Sam Hwang, MD/PhD
 Maranke I. Koster, PhD
 David J. Margolis, MD/PhD
 Anthony E. Oro, MD/PhD
 John Seykora, MD/PhD
 Cory Simpson, MD/PhD*
 J.P. Therrien, PhD

*Resident/Post-Doctoral Members

SID Administrative Staff

Jim Rumsey
 Chief Operating Officer

Rebecca Minnillo, DM/MPA
 Chief Program and
 Development Officer

Robyn Cipolletti
 Director, Association Services

Stephanie Flanagan
 Manager, Member Services

Deborah Kovacs
 Director, Program Services

Wendy Talerman
 Manager, Communications and
 Development

JID Administrative Staff

Elizabeth Nelson Blalock
 Managing Editor, JID

Sarah Forgeng
 Editorial Process Manager

JOURNAL OF INVESTIGATIVE DERMATOLOGY

Editor

Barbara A Gilchrest, MD

Editor-Elect

Mark C. Udey, MD/PhD

Advisory Board

Paul R. Bergstresser, MD
 Lowell A. Goldsmith, MD
 Erwin Tschachler, MD

Deputy Editor

Angela Christiano, PhD

Statistical Editor

Beverley Adams-Huet

JID Connector Editor

Kavitha K. Reddy, MD

JID Jottings Editor

Lowell Goldsmith, MD

Cells to Surgery Quiz Editor

Keyvan Nouri, MD

Meet the Investigator Editor

Ayman Grada, MD

Meeting Reports Editor

Gerald S. Lazarus, MD

Milestones Editor

Hensin Tsao, MD/PhD

Podcast Editors

Abigail Baird Waldman, MD
 Robert Dellavalle, MD
 Olivier Gaide, MD/PhD

Research Techniques

Made Simple

Jodi Lynn Johnson, PhD,
 Editor

SnapshotDx Quiz Editor

Mariya Miteva, MD

Section Editors

Masayuki Amagai, MD/PhD
 Tilo Biedermann, MD
 Vladimir Botchkarev, MD/PhD
 Paul E. Bowden, MD/PhD
 Tatiana Efimova, MD
 James T. Elder, MD/PhD
 Meenhard Herlyn, DVM
 Sam Hwang, MD/PhD
 Alan D. Irvine, MD
 Ethan A. Lerner, MD/PhD
 John McGrath, MD
 Tamar Nijsten, PhD
 Thomas Schwarz, MD
 Vijayasaradhi Setaluri, PhD
 John R. Stanley, MD
 Robert S. Stern, MD
 Robert Swerlick, MD
 Jouni Uitto, MD/PhD
 Thomas Werfel, MD/PhD
 Stuart Yuspa, MD

Editors Emeriti

Marion B. Sulzberger, 1938-1949
 Naomi M. Kanof, 1949-1967
 Richard Stoughton, 1967-1972
 Irwin M. Freedberg, 1972-1977
 Ruth K. Freinkel, 1977-1982
 Howard P. Baden, 1982-1987
 David A. Norris, 1987-1992
 Edward J. O'Keefe, 1992-1997
 Conrad Hauser, 1997-2002
 Lowell Goldsmith, 2002-2007
 Paul R. Bergstresser, 2007-2012

Medical Writer

Heather Yarnall Schultz, PhD

Associate Editors

Maryam Asgari, MD/PhD
 Martine Bagot, MD/PhD
 Boris Bastian, MD/PhD
 Jurgen Becker, PhD
 Carola Berking, MD
 Mark Berneburg, MD
 Wendy B. Bollag, PhD
 Luca Borradori, MD
 Jan Nico Bouwes Bavinck, MD
 Joke Bouwstra, PhD
 Leena Bruckner-Tuderman, MD
 Julide Celebi, MD
 Cheng-Ming Chuong, MD/PhD
 Thomas N. Darling, MD
 Jeffrey M. Davidson, MD
 Mitchell F. Denning, PhD
 Richard L. Eckert, PhD
 Alexander H. Enk, MD
 Kenneth Feingold, MD
 David E. Fisher, MD/PhD
 Gary J. Fisher, MD
 Carsten Flohr, MD
 Mayumi Fujita, MD/PhD
 Richard L. Gallo, MD/PhD
 Luis A. Garza, MD
 Spiro Getsios, PhD
 Michel F. Gilliet, MD
 Michael Girardi, MD

Matthias Goebeler, MD
 Kathleen J. Green, PhD
 Emma Guttman, MD/PhD
 Michael Hertl, MD
 Alain Hovnanian, MD/PhD
 Rivkah Isseroff, MD
 Andrew Johnston, PhD
 Kenji Kabashima, MD/PhD
 Veli-Matti Kahari, MD/PhD
 Sarolta K. Karpati, MD
 Tatsuyoshi Kawamura, MD/PhD
 Reinhard Kirnbauer, MD
 Heidi Kong, MD
 Andrew P. Kowalczyk, PhD
 Thomas Krieg, MD
 Jo Lambert, MD/PhD
 Michelle A. Lowes, MD/PhD
 David Margolis, MD/PhD
 Alexander G. Marneros, MD/PhD
 Alain Mauviel, PhD
 Caterina Missero, PhD
 Akimichi Morita, MD/PhD
 Paul Nghiem, MD/PhD
 Manabu Ohyama, MD
 Amy S. Paller, MD
 Andrey A. Panteleyev, PhD
 Vincent Piguette, MD
 Carlo Pincelli, MD
 Graca Raposo, PhD
 Dennis Roop, PhD
 Sarbjit S. Saini, MD
 Fernanda Sakamoto, MD/PhD
 Helmut Schaidt, MD
 Christoph Schlapbach, MD/PhD
 Martin Schmelz, MD/PhD
 Julia A. Segre, PhD
 John Seykora, MD/PhD
 Jan C. Simon, MD
 Eli Sprecher, PhD
 Richard Spritz, MD
 Phyllis I. Spuls, MD/PhD
 Georg Stingl, MD
 Makoto Sugaya, MD
 John P. Sundberg, PhD
 Marjana Tomic-Canic, PhD
 Sergey M. Troyanovsky, PhD
 Mark C. Udey, MD/PhD
 Maurice van Steensel, MD/PhD
 Baoxi Wang, MD
 Xiao-Jing Wang, MD/PhD
 Nicole L. Ward, PhD
 Stephan Weidinger, MD
 Wendy Weinberg, PhD
 Philip Wertz, PhD
 Traci Wilgus, PhD
 Giovanna Zamboni, MD
 Xuejun Zhang, MD/PhD
 Bin Zheng, PhD
 Detlef Zillikens, MD

SID Governance

STANDING COMMITTEES

Auditing Committee

Martin Weinstock, MD/PhD,
Chair
Lisa Beck, MD
Mitchell Denning, PhD
Anthony Gaspari, MD
Jim Rumsey, Staff Liaison

Committee on Education

Douglas Grossman, MD/PhD,
Co-Chair
Maria I. Morasso, PhD, Co-Chair
Heidi Kong, MD
My Mahoney, PhD
Alexander Marneros, MD
Kavitha Reddy, MD
Todd Ridky, MD
John Seykora, MD/PhD
Cory Simpson, MD/PhD
Lisa Beck, MD, (ex-officio)
Ryan Hobbs, PhD, (ex-officio)
Martin Weinstock, MD/PhD,
(ex-officio)
Becky Minnillo, DM/MPA,
Staff Liaison

Committee on Finance

David Margolis, MD/PhD, Chair
Maranke I. Koster, PhD
Aimee S. Payne, MD/PhD
Thomas Ruenger, MD/PhD
Robert Swerlick, MD
Richard L. Gallo, MD/PhD,
(ex-officio)
Barbara A. Gilchrest, MD,
(ex-officio)
Alice P. Pentland, MD,
(ex-officio)
Jim Rumsey, Staff Liaison

Committee on Membership

George Sen, PhD, Chair
Raymond Cho, MD/PhD
Lisa DeLouise, MD/PhD
Richard L. Gallo, MD/PhD,
(ex-officio)
Becky Minnillo, DM/MPA,
Staff Liaison

Committee on Nominations

Thomas S. Kupper, MD, Chair
Paul Bergstresser, MD
S. Wright Caughman, MD
Becky Minnillo, DM/MPA,
Staff Liaison

Committee on Diversity & Inclusion

Angela Christiano, PhD, Chair
Niroshana Anandasabapathy,
MD/PhD
Oscar Colegio, MD/PhD
Lynn Cornelius, MD
Richard L. Gallo, MD/PhD
Barbara Gilchrest, MD
Donald Glass, MD/PhD
Valentina Greco, PhD
Valerie Horsley, PhD
Akemi Ishida-Yamamoto,
MD/PhD (JSID representative)
Kurt Lu, MD
Sarah Millar, PhD
Paul Nghiem, MD/PhD
Carien Niessen, PhD
(ESDR representative)
Cory Simpson, MD/PhD
Nicole Ward, PhD

Committee on Scientific Programs

Ponciano Cruz, MD, Co-Chair
Paul T. Nghiem, MD/PhD,
Co-Chair
Spiro Getsios, PhD
Daniel Kaplan, MD/PhD
Ethan Lerner, MD/PhD
Lloyd Miller, MD/PhD
Peggy Myung, MD/PhD
Kevin Wang, MD/PhD
Nicole Ward, PhD
Victoria P. Werth, MD
Angela Christiano, PhD,
President (ex-officio)
Alice P. Pentland, MD,
Secretary-Treasurer (ex-officio)
Richard L. Gallo, MD/PhD,
Secretary-Treasurer (ex-officio)
Jim Rumsey, Staff Liaison
Robyn Cipolletti, Staff Liaison

Ad Hoc Reviewers for Committee on Scientific Programs

Niroshana Anandasapathy,
MD/PhD
Marta Bertolini, PhD
Suephy Chen, MD
Raymond Cho, MD/PhD
Keith Choate, MD/PhD
Benjamin Chong, MD
Mary-Margaret Chren, MD
Shawn Demehri, MD/PhD
Anna DiNardo, MD/PhD
Ryan Driskell, PhD
Luis Garza, MD/PhD
Joel Gelfand, MD
Emma Guttman-Yassky,
MD/PhD
Alain Hovnanian, MD/PhD
Mayumi Ito, PhD
Sewong Kang, MD

Akinori Kawakami, MD/PhD
Masaaki Kawasumi, MD/PhD
Heidi Kong, MD
Alexa Mattheyses, PhD
Amanda McLeod, MD
Maksim Plikus, PhD
Brian Pollack, MD/PD
Christian Posch, MD
Thomas Ruenger, MD/PhD
Eric Simpson, MD
Jean Tang, MD/PhD
Marjana Tomic-Canic, PhD
George Wondrak, PhD

Executive Committee

Angela Christiano, PhD
JT Elder, MD/PhD
Russell Hall, MD
Richard L. Gallo, MD/PhD
Barbara A. Gilchrest, MD
Alice Pentland, MD
Mark C. Udey, MD/PhD
Jim Rumsey, (ex-officio)
Becky Minnillo, DM/MPA,
(ex-officio)

Honorary Members

H. Baden
E. Bauer
P. Bergstresser
E. Beutner
D. Bickers
O. Braun-Falco
I. Braverman
A. Breatnach
R. A. Briggaman
W. Bullough
H. D. Chen
L. H. Chiung
E. Christophers
R. Degos
L. Diaz
R. Dobson
R. Eady
R. Edelson
A. Eisen
P. Elias
A. ElMofty
E. Epstein
J. Fernandez
I. Freedberg
R. Freinkel
B. Gilchrest
I. Gigli
L. Goldsmith
R. Goltz
M. Greaves
H. Green
J. Grupenhoff
G. Hambrick, Jr.
J. Hanifan
F. Hu
Y. Ishibashi
S. Jablonska
R. Jordon

S. Katz
A. Kligman
K. Kraemer
G. Krueger
A. Kukita
C. Lapière
G. Lazarus
I. Leigh
A. Lerner
J. Leyden
W. Lobitz, Jr.
D. Lowy
I. Magnus
Y. Mishima
T. Nishikawa
D. Norris
S. Ofuji
H. Ogawa
J. Parrish
S. Pinnell
M. Prunieras
W. Quevedo, Jr.
H. Rorsman
W. Shelley
B. Shroot
S. Shuster
F. Snyder
D. Stevanovic
G. Stingl
J. Strauss
H. Tagami
N. Thyresson
J. Uitto
E. Van Scott
J. Voorhees
P. Weary
G. Weinstein
C. Wheeler, Jr.
K. Wolff
K. L. Yang



SID Governance

SID AWARDS

Stephen Rothman Memorial Award Recipients

Presented for distinguished service to investigative cutaneous medicine.

1967	Marion Sulzberger
1968	Donald Pillsbury
1969	Harvey Blank
1970	Thomas Fitzpatrick
1971	Aaron Lerner
1972	William Montagna
1973	Rudolf Baer
1974	Hermann Pinkus
1975	Eugene Van Scott
1976	Albert Kligman
1977	Irvin Blank
1978	George Odland
1979	Clayton Wheeler, Jr.
1980	Clarence Livingood
1981	Isadore Bernstein
1982	J. Lamar Callaway
1983	Richard Stoughton
1984	A. Gedeon Matoltsy
1985	Herman Beerman
1986	Otto Braun-Falco
1987	Walter Shelley
1988	John Strauss
1989	Walter Lobitz, Jr.
1990	Walter Lever
1991	Robert Goltz
1992	Irwin Freedberg
1993	Arthur Eisen
1994	Ruth Freinkel
1995	Howard Baden
1996	Irma Gigli
1997	Stephen Katz
1998	Klaus Wolff
1999	Lowell Goldsmith
2000	Richard Dobson
2001	Robert Briggaman
2002	Eugene Bauer
2003	Georg Stingl
2004	Stuart Yuspa
2005	John Voorhees
2006	Thomas Lawley
2007	Barbara Gilchrest
2009	Luis Diaz
2010	Dennis Roop
2011	John Stanley
2012	Paul Bergstresser
2014	Jouni Uitto
2015	Ervin H. Epstein
2016	R. Rox Anderson

Naomi M. Kanof Clinical Investigator Award

This award is given to enlighten present and future workers about the importance of clinical investigation. It honors an individual who has made significant contributions to our understanding of clinical medicine.

1993	Alvan Feinstein
------	-----------------

1994	R. Michael Blaese
1995	Judah Folkman
1996	Jean Wilson
1997	C. Garrison Fathman
1998	Jeffrey Bluestone
1999	Brian Strom
2000	William Kelley
2001	James Ostell
2002	Leena Peltonen
2003	Judith Campisi
2004	Brian Druker
2005	Joseph Nadeau
2006	John Schiller
2007	Thomas Pearson
2009	Mahlon DeLong
2010	Douglas Lowy
2011	David Lane
2012	Luis Parada
2014	Mark Chance
2015	Madeleine Duvic
2016	Roger Perlmutter

Julius Stone Lectureship

This lecture is intended to promote the advancement of knowledge in immunology as it relates to the skin and skin disease.

1999	Eli Gilboa
1999	Stephen Johnston
1999	Jeffrey Trent
2000	Nigel Bunnett
2000	Ronald Crystal
2000	Ralph Steinman
2001	Roland Martin
2002	Gerald Crabtree
2004	Adrian Hayday
2005	Polly Matzinger
2006	Alexander Rudensky
2007	Donald Y. M. Leung
2009	Jamey Marth
2010	Rafi Ahmed
2011	Casey Weaver
2012	Rebecca Buckley
2014	Alice P. Pentland
2015	Arlene H. Sharpe
2016	John O'Shea

William Montagna Lectureship

This annual award is intended to honor and reward young active investigators. Primary emphasis is given to researchers in skin biology.

1975	Kenneth Halprin
1976	Frank Parker
1977	Arthur Eisen
1978	Irma Gigli
1979	Marvin Karasek
1980	Irwin Freedberg
1981	Stephen Katz
1982	John Parrish
1983	Douglas Lowy
1984	Gerald Lazarus
1985	Eugene Bauer
1986	Georg Stingl

1987	Jouni Uitto
1988	Stuart Yuspa
1989	Tung-Tien Sun
1990	Karen Holbrook
1991	Luis Diaz
1992	Dennis Roop
1993	Ervin Epstein, Jr.
1994	John Stanley
1995	Elaine Fuchs
1996	Thomas Kupper
1997	Barbara Gilchrest
1998	Robert Modlin
1999	Fiona Watt
2000	Thomas Luger
2001	Peter Elias
2002	Kathleen Green
2003	Masayuki Amagai
2004	Akira Takashima
2005	Paul Khavari
2006	Richard Gallo
2007	George Cotsarelis
2008	Pierre Coulombe
2009	Angela Christiano
2010	W. H. Irwin McLean
2011	John McGrath
2012	Howard Chang
2013	Andrzej Dlugosz
2014	Xiao-Jing Wang
2015	Hensin Tsao
2016	Anthony Oro

Herman Beerman Lectureship

This lecture is given by a distinguished medical scholar, traditionally from fields other than dermatology.

1961	Rene Dubos
1962	Hans Selye
1963	Rupert Billingham
1964	Curt Stern
1965	Albert Szent-Gyorgyi
1966	Jerome Gross
1967	G.J.V. Nossal
1968	John Buettner-Janusch
1969	Henry Kunkel
1970	Norman Wessells
1971	Aiden Breathnach
1972	Frank Dixon
1973	H. Hugh Fudenberg
1974	Charles Cochrane
1975	David Katz
1976	Bert O'Malley
1977	Russell Ross
1978	Hilary Koprowski
1979	Michael Brown
1980	Phil Leder
1981	Pedro Cuatrecasas
1982	Frank Ruddle
1983	Lawrence Lichtenstein
1984	Robert Gallo
1985	Thomas Waldmann
1986	Torsten Wiesel
1987	Leroy Hood
1988	Joseph Goldstein
1989	Pierre Chambon

1990	Ronald Herberman
1991	K. Frank Austen
1992	Bert Vogelstein
1993	Charles Janeway, Jr.
1994	Solomon Snyder
1995	Eric Lander
1996	Irving Weissman
1997	Michael Karin
1998	Günter Blobel
1999	Philippa Marrack
2000	Robert Langer
2001	William Haseltine
2002	Ronald DePinho
2003	Thomas Jessell
2004	Robert Weinberg
2005	Timothy Ley
2006	Amita Sehgal
2007	Stuart Schreiber
2009	Daniel Kastner
2010	Raymond Schinazi
2011	Jennifer Lippincott-Schwartz
2012	Mina Bissell
2013	Allan Balmain
2014	Hopi Hoekstra
2015	Drew M. Pardoll
2016	Tom Misteli

Eugene M. Farber Lectureship

This lecture is presented by an investigator whose work is relevant to expanding our insights into the pathophysiology and treatment of psoriasis.

2007	Brian Nickoloff
2008	Enno Christophers
2009	James T. Elder
2010	James Krueger
2011	Kevin Cooper
2012	Frank Nestle
2014	Joel Gelfand
2015	Christopher E.M. Griffiths
2016	Nicole Ward

Albert M. Kligman/Phillip Frost Leadership Lecture & Award

This award is made to an individual in acknowledgment of significant contributions to the understanding of structure and function of skin in the past five years.

2008	Jouni Uitto
2009	Stephen Katz
2010	John R. Stanley
2011	Peter Elias
2012	Robert Lavker
2013	Elaine Fuchs
2014	Robert Modlin
2015	Kathleen J. Green
2016	Cheng-Ming Chuong

Notable Annual Meeting Programming

Selected ePoster Discussions

In an effort to further increase participation and visibility of abstracts submitted to the Annual Meeting, the SID is pleased to add this new feature to the meeting.

Selected ePoster Discussions will take place during Poster Sessions that will occur on Thursday, Friday, and Saturday of the Annual Meeting at five (5) iPad terminals located outside of the Poster/Exhibit Hall. The discussions will be thematic tours of selected electronic posters accompanied by a presenting author. Each poster presenter will be asked to briefly describe their work (3 min), followed by a short group discussion (3 min), that will be held with the help of a moderator. If your poster has been selected for ePoster Discussions, please join the appropriate group at the relevant ePoster kiosk. See the venue map when on site for dates, times, categories, featured posters, and moderators.



Speed Dating at SID

April 28, 2017, 12:00 pm – 2:00 pm

This signature SID event features a novel interface between academic investigators and industry representatives. The SID office schedules meetings by matching keywords defined by industry that match submitted abstracts, based on synergistic areas of research. Partners meet for 15 minutes to determine if there is potential for collaboration.

#speeddatingatsid

Note: These individual meetings are all pre-arranged and confirmed before the session.

Come See My Poster

Following in the success of both the ESDR and JSID's innovative programming, the SID will once again offer three 15-minute sessions during the Annual Meeting, titled "Come See My Poster."

These sessions will give opportunities to select presenting authors of highly scored abstracts to give a brief one-minute/one slide introduction to their submitted abstract. This rapid paced session is in advance of one of the SID's Poster Sessions, providing both an excellent starting point into the Poster Hall and the generation of excitement for all attendees.

Trainee/Faculty Breakfast

Throughout the years, the SID has encouraged meetings between Residents and Post-Doc Fellows. To continue its promotion of collegiality, the SID presents a Trainee Breakfast. These small group meetings in which senior/ junior scientists and a group of four to six residents and post-doc fellows to discuss issues over coffee and light fare. These sessions provide an opportunity to talk informally about subject matter of interest including research opportunities in dermatology, life in academia or how to combine clinical work with research.

Going Mobile


Navigate the 76th Annual Meeting from your mobile device! In partnership with Cadmium CD, the SID is proud to present the 2017 Annual Meeting mobile event app.

This year's app will make it easy for attendees, exhibitors, and speakers to connect. Attendees can access their personal schedules right from the palm of their hand. They can track the exhibitors they've visited, see all the full text abstracts, have

access to the meeting schedule and floor plans, apply for CME credit, take notes, call for an Uber ride, check the weather, check-in with their airline, access social media sites, and interact with fellow attendees to name just a few of the features.

Download the 2017 SID Annual Meeting Mobile app from the Apple iTunes and the Google Play Stores.

A Guide to Using the SID 2017 Annual Meeting App



STEP 1

Download the “SID 2017 Annual Meeting” app from the Apple App Store or Google Play Store. To start using the app, select “**Create Account**” and type your **name** and **email address**. If you already have an account, select “**Login**” and enter your **username** (your email) and **password**.

STEP 2

Browse the event schedule and create a personal schedule by selecting the star adjacent presentation titles. Starred presentations can be found under “My Schedule.” Review presentation, speaker and exhibitor details. Take notes in the schedule and exhibitors modules.



STEP 3

If you don't have a device that is able to download the app, you can use your **laptop**. As long as you have an internet connection, you can view the schedule, speaker information, and exhibitor information through your laptop via the following website link:

<https://tinyurl.com/SID-Annual-2017>

If you already have an account on a mobile device, use the same account information that was emailed to you. Otherwise follow the steps to create an account.

CME Statement & Objectives

The University of Rochester, Center for Experiential Learning presents:

The 2017 Society for Investigative Dermatology (SID) Annual Meeting

COMMERCIAL SUPPORT STATEMENT

Commercial Support Acknowledgment: This CME activity is supported by educational grants. A complete list of supporters will be published in the course syllabus.

STATEMENT OF NEED

The educational programming of the SID is designed to develop, maintain, and/or increase the abilities, skills, and professional performance of its target audiences. SID CME activities will:

- 1) Disseminate updated evidence-based knowledge of skin biology/disease and applications for maintaining health and preventing, diagnosing, and treating disease in a manner that fosters scientific excellence, elevates the standard of care, and meets high ethical standards.
- 2) Provide target audiences with a relevant forum for the exchange of cutting-edge scientific ideas, information, and methodology.
- 3) Advance the science involved in basic skin biology and clinical care of patients with skin disease.
- 4) Provide exposure to novel science (both concepts and methods) which may be relevant in the future to understanding and treatment of skin disease.

TARGET AUDIENCE

The primary target audiences for SID CME activities include all of the sectors of the dermatology community, consisting of research investigators, clinicians, research and clinical trainees, members of industry, and community advocates for skin health/disease.

LEARNING OBJECTIVES

At the conclusion of this activity, participants should be able to:

- Identify which disease states require new or additional research.
- Evaluate state-of-the-art information relating to basic skin biology research

- Describe how newly discovered, evidence-based scientific information may or may not be applied to the current practice of investigative or clinical dermatology.
- Apply strategies to structure and design successful research proposals, abstracts, and manuscripts.
- Facilitate interdisciplinary and/or collaborative investigation in clinical dermatology and skin biology to improve research hypotheses, processes and/or techniques.
- Incorporate knowledge gained from interactions between basic scientists and clinicians into daily decision-making.

FACULTY LISTING

Activity Medical Director:

Alice P. Pentland, MD
Chair, Department of Dermatology
University of Rochester

SUMMARY OF FACULTY DISCLOSURE/CONFLICT RESOLUTION

Staff and Content Validation Reviewer Disclosure

The staff involved with this activity and any content validation reviewers of this activity have reported no relevant financial relationships with commercial interests.

Resolution of Conflicts of Interest

In accordance with the ACCME Standards of Commercial Support of CME, the University of Rochester School of Medicine and Dentistry will implement mechanisms, prior to the planning and implementation of this CME activity, to identify and resolve conflicts of interest for all individuals in a position to control content of this CME activity.

UNAPPROVED USE DISCLOSURE STATEMENT

The University of Rochester requires CME faculty (speakers) to disclose to attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. This information is intended solely for continuing medical education and is not intended to promote

off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information. Faculty will not be discussing information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling.

DISCLAIMER

The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition.

INSTRUCTIONS ON HOW TO RECEIVE CREDIT

In order to receive CME credit, participants must sign-in, review the CME information (accreditation, learning objectives, faculty disclosures, etc.) and attend the CME activity. To access the program evaluation, claim CME Credits, or print your certificate go to www.cme.urmc.edu or use the QR Code.



ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Rochester School of Medicine and Dentistry and the Society for Investigative Dermatology. The University of Rochester School of Medicine and Dentistry is accredited by the ACCME to provide continuing medical education for physicians.

AMA CREDIT STATEMENT

The University of Rochester School of Medicine and Dentistry designates this live activity for a maximum of 26.5 *AMA PRA Category 1 Credit(s)*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Planning Committee / Speaker Declarations

All of the planning committee members* and speaker listed below have disclosed that they have no relevant financial interests/arrangements or affiliations with organization(s) that could be perceived as a real or apparent conflict of interest in the context of the subject of their presentation(s).

Hasan Erbil Abaci, PhD
Katrina Abuabara, MD/MA/MSCE
Katrina Abuabara, MD/ MA/MSCE
Shivani Agarwal, PhD
Feras Al-Ghazawi, PhD/MD/ MSc
Timothy Almazan, MD
Sanjay Anand, PhD
Niroshana Anandasabapathy, MD/PhD
Nate Archer, PhD
Christopher Arnette, PhD
Kauschal Asrani, PhD/MBBS
Kwabena Badu-Nkansah, PhD
John Cannon, BA
Brian Capell, PhD/PhD
Joseph Carroll, PhD
Yu-Ling Chang, BA
Peter Chansky, BA
Yonglu Che, BS
Mei Chen, PhD
Raymond Cho, MD/PhD
Keith Choate, MD/PhD
Abigail Coffman
Idan Cohen, PhD
Maclean Cook
Acacia Crouch, MS
Zhenpeng Dai, PHD
Duncan Dam, PhD
Mohammed Dany, PhD
Lopa Das, PhD
K. Sanjana P. Devi, PhD
Sally Dickinson, PhD
Joanna Dong, BA
John Doux, MD
Peter Elias, MD
Christoph Ellebrecht, MD
Robert Feehan, BS
Cheng Feng, BS
Alexander Fischer, MPH
Agnes Forsthuber, MSc
Chisako Fujiwara, Pre-Doctoral Student
Yuki Furuichi, MD
Lilit Garibyan, MD/PhD
Tara Gelb, PhD
Brian Gibbs, PhD/MPA
Barbara Gilchrist, MD
Ayman Grada, MD/MS
Teri Greiling, MD/PhD
Douglas Grossman, MD/PhD
Zongyou Guo, PhD
Thomas Haarmann-Stemmann, PhD
Robert Hamanaka, PhD
Helen He, BS
Nicholas Heitman
Ryan Hobbs, PhD
Wen-Yen Huang, PhD
Anke Huels, MSc
Bin-Jin Hwang, PhD candidate
Zhou Joshua
Veli-Matti Kähäri, MD/PhD
Kimberly Kahn, PhD
Pankaj Karande, PhD
Sakeen Kashem, PhD
Michelle Kerns, MD
Habib Khan, BA
Dongwon Kim, PhD
Jin Yong Kim
Tetsuro Kobayashi, PhD
Heidi Kong, MD, MHSc
Heidi Kong, MD, MHSc
Heather Kornmehl, BS
Thomas Kupper, MD
Michael Kwa, BA
Shawn Kwatra, MD
Eunjeong Kwon, PhD
Lu Le, MD, PhD
Charlene Le Fauve, PhD
Dustin Lee, BS
Jie Lei, Master
Katherine Levandoski, BS
Jonathan Levinsohn, BA
Katherine Lewandowski, PhD
Joshua Lewis, PhD (in progress)
Xi Li
Liang Liang, PhD
Chung-Ping Liao, PhD
Young Lim, BS
Yuangang Liu, PhD
Ming-Lin Liu
Vanessa Lopez-Pajares, PhD
Catherine Lu, PhD

Kurt Lu, MD
David Margolis, MD/PhD
Anubhav Mathur, MD/PhD
Mary Mathyer, BA
Alexa Mattheyses, PhD
Aubriana McEvoy, BA
John McGrath, MD FMedSci
Alex Means, MD
Terry Medler, PhD
Eric Merrill, BA
Arlee Mesler, BS
Natalie Miller, PhD
Michael Milliken, MD/MPH
Amar Mirza, BA
Carolina Motter Catarino, PhD student
Teruasa Murata, MD/PhD
Alessio Mylonas, MSc
*Peggy Myung, MD/PhD
Lekha Nair
Seitaro Nakagawa, MD
Teruaki Nakatsuji, PhD
Benjamin Nanes, MD/PhD
Tran Nguyen, Bachelor of Pharmacy
Megan Noe, MD/MPH
Hisashi Nomura, MD
John O'Malley, MD/PhD
Mari Oda, MD
Landon Oetjen
Ryusuke Ono, MD/PhD
Anthony Oro, MD/PhD
Harish Pal, PhD
Amy Paller, MD
Youdong Pan, PhD
Jeannie Park, BA
Chang Ook Park, MD/PhD
Irena Pastar, PhD
Matthew Patrick, PhD
*Alice Pentland, MD
Manosika Perera, MBBS
Bethany Perez White, PhD
Lynn Petukhova, PhD
Joanie Pinard, MD
Hyemin Pomerantz, MD
Steven Prewitt, JD
Adam Raff, MD, PhD
Julia Ransohoff, BA
Clare Rogerson, MA/MSc
Rebecca Russell, BA
Julie Ryan Wolf, PhD/MPH
Ryan Sacotte, BS
Ryosuke Saigusa, MD
Ashley Sample, MS
Jenny Mae Samson, BA
Karen Sanchez Armendariz, MD
Freda Sansaricq, MD
Mrinal Sarkar, PhD
Markus Schober, PhD
Donna See, MBA/MPH
Susana Serrate Szein, MD
Palak Shah, PhD Candidate
Yohya Shigehara, MD
Daniel Shin, PhD
Brett Shook, PhD
Sigrun Sigurdardottir, PhD
Caroline Simard, PhD
Cory Simpson, MD/PhD
Jeffrey Smith, BS
Kevin Sondenheimer, Toxicology
Jutamas Suwanpradid, PhD
William Swindell, PhD/MS
Katsuto Tamai, MD/PhD
Catherine Tchanque-Fossuo, MD/MS
Hitoshi Terui, MD
Nicholas Theodosakis, PhD
Chen Ting, PhD
Jakub Tolar, MD/PhD
Lam Tsoi, PhD
Rosa Ventrella, BS
Steven Vernali, BA
James Wahl, PhD
Eddy Hsi Chun Wang, PhD
Etienne Wang, MBBS
Yan Wang, MD/PhD
*Kevin Wang, MD/PhD
Zhenping Wang, PhD
Ajith Welihinda, PhD
Ramon Whitson, PhD
Marten Winge, MD/PhD
Julie Wu
Nan Xu, MD
Mingang Xu, PhD
Takeshi Yamauchi, PhD
Kun Yang, PharmD
Lucio Zapata, BS
Zili Zhai, PhD
Ling-juan Zhang, PhD
Jennifer Zhang, PhD
Jingyi Zhao, MD

Guannan Zhu, MD/PhD
* Planning Committee Members

The following planning committee members and speakers have disclosed financial interest/arrangements or affiliations with an organization that could be perceived as a real or apparent conflict of interest in the context of the subject of their presentation(s). Only current arrangements/interests are included:

Nihal Ahmad, PhD, Grant/Research Support: California Table Grape Commission

Jonathan Barker, MD/BS, Grant/Research Support: Abbvie, Pfizer, J&J, Novartis, Celgene, GSK, MedImmune; Other: Advisory Board/Speaker: Abbvie, Pfizer, J&J, Novartis, Celgene, Sun Pharmaceuticals, Almiral

Bruce Beutler, MD, Other Financial or Material Support: Pfizer

Vladimir Botchkarev, MD/PhD, Grant/Research Support: Amway Research Grant

*Angela Christiano, PhD, Grant/Research Support: NIH/NIAMS NCI, NCATS, NAAF, NYSTEM, DEBRA, Pfizer; Consultant: Aclaris Therapeutics; Stock Shareholder: Aclaris Therapeutics; Other: Patents from Columbia University licensed to Aclaris Therapeutics.

Raphael Clynes, MD/PhD, Consultant: Aclaris Therapeutics; Shareholder (minor): Aclaris Therapeutics

George Cotsarelis, MD, Grant/Research Support: Allergan, Johnson and Johnson; Consultant: Cassiopea, Lilly; Other Financial or Material Support: Follica, Scientific Advisory Board

*Ponciano Cruz, MD, Grant/Research Support: Astellas

Vishal Deshmukh, PhD, Other Financial or Material Support: Samumed LLC Employee, and Employee Equity

Ariane Dimitrov, PhD, Other: L'Oréal Employee

Allison Dobry, BS, Grant/Research Support: Pfizer

Jessica Fuhrman, BS Biology, Grant/Research Support: Principia Biopharma Inc.; Other Financial or Material Support: California Research Institute of Regenerative Medicine

*Richard Gallo, MD/PhD, Consultant: Sente Inc., MatriSys Biotherapeutics

*Spiro Getsios, PhD, Grant/Research Support: AbbVie

Eric Ghorayeb, MD, Other: Sanofi Genzyme Employee

Michael Girardi, MD, Other Financial or Material Support: Inventor on Yale University-owned patent rights, and Executive at StraDEFY, LLC a spinout company.

Johann Gudjonsson, MD/PhD, Grant/Research Support: Pfizer, Genentech, AbbVie, AnaptysBio, Novartis; Consultant: Novartis

Christian Guerrero-Juarez, PhD Candidate, Grant/Research Support: NSF, MBRS-IMSD; Other: Co-Inventor on patent filed by U Penn describing the BMP pathway as a target for promoting neogenic fat formation

Emma Guttman, MD/PhD, Grant/Research Support: LEO Pharma, Novartis, MedImmune, Eli Lilly, Regeneron, Celgene; Consultant: AbbVie, Anaco, Celgene, Dermira, Galderma, Glenmark, LEO Pharmaceuticals, MedImmune, Novartis, Pfizer, Regeneron, Sanofi, Stiefel/GlaxoSmithKline, Vitae, Mitsubishi Tanabe, Eli Lilly, Asana Biosciences, Kiowa Kirin, Almiral

Tamia Harris-Tryon, MD/PhD, Grant/Research Support: Dermatology Foundation, Burroughs Wellcome Fund

Steven Jones, PhD, Grant/Research Support: Nu Skin Enterprises

William Ju, MD, Consultant: Aclaris Therapeutics, Inc., Amicus Pharmaceuticals, Inc., Brickell Biotech, Inc.

*Daniel Kaplan, MD/PhD, Grant/Research Support: Hapten Pharmaceuticals

Youn Kim, MD, Grant/Research Support: Seattle Genetics; Takeda; Other (please identify): Advisory Board of Seattle Genetics; Steering Committee member for Takeda

*Ethan Lerner, MD/PhD, Consultant: Thesun Pharmaceuticals, Tioga Pharmaceuticals, Nuvo Research, Procter & Gamble (Speaker), Dermira, Kiniksa Pharmaceuticals

Haiyun Liu, PhD, Grant/Research Support: Pfizer; Other Financial or Material Support: Amgen, Genentech

Julian Mackay-Wiggan, MD, Grant/Research Support: Locks of Love; Consultant Aclaris Therapeutics, Inc. Concert Pharmaceuticals, Inc.; Other Financial or Material Support: Advisory Board for BiologicsMD

David Margolis, MD/PhD, Grant/Research Support: Valeant Pharmaceuticals Pediatric Eczema Elective Registry; Consultant: Sanofi/Regeneron GlaxoSmithKline

Kimberly McHale, PhD, Other Financial or Material Support: Novan, Inc. Employee

Sarah Millar, PhD, Consultant: Samumed

*Lloyd Miller, MD/PhD, Grant/Research Support: MedImmune, Pfizer, Chan Soon-Shiong Institute for Advanced Health, Nantworks, BioAegis Therapeutics, Regeneron Pharmaceuticals; Consultant: Chan Soon-Shiong Institute for Advanced Health, Nantworks, Noveome Biotherapeutics, Syntiron; Major Stock Shareholder: Noveome Biotherapeutics.

*Paul Nghiem, MD/PhD, Grant/Research Support: Bristol-Myers Squibb; Consultant: EMD Serono

Atsushi Otsuka, MD/PhD, Grant/Research Support: ONO Pharmaceutical LTD.

Aimee Payne, MD/PhD, Grant/Research Support: Sanofi; Consultant: Syntimmune

John Seykora, MD/PhD, Grant/Research Support: NIH, Rohto Pharmaceutical, Piquar Pharmaceutical; Consultant: Samumed; Other Financial or Material Support: Speakers Bureau for Myriad Genetics

Stuart Shanler, MD, Major Stock Shareholder: Aclaris Therapeutics; Other Financial or Material Support: Executive at Aclaris Therapeutics; Other: Allergan

Zurab Siprashvili, PhD, Other Financial or Material Support: Autologous skin graft LEAES technology was licensed to Abeona Therapeutics who is funding phase 2 trial

Neal Walker, DO/FAAD/MBA, Major Stock Holder: Aclaris Therapeutics, Ralexar Therapeutics Sebacia Nexception; Other Financial or Material Support: CEO at Aclaris Therapeutics; Other (please identify): Allergan

Patricia Walker, MD/PhD, Consultant: Neothetics, Sebacia; Other Financial or Material Support: President of Brickell Biotech

*Nicole Ward, PhD, Grant/Research Support: Allergan; Consultant: AbbVie; Other Financial or Material Support: Reagents from Amgen, Eli Lilly

*Victoria Werth, MD, Grant/Research Support: Celgene, Janssen, Biogen, Roche, Corbus Pharmaceuticals; Consultant: Celgene, Janssen, Genentech, Idera, Principia, Pfizer, Biogen, Momenta, MedImmune, Xoma, Cipher, Lilly, Resolve, Malincrodt, Syntimmune; Other Financial or Material Support: Penn owns the copyright for the CLASI and CDASI

David Woodley, MD, Consultant: Biofusion, Shire, Lotus

Bin Zheng, PhD, Consultant: Enlilium

* Planning Committee Members

Meeting-At-A-Glance

TUESDAY, APRIL 25, 2017

Resident Retreat By Invitation Only
Registration and Informal Networking 12:00 pm – 1:00 pm
Program Session 1:00 pm – 6:30 pm
B113-116

PhD Retreat By Invitation Only
Registration and Informal Networking 12:00 pm – 1:00 pm
Program Session 1:00 pm – 6:30 pm
B113-116

Resident/PhD Retreat By Invitation Only
Welcome Dinner and Reception 6:30 pm – 8:30 pm
Lobby B

WEDNESDAY, APRIL 26, 2017

Resident/PhD Retreat By Invitation Only
Breakfast 7:00 am – 8:00 am
B113-116

Resident Retreat By Invitation Only
Program Session 7:15 am – 12:00 pm
B113-116

PhD Retreat By Invitation Only
Program Session 7:15 am – 12:00 pm
B113-116

Registration 8:00 am – 7:00 pm
Pre-Function A Foyer

T Translational Science Symposium 12:00 pm – 3:00 pm
Bridging the Valley of Death: Moving Technologies from the Lab to the Clinic
Oregon Ballroom 201-202

T Irvin H. Blank Forum 3:00 pm – 5:00 pm
Building Team Science: Creating a Culture of Diversity and Inclusion
Oregon Ballroom 201-202

State-of-the-Art Plenary Lecture I 5:00 pm – 5:30 pm
Chimeric Immunoreceptor T cells for Pemphigus: Fighting Autoimmunity with Immunity
Aimee Payne, MD/PhD
Oregon Ballroom 201-202

State-of-the-Art Plenary Lecture II 5:30 pm – 6:00 pm
Identification of Hair Shaft Progenitors that Create a Niche for Hair Pigmentation and Graying
Lu Le, MD/PhD
Oregon Ballroom 201-202

President's Welcome 6:00 pm – 6:15 pm
Angela Christiano, PhD
Oregon Ballroom 201-202

American Skin Association (ASA Awards) 6:15 pm – 6:30 pm
Oregon Ballroom 201-202

Dermatology Foundation 6:30 pm – 6:35 pm
Oregon Ballroom 201-202

Albert M. Kligman/Phillip Frost Leadership Lecture 6:35 pm – 7:05 pm
Memory T Cells and Protective Immunity: Lessons from the Smallpox Vaccine
Thomas S. Kupper, MD
Oregon Ballroom 201-202

Welcome Reception 7:05 pm – 8:30 pm
Oregon Ballroom Lobby

THURSDAY, APRIL 27, 2017

Trainee/Faculty Breakfast 7:00 am – 8:00 am
B110-112

Registration 7:30 am – 4:30 pm
Pre-Function A Foyer

I Plenary Session I 8:00 am – 9:00 am
Oregon Ballroom 201-202

I Eugene M. Farber Lecture 9:00 am – 9:30 am
From Genetic Discovery To Personalized Outcomes In Psoriasis
Jonathan Barker, MD
Oregon Ballroom 201-202

S Naomi M. Kanof Lecture 9:30 am – 10:00 am
Targeting the Epigenome in Cutaneous and Disseminated Malignancies
James Bradner, MD
Oregon Ballroom 201-202

Come See My Poster I 10:00 am – 10:15 am
Poster #'s 046, 072, 096, 106, 148, 647, 661, 671, 777, 813, 901, 921
Oregon Ballroom 201-202

T Clinical Scholars Program Session I 10:15 am – 12:00 pm
Base Pairs to Bedside- Personalized Medicine
Oregon Ballroom 201-202

Poster Session I/Coffee Break 10:15 am – 12:15 pm
Odd Poster #'s 625-935
Even Poster #'s 002-312
Odd Late-Breaking Poster #'s 987-1007
Even Late-Breaking Poster #'s 936-960
Exhibit Hall A

Selected ePoster Discussions I 10:45 am – 11:45 am
See Page #46
Exhibit Hall A Foyer

Aclaris Sponsored Symposium 12:00 pm – 1:45 pm
You Don't Know JAK
Oregon Ballroom 201-202

Concurrent Mini-Symposia 2:00 pm – 4:30 pm

- I** Adaptive and Autoimmunity Oregon Ballroom 204
- I** Clinical Research: Pathophysiology and Therapeutics Oregon Ballroom 203
- I** Interdisciplinary Spotlight: Frontiers in Atopic Dermatitis B113-116
- S** Pigmentation and Melanoma A105-106
- S** Skin and Hair Developmental Biology C123-124

T Mini-Symposia Mixers 4:30 pm – 5:00 pm
Individual Concurrent Meeting Rooms

Social Event 6:30 pm – 10:30 pm
World Trade Center Portland
Ticketed Event: Pre-Registration Required

Meeting-At-A-Glance

FRIDAY, APRIL 28, 2017

Registration 7:30 am – 4:30 pm
Pre-Function A Foyer

S Plenary Session II 8:00 am – 9:00 am
Oregon Ballroom 201-202

Stephen Rothman Memorial Award 9:00 am – 9:15 am
Presented to Oregon Ballroom 201-202
Amy Paller, MS/MD

I T Julius Stone Lecture 9:15 am – 9:45 am
Automated Discovery of Genetic Diseases by Saturation Mutagenesis in Mice
Bruce Beutler, MD
Oregon Ballroom 201-202

S State-of-the-Art Plenary Lecture III 9:45 am – 10:15 am
Border Patrol and Melanoma: Keeping the Peace at a Cost?
Niroshana Anandasabapathy, MD/PhD
Oregon Ballroom 201-202

State-of-the-Art Plenary Lecture IV 10:15 am – 10:45 am
3D Bioprinting-An Emerging Paradigm in Tissue Engineering
Pankaj Karande, PhD
Oregon Ballroom 201-202

Come See My Poster II 10:45 am – 11:00 am
Poster #'s 033, 091, 107, Oregon Ballroom 201-202
127, 233, 279, 287, 348, 370, 424, 478, 512

Business Meeting for Members 11:00 am – 11:30 am
Oregon Ballroom 201-202

Poster Session II/Coffee Break 11:30 am – 1:30 pm
Odd Poster #'s 001-311 Exhibit Hall A
Even Poster #'s 314-624
Odd Late-Breaking Poster #'s 937-959
Even Late-Breaking Poster #'s 962-984

Selected ePoster Discussions II 12:00 pm – 1:00 pm
See Page #65 Exhibit Hall A Foyer

Satellite Symposium 12:00 pm – 2:00 pm
Academic-Industry Partnership C120
Project (AIPP)
Individual Meetings (set up in advance by the SID)

Concurrent Mini-Symposia 2:00 pm – 4:30 pm

- 6. Clinical Research: Patient Outcomes Research Oregon Ballroom 204
- I** 7. Genetic Disease, Gene Regulation, B113-116
Gene Therapy
- I** 8. Innate Immunity, Microbiology, Inflammation Oregon Ballroom 203
- S** 9. Photobiology C123-124
- 10. Tissue Regeneration and Wound Healing A105-106

T Mini-Symposia Mixers 4:30 pm – 5:00 pm
Individual Concurrent Meeting Rooms

Pfizer Symposium 5:00 pm – 5:45 pm
Oregon Ballroom 201-202

SATURDAY, APRIL 29, 2017

Registration 7:30 am – 12:00 pm
Pre-Function A Foyer

S I Plenary Session III 8:00 am – 9:00 am
Oregon Ballroom 201-202

William Montagna Lecture 9:00 am – 9:30 am
From Morphogenesis to Disease: A Wnt's Tale
Sarah Millar, PhD
Oregon Ballroom 201-202

S Herman Beerman Lecture 9:30 am – 10:00 am
How to Make Antibodies for Tumor Immunotherapy
Alan J. Korman, PhD
Oregon Ballroom 201-202

Come See My Poster III 10:00 am – 10:15 am
Poster #'s 325, 357, 421, 427, Oregon Ballroom 201-202
535, 623, 714, 812, 884

S T Clinical Scholars Program Session II 10:15 am – 12:00 pm
Emerging Immunotherapies
Oregon Ballroom 203

Poster Session III/Coffee Break 10:15 am – 12:15 pm
Odd Poster #'s 313-623 Exhibit Hall A
Even Poster #'s 626-934
Odd Late-Breaking Poster #'s 961-985
Even Late-Breaking Poster #'s 986-1008

Selected ePoster Discussions III 10:45 am – 11:45 am
See Page #91 Exhibit Hall A Foyer

Concurrent Mini-Symposia 12:30 pm – 3:00 pm

- S** 11. Carcinogenesis and Cancer Genetics B113-116
- 12. Clinical Research: Epidemiology of Skin Diseases Oregon Ballroom 203
- I** 13. Epidermal Structure and Barrier Function Oregon Ballroom 204
- 14. Growth Factors, Cell Adhesion and Matrix Biology C123-124
- 15. Pharmacology and Drug Development A105-106

2017 EDUCATIONAL TRACKS

T YOUNG INVESTIGATOR/TRAINEE

I INFLAMMATORY SKIN DISEASE

S SKIN CANCER

Associate Groups: Meeting-At-A-Glance

TUESDAY, APRIL 25, 2017

International Pachyonychia Congenita Consortium (IPCC) Meeting 2017	12:00 pm - 6:00 pm C123-124
----------------------------------------------------------------------------	--------------------------------

WEDNESDAY, APRIL 26, 2017

International Pachyonychia Congenita Consortium (IPCC) Meeting 2017	8:00 am - 1:00 pm C123-124
----------------------------------------------------------------------------	-------------------------------

Pan-Pacific Skin Barrier Symposium (PAPSBRS)	9:00 am - 4:30 pm A105-106
-----------------------------------------------------	-------------------------------

American Acne and Rosacea Society (AARS)	12:00 pm - 3:00 pm Oregon Ballroom 203
-------------------------------------------------	-------------------------------------------

THURSDAY, APRIL 27, 2017

Pediatric Dermatology Research Alliance/Society for Pediatric Dermatology Session	7:00 am - 8:00 am A105-106
------------------------------------------------------------------------------------------	-------------------------------

International Transplant Skin Cancer Collaborative (ITSCC) Symposium	7:00 am - 8:00 am B117-119
-----------------------------------------------------------------------------	-------------------------------

debra of America's EB Symposium	12:00 pm - 2:00 pm B117-119
----------------------------------------	--------------------------------

FRIDAY, APRIL 28, 2017

Women's Dermatologic Society	6:30 am - 7:15 am
Networking & Breakfast	7:15 am - 8:00 am
Panel Discussion	B117-119

Pediatric Dermatology Research Alliance/ Society for Pediatric Dermatology Session	7:00 am - 8:00 am A105-106
-------------------------------------------------------------------------------------------	-------------------------------

International Eczema Council	12:00 pm - 1:30 pm Oregon Ballroom 204
-------------------------------------	-------------------------------------------

International Psoriasis Council	12:00 pm - 1:30 pm B113-116
----------------------------------------	--------------------------------

American Dermato-Epidemiology Network (ADEN) Symposium	12:00 pm - 1:30 pm B117-119
---------------------------------------------------------------	--------------------------------

Medical Dermatology Society	12:00 pm - 1:45 pm A105-106
------------------------------------	--------------------------------

International Society for Cutaneous Lymphomas / Cutaneous T-Cell Lymphoma Symposium (ISCL/CTCL)	12:00 pm - 1:30 pm C123-124
--------------------------------------------------------------------------------------------------------	--------------------------------

Research in Cutaneous Surgery Mini-Symposium	12:00 pm - 1:30 pm B112
-----------------------------------------------------	----------------------------

National Eczema Association	6:00 pm - 7:00 pm A105-106
------------------------------------	-------------------------------

North American Hair Research Society (NAHRS)	6:00 pm - 8:30 pm Oregon Ballroom 203
-----------------------------------------------------	------------------------------------------

National Psoriasis Foundation Reception	6:00 pm - 7:30 pm B117-119
------------------------------------------------	-------------------------------

SATO Japan Scientific Forum	6:30 pm - 9:30 pm C123-124
------------------------------------	-------------------------------

2017 SID Educational Tracks

The SID is pleased to offer special educational tracks/special collections of focused topics within the 2017 Annual Meeting: The Skin Cancer, Inflammatory Skin Disease, and Trainee Tracks. The SID has been increasing the variety of sessions offered at the Annual Meeting that are geared toward residents, fellows, students and clinicians. The Track system is an easy way for attendees to identify components of the Meeting that provide in-depth coverage.

Session components of each track are indicated with initials on the 'Meeting at a Glance' pages:

- Young Investigator/Trainee Track (T)
- Inflammatory Skin Disease (I)
- Skin Cancer Track (S)

Tracks include portions of the meeting that offer a density of thematic content, providing a cohesive learning experience. They also provide significant opportunities for networking and collaboration, as attendees share common clinical and research interests.

Note: These tracks merely highlight themes that run throughout the meeting. Attendees are encouraged to select sessions by conducting keyword searches for disease, mechanism, gene, etc.

YOUNG INVESTIGATOR/TRAINEE T

There are several sessions offered during the SID meeting that are designed for Trainees. They are intended to provide an overview of basic, clinical and translational science, along with opportunities to interact with senior faculty. The target audience includes medical and biomedical science students, research fellows, Dermatology residents, PhD/Post-doctoral candidates, and Junior Faculty.

TRACK COMPONENTS

Wednesday, April 26

- Translational Science Symposium
- Irvin H. Blank Forum

Thursday, April 27

- Clinical Scholars Program Session I
- Mini-Symposia Mixers

Friday, April 28

- Julius Stone Lecture
- Mini-Symposia Mixers

Saturday, April 29

- Clinical Scholars Program Session II

INFLAMMATORY SKIN DISEASE I

This track includes special sessions occurring over the four-day SID meeting, and offers an in-depth view of Inflammatory Skin Diseases, both common and rare, through a variety of lenses. Presentations span the full translational continuum—from animal surrogate models to human trials, utilizing genetic, mechanistic, epidemiological, and technical approaches.

TRACK COMPONENTS

Thursday, April 27

- Plenary Session I
- Eugene M. Farber Lecture
- Concurrent Mini-Symposia 1: Adaptive and Autoimmunity
- Concurrent Mini-Symposia 2: Clinical Research: Pathophysiology and Therapeutics
- Concurrent Mini-Symposia 3: Interdisciplinary Spotlight: Frontiers in Atopic Dermatitis

Friday, April 28

- Julius Stone Lecture
- Concurrent Mini-Symposia 7: Genetic Disease, Gene Regulation, Gene Therapy
- Concurrent Mini-Symposia 8: Innate Immunity, Microbiology, Inflammation

Saturday, April 29

- Plenary Session III
- Concurrent Mini-Symposia 13: Epidermal Structure and Barrier Function

SKIN CANCER S

A significant amount of research will be presented during this year's SID meeting. More than a fourth of abstracts submissions relate to all types of skin cancers, and many of the Invited/Named Lectures relate to emergent areas of cutaneous oncology.

TRACK COMPONENTS

Thursday, April 27

- Naomi M. Kanof Lecture
- Concurrent Mini-Symposia 2: Clinical Research: Pathophysiology and Therapeutics
- Concurrent Mini-Symposia 4: Pigmentation and Melanoma

Friday, April 28

- Plenary Session II
- State-of-the Art Plenary Lecture III
- Concurrent Mini-Symposia 9: Photobiology

Saturday, April 29

- Plenary Session III
- Herman Beerman Lecture
- Clinical Scholars Program Session II
- Concurrent Mini-Symposia 11: Carcinogenesis and Cancer Genetics

2017 SID Retreat Attendees & Travel Awardees

2017 SID RETREAT

ATTENDEES

Annalise Abiodun, MD
 Richard Ahn, PhD
 Christopher Arnette, PhD
 Adam Aronson, MD
 Velina Atanasova
 John Barbieri, MD/MBA
 Nicole Bender, MD
 Elizabeth Berry, MD
 Daniel Butler, MD
 Natasha Carter, MD/PhD
 Elizabeth Chao, MD/PhD
 Yeun Ja Choi, PhD
 Nashay Clemetson, MD
 Emily Cole, MD
 K. Sanjana P. Devi, PhD
 Brittany Dulmage, MD
 Robert Feehan
 Cheng Feng
 Jade Fettig, MD
 Teal Furnholm, PhD
 Maria Gnarra, MD/PhD
 Farzam Gorouhi, MD
 Tamar Hajarm, MD
 Claire Hamilton, MD/PhD
 Natasha Hill, PhD
 Chante Karimkhani, MD
 Nour Kibbi, MD
 Grace Kim, MD
 Chelsey Kline, PhD
 Sara Knowlden, PhD
 Betty Kong, MD/PhD
 Karen Kuo, MD
 Ryan Lane, PhD
 Jamie Langenhan, MD
 Nayoung Lee, MD
 Katherine Lewandowski, PhD
 Joshua Lewis, PhD
 Chung-Ping Liao, PhD
 Isabelle Lorthois, PhD student
 Olivia Lucero, MD
 Silvia Mancebo, MD
 Matthew Mansh, MD
 Jeffrey McBride, MD/PhD
 Jason Meyer, MD/PhD
 Michael Milliken, MD/MPH
 Yukari Mizukami, MD
 Christine Monteleon, PhD
 Ata Moshiri, MD/MPH
 Farah Moustafa, MD
 Era Murzaku, MD
 Caroline Nelson, MD
 Tran Nguyen
 Neda Nikbakht, MD/PhD
 Lauren Ogrich, MD
 Xiaoming Ouyang, PhD
 Andrew Overmiller
 Joshua Owen, MD/PhD

Youdong Pan, PhD
 Elyse Paterson, PhD
 David Perry, MD/PhD
 Hyemin Pomerantz, MD
 Mehdi Rashighi, MD
 Jason Rizzo, MD/PhD
 Clare Rogerson, MA/MSci
 Daiki Rokunohe, MD/PhD
 Veronica Rotemberg, MD/PhD
 James Sanford
 Timothy Schmidt, MD/PhD
 Brittney Schultz, MD
 Yevgeniy Semenov, MD
 Jessica Shiu, MD/PhD
 Leonid Shmuylovich, MD/PhD
 Sigrun Sigurdardottir, PhD
 Titilola Sode, MD
 Rivka Stone, MD/PhD
 Kumar Sukhdeo, MD/PhD
 Joel Sunshine, MD/PhD
 Jutamas Suwanpradid, PhD
 Rie Takahashi, MD/PhD
 Shivani Tripathi, MD
 Amanda Truong
 Akihiko Uchiyama, MD/PhD
 Antia Veal
 Priyanka Vedak, MD
 Benjamin Voisin, PhD
 Elizabeth Wallace, MD
 Chen Wang, MD/PhD
 Vivian (Wai Chong) Wong, MD/PhD
 Chao Yang, MD
 Zhaolin Zhang, PhD

2017 SID/ALBERT M. KLIGMAN TRAVEL FELLOWSHIP AWARDEES

Timothy Almazan, MD
 Kaushal Asrani, PhD
 Kwabena Badu-Nkansah
 Peter Chansky
 Isan Cohen, PhD
 Allison Dobry
 Cheng Feng
 Agnes Forsthuber, MSc
 Tara Gelb, PhD
 Ayman Grada, MD
 Helen He
 Sakeen Kashem, PhD
 Heather Kornmehl
 Jonathan Levinsohn
 Xi Li, MD
 Haiyun Liu, PhD
 Aubriana McEvoy
 Eric Dean Merrill
 Natalie Miller, PhD
 Amar Mirza
 Terusa Murata, MD

Alessio Myloans, MSc
 Lekha Nair
 Seitaro Nakagawa, MD
 Landon Oetjen
 Youdong Pan, PhD
 Jeannie Park
 Catherine Pei-ju Lu, PhD
 Julia Ransohoff
 Claire Rogerson, MA/MSci
 Ryan Sacotte
 Jenny Mae Samson
 Freda Sansaricq, MD
 Brett Shook, PhD
 Sigrun Sigurdardottir, PhD
 Jeffrey Smith
 Jutamas Suwanpradid, PhD
 Rosa Ventrella
 Zili Zhai, PhD

2017 SID STUDENT RESEARCH/FELLOW TRAVEL AWARDEES

Shivani Agarwal, PhD
 Feras Al-Ghazawi, MD/PhD
 Christopher Arnette, PhD
 Carolina Catarino
 Mohammed Dany, PhD
 Sally Dickinson, PhD
 Jessica Fuhriman
 Robert Hamanaka, PhD
 Habib Khan
 Dongwon Kim, PhD
 Jin Yong Kim
 Sergei Korolov, PhD
 Michael Kwa
 Shawn Kwatra, MD
 Eunjeong Kwon, PhD
 Katherine Levandoski
 Joshua Lewis
 Alexander Means, MD
 Terry Medler, PhD
 Arlee Mesler
 Michael Milliken, MD/PhD
 Shin Morizane, MD/PhD
 Tran Nguyen
 Hisashi Nomura, MD
 Matthew Patrick, PhD
 Ashley Sample
 Catherine Tchanque-Fossuo, MD
 Nicholas Theodosakis, PhD
 Steven Vernali
 Yan Wang, MD/PhD
 Nan Xu, MD
 Kun Yang
 Lucio Zapata, Jr.
 Jingyi Zhao, MD

Meeting Information & Policies

REPRODUCTION AND PHOTOGRAPHY POLICY

Any photography, filming, taping, recording or reproduction in any medium of any of the programs, exhibits, or lectures (oral or posters) presented at the 2017 SID Annual Meeting is strictly forbidden. Failure to comply with this rule may lead to the removal of your meeting credentials.

ON-SITE REGISTRATION

On-site registration will take place at the SID Registration Counter in the Pre-Function A Foyer during the following hours:

Wednesday, April 26, 2017	8:00 am – 7:00 pm
Thursday, April 27, 2017	7:30 am – 4:30 pm
Friday, April 28, 2017	7:30 am – 4:30 pm
Saturday, April 29, 2017	7:30 am – 12:00 pm

BADGES

Badges for both advanced and on-site registration can be picked up at the SID Registration Counter in the Pre-Function A Foyer. Meeting attendees are required to wear their badges at all times for entry to all sessions and other meeting activities.

TABLETOP EXHIBITORS

Aclaris Therapeutics
www.aclaristx.com

American Acne and Rosacea Society
www.acneandrosacea.org

International Psoriasis Council
www.psoriasis council.org

National Alopecia Areata Foundation
www.naaf.org

National Eczema Association
www.nationaleczema.org

National Psoriasis Foundation
www.psoriasis.org

Pachyonychia Congenita Project
www.pachyonychia.org

SPECIAL SERVICES FOR THE PHYSICALLY CHALLENGED

The Oregon Convention Center is fully accessible to the physically challenged.

If you have any special needs, please stop at the SID Registration Counter upon arrival or contact Danelle Hauther 503.235.7575 or danellehauther@oregoncc.org.

TECHNICAL EXHIBITS

Exhibits will be on display during the following times in the Exhibit Hall A:

Thursday, April 27, 2017	10:15 am – 12:15 pm
Friday, April 28, 2017	11:30 am – 1:30 pm
Saturday, April 29, 2017	10:15 am – 12:15 pm

THE SID WELCOMES REPRESENTATIVES FROM THE FOLLOWING ORGANIZATIONS

CYTOO
FibroTx
Galderma
Genemarkers
ImaBiotech Corp
Innovaderm Research Inc.
Lilly USA, LLC
MatTek Corporation
Metabolon
NIAMS
Perimed Inc.
Pfizer
Zen-Bio Inc.


COMMERCIAL SUPPORT OF CME SESSIONS AS OF (APRIL 1, 2017)


Actelion
Galderma
LEO Pharma
Novartis
Sanofi Genzyme and Regeneron Pharmaceuticals
Valeant

SPONSORS AS OF (APRIL 1, 2017)

Aclaris Therapeutics
Incyte
Pfizer
Rodan and Fields
Sun Pharma

Oregon Convention Center Map - Lower Level





Abstract Presentation Information

ORAL PRESENTATIONS

All oral presentations and lectures will take place at the Oregon Convention Center (OCC). Minisymposium and Plenary oral presentations are scheduled at the rate of five (5) per hour. This allows ten (10) minutes for presentation and two (2) minutes for discussion. In order to coordinate sessions, the time limit will be strictly adhered to, or you will be asked to terminate your presentation by the session moderators.

LCD projectors will be available in each lecture room. There will be resources to display only with IBM-compatible PowerPoint MS Office 2015 or earlier versions. 35mm projectors will not be available. Computer technicians will be able to download ZIP and CD files. All oral presentations must also be presented as posters.

All presentations must be uploaded at least six (6) hours prior to your presentation and uploads are to be completed in the Speaker Ready Room (A103). Technical support will be available.

CONFLICT OF INTEREST

Due to CME guidelines, all oral presentations must include a disclosure slide at the beginning of your presentation. If there is a real or perceived conflict of interest pertaining to your work, an announcement must be made prior to your oral presentation and also displayed on your poster.

SPEAKER READY ROOM WILL BE HELD IN ROOM A103 ON THE LOWER LEVEL

The room will be available to all presenters during the following hours:

Wednesday, April 26, 2017	7:00 am – 8:00 pm
Thursday, April 27, 2017	7:00 am – 5:00 pm
Friday, April 28, 2017	7:00 am – 5:00 pm
Saturday, April 29, 2017	7:00 am – 2:00 pm

TO VIEW ALL ABSTRACTS PLEASE DOWNLOAD THE MEETING APP (SEE PAGE 7 FOR INSTRUCTIONS) OR SEE THE MAY 2017 SUPPLEMENT TO THE JOURNAL OF INVESTIGATIVE DERMATOLOGY (JID)

POSTER PRESENTATIONS

All poster will be displayed until Saturday, April 29th at 12:15 pm in Exhibit Hall A. Posters will be viewed in three (3) sessions as outlined below. Presenters should be at their posters for the entire discussion session. Posters may not be removed early. The SID is not responsible for posters left unclaimed as of 1:00 pm on Saturday, April 29, 2017, and unclaimed posters will not be returned.

Install All Posters

Wednesday, April 26, 2017 8:00 am – 5:00 pm

Poster Session I

Thursday, April 27, 2017 10:15 am – 12:15 pm
 Odd Poster #'s 625-935
 Even Poster #'s 002-312
 Odd Late-Breaking Poster #'s 987-1007
 Even Late-Breaking Poster #'s 936-960

Selected ePoster Discussions I

Thursday, April 27, 2017 10:45 am – 11:45 am
 See Page #46

Poster Session II

Friday, April 28, 2017 11:30 am – 1:30 pm
 Odd Poster #'s 001-311
 Even Poster #'s 314-624
 Odd Late-Breaking Poster #'s 937-959
 Even Late-Breaking Poster #'s 962-984

Selected ePoster Discussions II

Friday, April 28, 2017 12:00 pm – 1:00 pm
 See Page #65

Poster Session III

Saturday, April 29, 2017 10:15 am – 12:15 pm
 Odd Poster #'s 313-623
 Even Poster #'s 626-934
 Odd Late-Breaking Poster #'s 961-985
 Even Late-Breaking Poster #'s 986-1008

Selected ePoster Discussions III

Saturday, April 29, 2017 10:45 am – 11:45 am
 See Page #91

Dismantle All Posters

Saturday, April 29, 2017 12:15 pm – 1:00 pm



Wednesday Sessions

PAGE TITLE

- | | |
|----|----------------------------------------------------------------|
| 21 | Meeting-at-a-Glance |
| 22 | International Pachyonychia Congenita Consortium Meeting (IPCC) |
| 23 | Pan-Pacific Skin Barrier Symposium (PAPSBRS) |
| 24 | American Acne & Rosacea Society (AARS) |
| 25 | Translational Science Symposium |
| 29 | Irvin H. Blank Forum |
| 31 | State-of-the-Art Plenary Lecture I & II / President's Welcome |
| 32 | American Skin Association (ASA Awards) |
| 33 | Dermatology Foundation |
| 34 | Albert M. Kligman/Phillip Frost Leadership Lecture |

Welcome Reception

Wednesday, April 26, 2017**7:05 pm - 8:30 pm****Oregon Ballroom Lobby
Oregon Convention Center**

All attendees are invited to join us for a Welcome Reception to kick off the 2017 SID Annual Meeting! Gather with your colleagues at the Oregon Convention Center immediately following the last session of the day for cocktails and light snacks.

This event is free of charge, beverage tokens can be found in your meeting registration packet.



Meeting-At-A-Glance

WEDNESDAY, APRIL 26, 2017

International Pachyonychia Congenita Consortium (IPCC) Meeting 2017 8:00 am – 1:00 pm
C123-124

Resident/PhD Retreat By Invitation Only
Breakfast 7:00 am – 8:00 am
B113-116

Resident Retreat By Invitation Only
Program Session 7:15 am – 12:00 pm
B113-116

PhD Retreat By Invitation Only
Program Session 7:15 am – 12:00 pm
B113-116

Registration 8:00 am – 7:00 pm
Pre-Function A Foyer

Pan-Pacific Skin Barrier Symposium (PAPSBRS) 9:00 am – 4:30 pm
A105-106

American Acne and Rosacea Society (AARS) 12:00 pm – 3:00 pm
Oregon Ballroom 203

Translational Science Symposium 12:00 pm – 3:00 pm
Bridging the Valley of Death: Moving Technologies from the Lab to the Clinic
Oregon Ballroom 201-202

Irvin H. Blank Forum 3:00 pm – 5:00 pm
Building Team Science: Creating a Culture of Diversity and Inclusion
Oregon Ballroom 201-202

State-of-the-Art Plenary Lecture I 5:00 pm – 5:30 pm
Chimeric Immunoreceptor T cells for Pemphigus: Fighting Autoimmunity with Immunity
Aimee Payne, MD/PhD
Oregon Ballroom 201-202

State-of-the-Art Plenary Lecture II 5:30 pm – 6:00 pm
Identification of Hair Shaft Progenitors that Create a Niche for Hair Pigmentation and Graying
Lu Le, MD/PhD
Oregon Ballroom 201-202

President's Welcome 6:00 pm – 6:15 pm
Angela Christiano, PhD
Oregon Ballroom 201-202

American Skin Association (ASA Awards) 6:15 pm – 6:30 pm
Oregon Ballroom 201-202

Dermatology Foundation 6:30 pm – 6:35 pm
Oregon Ballroom 201-202

Albert M. Kligman/Phillip Frost Leadership Lecture 6:35 pm – 7:05 pm
Memory T Cells and Protective Immunity: Lessons from the Smallpox Vaccine
Thomas S. Kupper, MD
Oregon Ballroom 201-202

Welcome Reception 7:05 pm – 8:30 pm
Oregon Ballroom Lobby

ASSOCIATE
GROUPS ARE
LISTED IN GREEN



International Pachyonychia Congenita Consortium (IPCC) Meeting 2017

New Horizons in Keratoderma Research

Wednesday, April 26, 2017	8:00 am - 1:00 pm	C123-124
---------------------------	-------------------	----------

8:00 am Breakfast Buffet

9:00 am ***Scanning the PC pain and itch horizons***
 Michael Polydefkis (Johns Hopkins Medicine, Baltimore)
 Pain in PC - why is it a problem and what can we do about it?

9:30 am Thomas Magin (University of Leipzig, Leipzig)
 Keratins at the crossroads of itch and mechanotransduction.

10:00 am Break

10:15 am Special Guest Lecture - Howard Chang
 (Stanford University, Stanford)
 How does palmoplantar epidermis know that it is palmoplantar? Molecular mechanisms controlling development and maintenance of ridged skin.

11:00 am Break

11:30 am **Towards new horizons - brainstorming session**
 Group discussion
 Themes: Pain in PC
 Therapeutic tractability of PPKs - what are the low-hanging fruit?
 Drug repurposing in PPKs - genes and screens
 Oligonucleotide therapeutics for PPKs
 2018 meeting - onwards and upwards

12:30 pm Box lunch available and discussion continues

1:00 pm Close of meeting

8TH PAN-PACIFIC SKIN BARRIER SYMPOSIUM (PAPSBRS)

Wednesday, April 26, 2017

9:00 am – 4:30 pm

A105-106

9:00 am	WELCOME, Drs. Peter M. Elias (VA Med Ctr/UCSF) and Seung Hun Lee (Yonsei U)
SESSION ONE	“Ichthyosis” – Chairs: Drs. A. Ishida-Yamamoto (Asahikawa Med U) and S. Sano (Kochi U)
9:15 am	Plenary Talk #1 , Dr. M. Schmuth (Innsbruck, AT), Eicosanoid derivatives in ichthyosis vulgaris and atopic dermatitis
9:45 am	Platform #1, D. Crumrine (UCSF), Mutations in the Epidermal Fatty Acid and Ceramide Metabolic Pathway Reveal Functions of the CLE
10:00 am	Platform #2, Dr. E. Mauldin, DVM (UPenn), Cellular and metabolic basis for the ichthyotic phenotype in ichthyin deficiency
10:15 am	Platform #3, Dr. K. Nakajima (Kochi Med Sch), Cold-sensing ameliorated ichthyosis in a patient with Dorfman-Chanarin syndrome
SESSION TWO	“Skin Aging” – Chairs: Drs. X.L. Fan (Fourth Military Med U) and S.K. Jeong (Seowon U)
10:30 am	Plenary Talk #2 , Dr. J-H Chung (Seoul Natl U), ABO blood type sugars in brick and mortar
11:00 am	Platform #4, Dr. S.E. Lee (Yonsei Univ), ER stress regulates epidermal tight junction and PPARalpha activation attenuates ER stress-induced unfolded protein response and TJ damage in cultured keratinocytes
11:15 am	COFFEE BREAK (poster viewing)
SESSION THREE	“Barrier Formation-1” – Chairs: Drs. J. Common (A*STAR, Singapore) and T-K Lin (Kaohsiung CH Mem Hosp)
11:30 am	Plenary Talk #3 , Dr. M. Denda (Shisheido), Physicochemical studies of epidermal barrier homeostasis
12:00 pm	Platform #5, H. Yamanishi, MSc (Shisheido), 3 dimensional ultrastructural analysis of lamellar granules in stratum granulosum by focused ion beam scanning electron microscopy
12:15 pm	Platform #6, Dr. C. Mainzer (Silab), New insights for skin barrier function analysis: an in vivo quantitative approach through confocal microscopy coupled to image processing
12:30 pm	LUNCH BREAK (poster viewing)
	“Barrier Formation-2” – Chairs: Drs. S.Y. Cho (Seoul Natl U) and E. Proksch (Kiel Univ)
1:00 pm	Platform #7, Dr. Y. Obata (Hoshi U), The ratio of sphingosine to sphinganine in the SC determines lipid lamellar structure packing
1:15 pm	Plenary Talk #4 , Dr. E.H. Choi (Yonsei U Wonju), Stratum corneum acidification and its potential clinical application
SESSION FOUR	“Atopic Dermatitis” – Chairs: Drs. L. Ma (Beijing Child Hosp) and H.J. Kim (Seoul Med Ctr)
1:45 pm	Plenary Talk #5 , Dr. K. Kabashima (Kyoto U), Cutaneous biological responses to external stimuli
2:15 pm	Platform #8, Dr. S.J. Choe (Yonsei U Wonju), 11beta-hydroxysteroid dehydrogenase 1 expression in the skin might have a role in the occurrence of AD
2:30 pm	Platform #9, Dr. M. Kishibe (Asahikawa Med U), Incomplete secretion of KLK7 and upregulated LEKTI are related to hyperkeratosis in stratum corneum in AD
2:45 pm	Platform #10, Dr. A. Lowe (U Melbourne, AU), A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: PEBBLES pilot study
SESSION FIVE	Chair: Dr. W.M. Holleran (VA Med Ctr/UCSF)
3:15 pm	Plenary Talk #6 , Dr. R. Gallo (UC San Diego), Links between barrier function, S. aureus colonization, and Th2 inflammation
3:30 pm	Meeting Summary – Dr. W. Holleran
3:45 pm	COFFEE AND POSTER DISCUSSION

American Acne & Rosacea Society



Wednesday, April 26, 2017

12:00 pm – 3:00 pm

Oregon Ballroom 203

Register NOW online at: <https://acneandrosacea.org/AARS-6th-SID-Symposium>

- 12:00 pm **Welcome and AARS Announcements**
Diane Thiboutot, MD, AARS Past President, Hershey, PA, USA
- 12:15 pm **Global Skin Disease Morbidity and Mortality: An Update from the Global Burden of Disease Study 2013**, Chante Karimkhani
Aksut, MD, University of Colorado, Department of Dermatology, Aurora, CO, USA. Abstract #181
- 12:30 pm **Inflammatory Gene Expression in Keratinocytes Is Regulated by HAC8 and HDAC9 and Is Modulated by Metabolites from the Microbiome**, James Sanford, PhD, University of California, San Diego, San Diego, CA, USA. Abstract #586
- 12:45 pm **Phenotype and Functions of Ribotype-Specific Th17 Cells Targeted Propionibacterium Acnes**, George Agak, PhD, University of California, Los Angeles, Los Angeles, CA, USA. Abstract #601
- 1:00 pm **SIG-1459 and SIG-1460: Novel Anti-Acne Phytyl-Cysteine Compounds**, Eduardo Perez, PhD, Signum Biosciences, Inc., Princeton, NJ, USA. Abstract #641
- 1:15 pm **Rosacea Associated with Increased Prevalence of Gastrointestinal Disorders in Absence of Systemic Antibiotics**, Hester Gail Lim, MD, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Abstract #175
- 1:30 pm **Increased LL-37 and KLK5 Expression in Conjunctival Epithelium Associated with Ocular Rosacea Severity**, Noori Kim, MD, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Abstract #610
- 1:45 pm **Influence of Bovine Milk Oligosaccharides on Sebocyte Lipid Content and Inflammatory Mediators**, Raja Sivamani, MD, University of California, Davis, Davis, CA, USA. Abstract #878
- 2:00 pm **Development of a Novel Self-Administered Screening Tool for Early Identification of Hidradenitis Suppurativa**, Virginia Moye, MD, MPH, Brown University, Providence, RI, USA. Abstract #166
- 2:15 pm **iPledge Disproportionately Affects Women, Minorities, and Low-Income Patients: A Retrospective Cohort Study**, Fan Di Xia, AB, Harvard Medical School, Boston, MA, USA. Abstract #384
- 2:30 pm **Acne Core Outcomes Research Network (ACORN) Reaches Consensus on Outcomes to Measure**, Diane Thiboutot, MD, AARS Past President, Penn State University College of Medicine, Hershey, PA, USA. Abstract #338
- 2:45 pm **Closing Comments**
Sewon Kang, MD, AARS Immediate Past President, Baltimore, MD, USA

Presentation times and topics are subject to change.

Visit www.acneandrosacea.org for more information about the AARS and its membership!

(888) 744-DERM (3376) • info@aarsmember.org



Translational Science Symposium

Bridging the Valley of Death: Moving Technologies from the Lab to the Clinic

Wednesday, April 26, 2017 12:00 pm – 3:00 pm Oregon Ballroom 201-202

12:00 pm	Opening Remarks William Ju, MD and Patricia S. Walker, MD/PhD Keynote Lecture Introduction: Joseph Carroll, PhD
12:10 pm	Brian J. Druker, MD <i>Imatinib as a Paradigm of Targeted Cancer Therapies</i> Opening Lectures Moderator: Patricia S. Walker, MD/PhD
12:35 pm	Joseph Carroll, PhD <i>Demystifying Tech Transfer</i>
12:50 pm	Steven J. Prewitt <i>Creating Intellectual Property</i>
1:05 pm	Real Life Stories Moderator: William Ju, MD Panelists: R. Rox Anderson, MD George Cotsarelis, MD Richard Gallo, MD/PhD Barbara Gilchrest, MD Michael Girardi, MD Aimee Payne, MD/PhD Stuart Shanler, MD David Woodley, MD
1:50 pm	Shark Tank: Making your Pitch: What do investors/partners look for when evaluating a University-based technology? Moderator: Neal Walker, DO Shark Tank Team #1 Shark Tank Team #2 Shark Tank Team #3 Panelists: Frederick Beddingfield, MD/PhD Joseph Carroll, PhD John Doux, MD William Ju, MD Donna See Patricia S. Walker, MD/PhD Closing Lectures Moderator: William Ju, MD
2:20 pm	Donna See <i>Unicorn Hunting: How do academic researchers begin?</i>
2:35 pm	John Doux, MD <i>What Now?</i>
2:50 pm	Concluding Remarks William Ju, MD and Patricia S. Walker, MD/PhD

CONTINUED



CONTINUED:

Translational Science Symposium**Wednesday, April 26, 2017****12:00 pm – 3:00 pm****Oregon Ballroom 201-202****R. Rox Anderson, MD**

Dr. Anderson graduated from MIT, and then received his MD degree magna cum laude from the joint MIT-Harvard medical program, Health Sciences and Technology. After completing his dermatology residency and an NIH research fellowship at Harvard, he joined the faculty where he is now Harvard Medical School Professor in Dermatology, Director of the Wellman Center for Photomedicine; and adjunct Professor of Health Sciences and Technology at MIT. Dr. Anderson conceived and developed many of the non-scarring laser treatments now widely used in medical care. Dr. Anderson's research has advanced the basic knowledge of human skin photobiology, drug photosensitization mechanisms, tissue optics, and laser-tissue interactions. In addition to research at the Wellman Center, he practices dermatology at Massachusetts General Hospital and teaches at Harvard and MIT. Dr. Anderson has been awarded over 60 national and international patents, and has co-authored over 250 scientific books and papers.

**Frederick Beddingfield III, MD/PhD**

Frederick Beddingfield III, MD/PhD is CEO of Sienna Biopharmaceuticals, Inc, a company focused on developing breakthrough products in aesthetics and dermatology. He is also a board-certified dermatologist and dermatologic surgeon. Dr. Beddingfield served as Chief Medical Officer of Kythera Biopharmaceuticals from March 2013 until it was acquired by Allergan in October 2015. Prior to his appointment at Kythera, he held the role of Vice President and Therapeutic Area Head, Dermatology and Aesthetics at Allergan, Inc. Dr. Beddingfield led the development of premier products in the dermatology and aesthetics industry, including KYBELLA®, BOTOX® Cosmetic, JUVEDERM XC®, VOLUMA XC®, and LATISSE®, all market-leading aesthetic treatments in their respective categories. During his tenure at Allergan, Dr. Beddingfield also led programs in acne, rosacea, scarring, hyperhidrosis, and hair loss. Dr. Beddingfield earned an MD Degree with Honors from the University of North Carolina and a PhD in Policy Analysis from RAND Graduate School of Policy Studies.

**Joseph Carroll, PhD**

Dr. Carroll received his PhD in Molecular and Cellular Biology at SUNY-Stony Brook in 1992. He has a background in commercializing and translating genomic technologies in various disease settings. Over his 15 year career initiating and managing research efforts in biopharma and biotech, Dr. Carroll has held management positions in companies such as Genetics Institute, Wyeth, Millennium Pharmaceuticals, and Sirna Therapeutics. Dr. Carroll moved back to the academic sector in 2008 (Univ. of Colorado), and the Biomedical Diagnostics Inst (Dublin, Ireland)) to facilitate greater academic-industry interactions. In his role managing business development for the Knight Cancer Institute, where he helps establish key alliances, partnerships and new ventures.

**George Cotsarelis, MD**

Dr. Cotsarelis received his B.A. and M.D. from the University of Pennsylvania, and did his dermatology residency at Penn. After a Dermatology Foundation Research award and a Howard Hughes Medical Institute Postdoctoral Research Fellowship for Physicians. He joined the faculty at Penn as an Assistant Professor of Dermatology in 1996. He was promoted to full Professor in 2009, and then was appointed as Milton B Hartzell Professor of Dermatology and Chairman of the Department in 2010. Through his research on epithelial stem cells, Dr. Cotsarelis has impacted dermatology through the launching of the hair follicle stem cell field and his work resulted in understanding the pathogenesis of alopecias. The resulting work has showed that stem cells are destroyed in scarring alopecia, but are still retained in male pattern baldness.

**John Doux, MD**

John Doux is a board certified dermatologist. He obtained his B.S. degree and M.D. from Stanford University, where he was a Howard Hughes Medical Institute Fellow. He completed an M.B.A. at the Wharton School of Business where he was a Palmer Scholar. Since 2004 he has served as an analyst at Palo Alto Investors, an investment fund specializing in healthcare.

**Brian J. Druker, MD**

Dr. Druker is Director of the Knight Cancer Institute at Oregon Health & Science University (OHSU), JELD-WEN Chair of Leukemia Research, and an Investigator of the Howard Hughes Medical Institute. Upon graduating from the University of California, San Diego School of Medicine in 1981, Dr. Druker completed his internship and residency in internal medicine at Barnes Hospital, Washington School of Medicine in St. Louis, Missouri. He trained in oncology at Harvard's Dana-Farber Cancer Institute and then returned to the lab to begin his research career studying the regulation of the growth of cancer cells and its practical application to cancer therapies. Dr. Druker's role in the development of imatinib and its application in the clinic has resulted in numerous awards for Dr. Druker, including the Warren Alpert Prize from Harvard Medical School, the 2009 Lasker-DeBakey Award for Clinical Medical Research, the Japan Prize in Healthcare and Medical Technology and the Albany Medical Center Prize in Medicine and Biomedical Research. He was elected to the Institute of Medicine of the National Academies in 2003, the American Association of Physicians in 2006, the National Academy of Sciences in 2007, and the American Academy of Arts and Sciences in 2012.

CONTINUED:

Translational Science Symposium

Wednesday, April 26, 2017

12:00 pm – 3:00 pm

Oregon Ballroom 201-202



Richard L. Gallo, MD/PhD

Richard L. Gallo, MD/PhD, is Professor of Medicine and Pediatrics, and Chair for the Department of Dermatology at the University of California, San Diego. His research focuses on the role of the innate immune system in skin health and disease, focusing on antimicrobial peptides and aspects of the basic functions of the skin immune system. He has contributed several landmark observations to the field of Dermatology including the first description of an antimicrobial peptide in mammalian skin, the first demonstration that mammals depend on antimicrobial peptides for defense against infection, and the first association of a human diseases (atopic eczema and Rosacea) with a defect in antimicrobial peptide production. His work has been seen in some of the most prestigious scientific and medical journals and is well supported by grants from the NIH, the Veterans Administration, and private foundations. Dr. Gallo trained in Dermatology at Harvard Medical School where he also completed a post-doctoral fellowship in Cell and Developmental Biology. He received his MD degree at the University of Rochester, where he also received his PhD in Radiation Biology and Biophysics. Prior to Dermatology Dr. Gallo trained in Pediatrics at Johns Hopkins Hospital.



Barbara Gilchrest, MD

Barbara A. Gilchrest, M.D., received her undergraduate and medical training from the Massachusetts Institute of Technology (MIT) and Harvard Medical School (HMS) respectively. After a post-doctoral fellowship in the laboratory of Howard Green at MIT, in 1977 Dr. Gilchrest joined the Department of Dermatology and Division on Aging at the HMS. From 1985 until 2008, Dr. Gilchrest served as Professor and Chairman of Dermatology at the Boston University School of Medicine, where she directed a large laboratory and an NIH-sponsored post-doctoral research training program. In 2015 she joined the Department of Dermatology at the Massachusetts General Hospital and HMS. She has served in leadership positions for all the major dermatologic organizations; on the National Advisory Council on Aging and the Board of Scientific Counselors of the National Cancer Institute; the Editor of the Journal of Investigative Dermatology, as Associate Editor or editorial board member of several other major clinical and research journals; as a consultant or scientific advisory board member for pharmaceutical and biotechnology companies; and as a member of the MIT Corporation (1995-2005). Dr. Gilchrest is a Fellow of the American Association for the Advancement of Science, an elected member of the National Academy of Medicine, and a Charter member of the National Academy of Inventors



Michael Girardi, MD

Dr. Girardi is Professor, Vice Chair, and the Residency Program Director for the Department of Dermatology of the Yale School of Medicine. Dr. Girardi graduated magna cum laude with degrees in Biology and Computer Science from Brown University, and from the Yale School of Medicine with the Honors. He has a broad research experience in cutaneous carcinogenesis and cutaneous immunology, funded by the National Cancer Institute for more than 15 years. His laboratory is credited with major contributions to our understanding of cutaneous immunoregulation of skin cancer, including the relative contributions of gamma-delta T cells, NKG2D ligands, innate lymphoid cells, Langerhans cells, and genetic drivers of cutaneous lymphoma. Dr. Girardi has served as the Co-Director for the Yale Comprehensive Cancer Center's Immunology and Immunotherapy Program, and is currently the Director of the Photopheresis and Phototherapy Unit. Dr. Girardi is holder of 4 biomedical patents on skin delivery of therapeutics including novel strategies for skin cancer prevention and treatment, and the efficient and global activation of monocytes for immunotherapy.



William Ju, MD

Dr. Ju is a board-certified dermatologist with over 20 years of experience in the biopharmaceutical industry within a wide variety of therapeutic areas (including dermatology), and in a broad range of entities at different stages of organizational development. This includes leadership positions in business startups to Fortune 100 companies and in nonprofits. Dr. Ju is currently President and a founding trustee of Advancing Innovation in Dermatology, Inc.



Aimee Payne, MD/PhD

Dr. Payne is an Albert M. Kligman Associate Professor of Dermatology at University of Pennsylvania. She obtained her BS in Biology from Stanford University and received her MD/PhD (Molecular and Cellular Biology) Degrees from Washington University School of Medicine in St. Louis. Her career interest has been in pemphigus: diagnosing and treating patients with this potentially fatal autoimmune disease, and performing research to understand what causes disease, with the goal of improving therapy. Her laboratory has contributed to 5 major areas of investigation: 1) cloning and characterization of B-cell repertoires to understand how autoimmunity occurs in pemphigus, a model autoantibody-mediated skin blistering disease; 2) cell biologic studies to understand mechanisms for loss of cell adhesion; 3) collaborative research to advance clinical trials in autoimmune blistering disease; 4) clinical studies to better understand current diagnostic tests and therapies; and 5) translational research to develop novel targeted therapies. In addition to her research activities, she is a board certified dermatologist with a special focus on autoimmune blistering skin diseases.

CONTINUED

CONTINUED:

Translational Science Symposium

Wednesday, April 26, 2017

12:00 pm – 3:00 pm

Oregon Ballroom 201-202



Steven J. Prewitt

Steven Prewitt is Schwabe's Intellectual Property Service Group Leader and a member of the firm's Technology Industry Group. He guides companies and research institutions through the technology development, protection, commercialization and enforcement life cycle to maximize the value of their intellectual property. Having drafted and prosecuted over 500 utility and design patent applications in more than 17 years of practice. Mr. Prewitt has a deep understanding of the value of technology as a critical business asset, and what it takes to effectively protect that asset. He has a diverse technical background, which includes biotechnology, medical devices, mechanical devices, and software technology. He holds a B.A. in Biology from the University of Virginia and a J.D. from George Mason University School of Law.



Donna See

Donna has over 15 years of experience in technology commercialization, as an investor, founder, and advisor to dozens of start-ups in the life sciences and technology sectors. Donna is currently a Vice President at Allied Minds, a publicly-traded venture capital firm, and Vice President of Allied-Bristol Life Sciences, a joint venture between Allied Minds and Bristol-Myers Squibb. She leads Allied Minds' pipeline development, overseeing scouting, diligence, and founding of new ventures based on intellectual property created by Allied Minds' network of over 160 university and federal lab partners. She currently serves as an advisor, mentor, or reviewer to technology development and translational funds at several universities, including the University of California at Davis, University of Southern California, Emory University, Georgia Tech, Columbia University, and the University of Michigan. Donna previously served as the Director of Licensing and Director of Strategic Initiatives for Columbia Technology Ventures, an internationally-recognized leader in the field of university tech transfer. Prior to Columbia, Donna was a Director of Business Development and Technology Transfer at New York-Presbyterian Hospital, forging strategic alliances with government and industry partners to evaluate, develop, and adopt healthcare innovations. She also spent over a decade in global and domestic public health, working with the World Bank, Centers for Disease Control, and other public and private sector organizations to improve health care access, delivery, and quality. Donna received her MBA from Columbia Business School and her MPH in Health Policy & Management from Columbia University's School of Public Health. She holds a BA in the Natural Sciences from The Johns Hopkins University.



Stuart Shanler, MD

Stuart D. Shanler, M.D. co-founded Aclaris Therapeutics, Inc. and has served as their Chief Scientific Officer since their inception in July 2012. Between July 2011 and July 2012, Dr. Shanler co-invented a topical rosacea drug for, and co-founded and served as Chief Scientific Officer of Vicept Therapeutics, Inc. from 2009 until its acquisition by Allergan, Inc. in July 2011. Previously, Dr. Shanler was a dermatologic surgeon in private practice. Dr. Shanler is a board-certified dermatologist and received his M.D. degree from Albany Medical College of Union University and received B.S. degrees in Biology and the Biological Basis of Behavior from the University of Pennsylvania.



Neal Walker, DO

Dr. Walker is a board certified dermatologist and serial entrepreneur with over 18 years of experience in the pharmaceutical industry. He served as a consultant to a number of pharmaceutical companies, co-founded and served as President and Chief Executive Officer and a member of the board of directors of Vicept Therapeutics, a dermatology-focused specialty pharmaceutical company, from 2009 until its acquisition by Allergan. Previously, Dr. Walker co-founded and led a number of life science companies including Octagon Research Solutions, Trigenesis Therapeutics, and Cutix.



Patricia S. Walker, MD/PhD

Dr. Walker is a Board-Certified Dermatologist and Pharmaceutical industry expert specializing in the fields of medical and aesthetic dermatology. Dr. Walker previously served as Chief Medical Officer of Kythera Biopharmaceuticals, Inc. and also was Executive Vice President and Chief Science Officer at Allergan Medical. From 1997 to 2004, Dr. Walker held positions at Allergan Inc. where she ultimately served as Vice President, Clinical Research and Development for skin care pharmaceuticals. Over the past 10 years, Dr. Walker was involved in key product approvals in dermatology and aesthetic medicine including the development and approval of Tazorac®, Azelex®, Avage®, BOTOX® Cosmetic, Hylaform®, Captique®, JUVEDERM®, Bioenterics®, LAP-BAND® and Inamed® Silicone gel-filled Breast Implants, and Kybella. Dr. Walker received an M.D. and a PhD in Physiology and Biophysics from the University of Iowa. Dr. Walker completed a residency in Dermatology and a research fellowship in the Dermatology Branch, National Cancer Institute at the National Institute of Health. Dr. Walker also maintains a private practice.



David Woodley, MD

Dr. Woodley completed his undergraduate degree in English Literature at Washington University in St. Louis and his medical school education at the University of Missouri in Columbia, Missouri. He completed his dermatology residency training at the University of North Carolina in Chapel Hill, North Carolina. He left Chapel Hill in 1989 to be Professor and Associate Chair of the Department of Dermatology at Stanford University. In 1992, he was appointed the Walter Hamlin Professor and Chair of Dermatology at Northwestern University. In 1999, he joined the medical faculty at the Keck School of Medicine of the University of Southern California (USC) and in 2004, he was named as the Founding Chair of the USC Department of Dermatology. He is the author of over 200 original articles and is a clinician-investigator with continuous NIH funding since 1982.

Irvin H. Blank Forum***Building Team Science: Creating a Culture of Diversity and Inclusion*****Wednesday, April 26, 2017 3:00 pm – 5:00 pm Oregon Ballroom 201-202****3:00 pm Welcome and Framing the Challenges****Barbara Gilchrest, MD**

Barbara A. Gilchrest, M.D., received her undergraduate and medical training from the Massachusetts Institute of Technology (MIT) and Harvard Medical School (HMS) respectively. After a post-doctoral fellowship in the laboratory of Howard Green at MIT, in 1977 Dr. Gilchrest joined the Department of Dermatology and Division on Aging at the HMS. From 1985 until 2008, Dr. Gilchrest served as Professor and Chairman of Dermatology at the Boston University School of Medicine, where she directed a large laboratory and an NIH-sponsored post-doctoral research training program. In 2015 she joined the Department of Dermatology at the Massachusetts General Hospital and HMS. She has served in leadership positions for all the major dermatologic organizations; on the National Advisory Council on Aging and the Board of Scientific Counselors of the National Cancer Institute; the Editor of the Journal of Investigative Dermatology, as Associate Editor or editorial board member of several other major clinical and research journals; as a consultant or scientific advisory board member for pharmaceutical and biotechnology companies; and as a member of the MIT Corporation (1995-2005). Dr. Gilchrest is a Fellow of the American Association for the Advancement of Science, an elected member of the National Academy of Medicine, and a Charter member of the National Academy of Inventors.

3:10 pm Susana Serrate-Sztejn, MD***The NIAMS Perspective***

Dr. Serrate-Sztejn is responsible for the Division of Skin and Rheumatic Diseases at the National Institute of Arthritis and Musculoskeletal and Skin Diseases. She oversees a large portfolio of grants and contracts dealing with etiology, pathogenesis, diagnosis, treatment and prevention of skin and rheumatic diseases. Dr. Serrate-Sztejn also directed the Common Fund Initiative on Patient Reported Outcomes Measurement Information Systems (PROMIS) and the National Institutes of Health (NIH) component of the ongoing private public partnership Accelerating Medicines Partnership (AMP) in rheumatoid arthritis and lupus. Between 1990 and 1993, Dr. Serrate-Sztejn was Chief, Autoimmunity Section, Division of Allergy Immunology and Transplantation, National Institute of Allergy and Infectious Diseases where she managed a scientific portfolio dealing with basic and translational research on immune mediated diseases. Before joining the NIH, Dr. Serrate-Sztejn was Assistant Professor, Department of Pathology, Uniformed Services University of the Health Sciences, in Bethesda Maryland where she worked on cytokine regulation of cell mediated immune responses. She received postdoctoral training at the laboratory of Immunodiagnosis, National Cancer Institute where she worked on natural killer cell activity against breast tumors in mice. Her clinical training is on anatomic and clinical pathology. Dr. Serrate-Sztejn is a graduate of Buenos Aires University School of Medicine.

3:20 pm Kimberly Kahn, PhD***Understanding and Counteracting Implicit Bias***

Dr. Kimberly Barsamian Kahn is an Assistant Professor of Social Psychology at Portland State University. She received her PhD in Social Psychology from the University of California, Los Angeles. Dr. Kahn's research addresses contemporary forms of implicit bias and subtle prejudice. Her work moves beyond studying broad categorical distinctions between groups to provide a more nuanced and fine-grained analysis of modern prejudice, stereotyping, and discrimination. Using experimental social psychological methods with diverse samples, her work addresses the psychological effects of subtle bias from multiple perspectives: the perceivers' perspectives, the targets' perspectives, and the social context.

CONTINUED ON NEXT PAGE



CONTINUED:

Irvin H. Blank Forum***Building Team Science: Creating a Culture of Diversity and Inclusion*****Wednesday, April 26, 2017 3:00 pm – 5:00 pm Oregon Ballroom 201-202****3:40 pm****Brian Gibbs, PhD/MPA*****Diversity in Research: Challenges & Opportunities***

Dr. Brian Gibbs serves as Vice President for Equity and Inclusion at Oregon Health & Science University (OHSU). In this position he serves as the chief diversity officer for the University, overseeing the Center for Diversity & Inclusion (CDI) and is responsible for diversity initiatives within the clinical, educational, and research missions.

4:00 pm**Charlene E. Le Fauve, PhD*****Enhancing Diversity in the Scientific Workforce: An Opportunity and Imperative for Excellence***

Charlene E. Le Fauve, PhD, became the first Senior Advisor to the National Institutes of Health (NIH) Chief Officer for Scientific Workforce Diversity (COSWD) in December 2016. In this role, Dr. Le Fauve supports Dr. Hannah Valentine who serves as the NIH COSWD as she leads NIH's effort to diversify the biomedical research workforce by developing a vision and comprehensive strategy to expand recruitment and retention, and promote inclusiveness and equity throughout the biomedical research enterprise. Dr. Le Fauve came to COSWD from the National Institute of Mental Health (NIMH) where she served as Deputy Director of the Office for Research on Disparities & Global Mental Health. Prior to joining NIMH, she was a Senior Policy Coordinator at the Department of Health and Human Services and also served as Branch Chief for the Co-occurring and Homeless Activities Branch at the Substance Abuse and Mental Health Services Administration, Division of State and Community Assistance. Before entering federal service, she served as an Assistant Professor of Human Genetics and Psychiatry at the Medical College of Virginia (MCV), Virginia Commonwealth University (VCU), with an adjunct position in the Department of Community Health and Preventive Medicine. Dr. Le Fauve studied clinical psychology and behavioral medicine at the University of Georgia after completing her undergraduate education at Howard University.

4:20 pm**Caroline Simard, PhD*****Creating Inclusive Workplaces: See Bias, Block Bias***

Caroline Simard is passionate about building better workplaces through evidence-based solutions. As Senior Director of Research at Stanford's Center for Advancement of Women's Leadership in the Clayman Institute of Gender Research, she is responsible for leading research designed to build more effective and inclusive organizations. Previously, she was Associate Director of Diversity and Leadership at the Stanford School of Medicine, where she implemented innovative models for increasing work-life integration to increase faculty satisfaction and retention. Prior to joining Stanford University, Caroline was Vice President of Research and Executive Programs at the Anita Borg Institute (ABI) for Women and Technology, where she led the creation and dissemination of research-based solutions to further gender diversity in scientific and technical careers, working with leading technology companies and academic institutions. Prior to ABI, Simard was a Researcher at the Center for Social Innovation of the Stanford Graduate School of Business and an Associate Director of Executive Programs. Caroline holds a PhD from Stanford University and a Masters from Rutgers University. Her publications have focused on technical human and social capital, solutions to recruit, retain, and advance women in technology, underrepresented minority talent in STEM, the diffusion of best practices, open innovation, and social networks.

4:40 pm**Closing Remarks**

Barbara Gilchrest, MD and Susana Serrate-Sztejn, MD

STATE-OF-THE-ART PLENARY LECTURES

LECTURE I

Chimeric Immunoreceptor T cells for Pemphigus: Fighting Autoimmunity with Immunity

Wednesday, April 26, 2017 5:00 pm – 5:30 pm Oregon Ballroom 201-202

Introduction by: Lloyd Miller, MD/PhD

Aimee Payne, MD/PhD

University of Pennsylvania, Philadelphia, PA



Dr. Payne is an Albert M. Kligman Associate Professor of Dermatology at University of Pennsylvania. She obtained her BS in Biology from Stanford University and received her MD/PhD (Molecular and Cellular Biology) Degrees from Washington University School of Medicine in St. Louis. Her career interest has been in pemphigus: diagnosing and treating patients with this potentially fatal autoimmune disease, and performing research to understand what causes disease, with the goal of improving therapy. Her laboratory has contributed to 5 major areas of investigation: 1) cloning and characterization of B-cell repertoires to understand how autoimmunity occurs in pemphigus, a model autoantibody-mediated skin blistering disease; 2) cell biologic studies to understand mechanisms for loss of cell adhesion; 3) collaborative research to advance clinical trials in autoimmune blistering disease; 4) clinical studies to better understand current diagnostic tests and therapies; and 5) translational research to develop novel targeted therapies. In addition to her research activities, she is a board certified dermatologist with a special focus on autoimmune blistering skin diseases.

LECTURE II

Identification of Hair Shaft Progenitors that Create a Niche for Hair Pigmentation and Graying

Wednesday, April 26, 2017 5:30 pm – 6:00 pm Oregon Ballroom 201-202

Introduction by: Kevin Wang, MD/PhD

Lu Le, MD/PhD

UT Southwestern Medical Center, Dallas, TX



Dr. Le is a Dermatologist with a scientific focus on neural-crest derived tissue development, regeneration and tumorigenesis, in particular the biology of neurofibromatosis. He graduated from the Medical Scientist Training Program at UCLA and completed residency training in Dermatology and a postdoctoral fellowship in Cancer Biology from UT Southwestern Medical Center. He is currently an Associate Professor and holds the Thomas L. Shield, MD Professorship in Dermatology at UT Southwestern.

OPEN TO ALL MEETING ATTENDEES

CME CREDITS: 0

PRESIDENT'S WELCOME

Angela Christiano, PhD

Wednesday, April 26, 2017 6:00 pm – 6:15 pm Oregon Ballroom 201-202





American Skin Association

American Skin Association (ASA Awards)

Wednesday, April 26, 2017 6:15 pm – 6:30 pm Oregon Ballroom 201-202

David Martin Carter Mentor Award

ASA's David Martin Carter Mentor Award honors a member of the dermatology community who embodies the characteristics of the late David Martin Carter, MD/PhD that made him an inspiration to many dermatologists/investigators, colleagues and medical students throughout the world.

*American Skin Association is delighted to present its'
2017 David Martin Carter Mentor Award to:*

Richard L. Edelson, MD
Yale School of Medicine

.....

Research Achievement Awards

Instituted in 1989 to identify established scientists in investigative dermatology and cutaneous biology and to recognize those who have greatly advanced work related to autoimmune and inflammatory skin diseases, skin cancer and melanoma, psoriasis, public policy and medical education, or vitiligo and pigment cell disorders.

*American Skin Association is delighted to present its'
2017 Research Achievement Awards to:*

Robert E. Tigelaar, MD
Yale School of Medicine

Research Achievement Award in Autoimmune & Inflammatory Skin Disorders

James G. Krueger, MD/PhD
Rockefeller University

Research Achievement Award in Psoriasis Research

Ruth Halaban, PhD

Yale School of Medicine

Research Achievement Award in Melanoma and Skin Cancer

Zalfa Abdel-Malek, PhD

University of Cincinnati Cancer Institute

Research Achievement Award in Vitiligo and Pigment Cell Biology

Henry W. Lim, MD

Henry Ford Health System

Research Achievement Award in Public Policy & Medical Education



Dermatology Foundation



Wednesday, April 26, 2017 6:30 pm – 6:35 pm Oregon Ballroom 201-202

The Foundation for all of Dermatology

For over fifty years, the Dermatology Foundation has been a major force in the development of the specialty's academic and scientific base.

The DF identifies and launches the early careers of promising new teachers, researchers and mentors in all aspects of the specialty, enabling advancements in patient care. With DF support, these individuals have the opportunity to begin the work needed to make major contributions to the specialty.

Earlier this year, the Foundation was proud to fund nearly **\$2.6 million** in research awards for **52** promising individuals.

Challenging Times

It is a very difficult time to pursue an investigative career in dermatology. While recently increased, NIH research funding in “real dollars” remains well below the level of support provided in 2003. New investigators are finding it tremendously discouraging to begin careers in the specialty, making the need for DF support urgent.

The Dermatology Foundation plays a crucial role in supporting and retaining emerging thought leaders. The DF's early career research awards enable today's newest generation of physician scientists to gain the experience and data needed to compete successfully for NIH grants.

DF support is effective in retaining tomorrow's leaders. Nearly **80%** of all career development awardees have remained in academics, and **74%** of these individuals received federal funding.

Individual Support is Essential

The need for DF research funding is critical and ongoing. Individual member support directly impacts the Foundation's ability to support tomorrow's new teachers and researchers.

To become a member or increase your support, visit **dermatologyfoundation.org**. There are many giving opportunities—and every option is meaningful and effective.



Albert M. Kligman / Phillip Frost Leadership Lecture *Memory T Cells and Protective Immunity: Lessons from the Smallpox Vaccine*

Wednesday, April 26, 2017

6:35 pm – 7:05 pm

Oregon Ballroom 201-202

Introduction by: Ervin Epstein, Jr., MD

Thomas S. Kupper, MD

**Brigham and Women's Hospital, Harvard Medical School
Boston, Massachusetts**



Dr. Kupper is the Thomas B. Fitzpatrick Professor of Dermatology at Harvard Medical School, Chair of the Departments of Dermatology at Brigham and Women's Hospital and the Dana Farber Cancer Institute, and Director of the Cutaneous Oncology Disease Center at the Dana Farber/Brigham and Women's Cancer Center (DFBWCC). He cares for Cutaneous T Cell Lymphoma patients, and leads the Cutaneous Lymphoma Program at the DFBWCC. For the past 30 years, he has been funded by the NIH to study skin immunology, inflammation, and skin cancer. His past NIH grants include a MERIT award, a Transformative Research Award, and a Skin Specialized Program of Research Excellence (SPORE). He is a past president of the SID, and is a past Montagna (SID), Sulzberger (AAD), Kihei (JSID) and Touraine (ESDR) lecturer, as well as a past Rook Orator (BJD). He was the founding Director of the BWH Biomedical Research Institute, and is a member of the ASCI and AAP, and is an honorary member of the JSID, the Korean SID, and the Austrian Dermatologic Society. He has made a number of pivotal scientific discoveries regarding epidermal cytokines, T cell trafficking, and T cell recruitment to the skin. Over the past 10 years, a major focus of his work has been on understanding the generation, long term maintenance, and protective properties of CD8 antiviral memory T cells in skin and other tissues. These cells are central to protective immune memory and are an important mechanism of action for successful vaccines. Their dysfunction may underlie many inflammatory dermatologic diseases.



LECTURESHIP HISTORY

Established in 2007 by Dr. Phillip Frost, the lectureship is intended to honor Dr. Albert M. Kligman, whose great commitment to dermatology and numerous contributions to the specialty has inspired generations of researchers and practitioners. The award is made to an individual in acknowledgment of significant contributions in the past five years to the understanding of structure and function of skin.



Thursday Sessions

PAGE TITLE

37	Meeting-At-A-Glance
38	Trainee/Faculty Breakfast
39	Pediatric Dermatology Research Alliance/ Society for Pediatric Dermatology Session
40	International Transplant Skin Cancer Collaborative (ITSCC) Symposium
41	Plenary Session I
42	Eugene M. Farber Lecture
43	Naomi M. Kanof Lecture
44	Come See My Poster I
45	Clinical Scholars Program Session I
46	Selected ePoster Discussions I
47	Aclaris Sponsored Symposium
49	debra of America's EB Symposium
50	Concurrent Mini-Symposium 1 Adaptive and Autoimmunity
51	Concurrent Mini-Symposium 2 Clinical Research: Pathophysiology and Therapeutics
52	Concurrent Mini-Symposium 3 Interdisciplinary Spotlight-Frontiers in Atopic Dermatitis
53	Concurrent Mini-Symposium 4 Pigmentation and Melanoma
54	Concurrent Mini-Symposium 5 Skin and Hair Developmental Biology

Social Event

Thursday, April 27, 2017**6:30 pm – 10:30 pm****World Trade
Center Portland**

Join us on Thursday, April 27, 2017 from 6:30 pm – 10:30 pm at the World Trade Center (WTC) Portland. WTC is regarded as one of the city's most elegant and spacious venues. This unique outdoor space is well known for providing a stunning ambiance, elegant backdrop and breathtaking views. On hand will be some of Portland's most popular food trucks, as well as craft beer and regional Oregon wines to enjoy!

TICKETED EVENT: PRE-REGISTRATION REQUIRED: \$75pp. For ticket availability please visit the registration desk in the Pre-Function A Foyer at the Oregon Convention Center.



Meeting-At-A-Glance

THURSDAY, APRIL 27, 2017

Trainee/Faculty Breakfast 7:00 am – 8:00 am
B110-112

Pediatric Dermatology Research Alliance/Society for Pediatric Dermatology Session 7:00 am – 8:00 am
A105-106

International Transplant Skin Cancer Collaborative (ITSCC) Symposium 7:00 am – 8:00 am
B117-119

Registration 7:30 am – 4:30 pm
Pre-Function A Foyer

Plenary Session I 8:00 am – 9:00 am
Oregon Ballroom 201-202

Eugene M. Farber Lecture 9:00 am – 9:30 am
From Genetic Discovery To Personalized Outcomes In Psoriasis
Jonathan Barker, MD

Naomi M. Kanof Lecture 9:30 am – 10:00 am
Targeting the Epigenome in Cutaneous and Disseminated Malignancies
James Bradner, MD

Come See My Poster I 10:00 am – 10:15 am
Poster #'s 046, 072, 096, 106, 148, 647, 661, 671, 777, 813, 901, 921
Oregon Ballroom 201-202

Clinical Scholars Program Session I 10:15 am - 12:00 pm
Base Pairs to Bedside- Personalized Medicine
Oregon Ballroom 201-202

Poster Session I/Coffee Break 10:15 am – 12:15 pm
Odd Poster #'s 625-935 Exhibit Hall A
Even Poster #'s 002-312
Odd Late-Breaking Poster #'s 987-1007
Even Late-Breaking Poster #'s 936-960

Selected ePoster Discussions I 10:45 am – 11:45 am
See Page #46 Exhibit Hall A Foyer

Aclaris Sponsored Symposium 12:00 pm – 1:45 pm
You Don't Know JAK
Oregon Ballroom 201-202

debra of America's EB Symposium 12:00 pm – 2:00 pm
B117-119

Concurrent Mini-Symposia 2:00 pm – 4:30 pm

1. Adaptive and Autoimmunity Oregon Ballroom 204
2. Clinical Research: Pathophysiology and Therapeutics Oregon Ballroom 203
3. Interdisciplinary Spotlight: Frontiers in Atopic Dermatitis B113-116
4. Pigmentation and Melanoma A105-106
5. Skin and Hair Developmental Biology C123-124

Mini-Symposia Mixers 4:30 pm – 5:00 pm
Individual Concurrent Meeting Rooms

Social Event 6:30 pm – 10:30 pm
World Trade Center Portland
Ticketed Event: Pre-Registration Required

ASSOCIATE
GROUPS ARE
LISTED IN GREEN

Trainee/Faculty Breakfast

Thursday, April 27, 2017

7:00 am – 8:00 am

B110-112

Throughout the years, the SID has encouraged meeting between Residents and Post-Doc Fellows. To continue this promotion of collegiality, the SID presents a Trainee/Faculty Breakfast – small group discussions in which senior and junior faculty Residents, Pre-Doctoral Students and Post-Doctoral Fellows-discuss issues in an informal atmosphere. These gatherings provide an opportunity to talk informally about subject matters of interest including research opportunities in dermatology, life in academia or how to combine clinical work with research.



PEDIATRIC DERMATOLOGY AT THE SID MEETING

Thursday, April 27, 2017

7:00 am – 8:00 am

A105-106

Coffee will be served

7:00 am

Welcome and Overview: Pediatric Dermatology at SID

Megha Tollefson, MD; Mayo Clinic

7:15 am



Something New Under the Sun for Tuberous Sclerosis Complex

Thomas Darling, MD/PhD; Professor and Chair of Dermatology,
Uniformed Services University of the Health Sciences

7:40 am

Rare constitutional variants influence phenotype of somatic cutaneous vascular malformations

Jenna Streicher, MD, et al.; Children's Hospital of Philadelphia.
Abstract #483

7:50 am

Discussion and Concluding Remarks

Special thanks to the Pediatric Dermatology Research Alliance (PeDRA) and the Society for Pediatric Dermatology (SPD) for supporting this session.



International Transplant Skin Cancer Collaborative (ITSCC) Symposium



Thursday, April 27, 2017

7:00 am - 8:00 am

B117-119

www.itsc.org

ITSCC's Mission: To integrate and support basic scientific and clinical research to address the special needs of immunosuppressed patients and organ transplant recipients with skin cancer in order to improve quality of care. To educate patients, scientists, primary care doctors and specialist physicians on the unique needs and clinical care issues in immunosuppressed and transplant patients.

PLENARY SESSION I

Presiders: Daniel Kaplan, MD/PhD and
Ethan Lerner, MD/PhD

Thursday, April 27, 2017 8:00 am – 9:00 am Oregon Ballroom 201-202

1. **Gut microbiota plays a role in the development of alopecia areata.** L. Nair, Z. Dai and AM. Christiano. New York, NY. *8:00 am, Abstract #649*
2. **Discovery of differential RNA binding and regulation by the APOL4 protein to disease-linked psoriasis CDSN gene variants using RaPID.** JD. Ransohoff, M. Ramanathan and PA. Khavari. Stanford, CA. *8:12 am, Abstract #408*
3. **Efficient *in vivo* gene editing using ribonucleoproteins in skin stem cells of recessive dystrophic epidermolysis bullosa mouse model.** W. Wu, Z. Lu, F. Li, W. Wang, N. Qian, J. Duan, Y. Zhang, F. Wang and T. Chen. Beijing, China. *8:24 am, Abstract #484*
4. **Targeting metabolic vulnerabilities of MDSCs to enhance the anti-tumor activity of PD-1 blockade in melanoma.** B. Zheng, S. Kim, M. Li and S. Trousil. Charlestown, MA. *8:36 am, Abstract #798*
5. **CD301b+ macrophages activate proliferation of CD29+;CD34+;Sca1+ fibroblasts through multiple secreted factors during wound healing.** B. Shook, G. Rivera Gonzalez, R. Wasko and V. Horsley. New Haven, CT. *8:48 am, Abstract #934*



EUGENE M. FARBER LECTURE*From Genetic Discovery To Personalized Outcomes In Psoriasis***Thursday, April 27, 2017****9:00 am – 9:30 am****Oregon Ballroom 201-202**

Introduction by: Nicole Ward, PhD

**Jonathan Barker, MD**St John's Institute of Dermatology, King's College
London, UK

Jonathan Barker is Professor of Medical Dermatology and Academic Head of Department at St John's Institute of Dermatology, King's College London. He is Co-Director of the Skin Therapy Research Unit and the Psoriasis Service at the Institute, a large tertiary referral service for patients with severe disease. His research interests extend from genetic discovery through to clinical outcome measurement. As such he is a key investigator in international consortia aiming to map psoriasis susceptibility genes and heads the International Psoriasis Council (IPC) exome consortium. He is deputy director of a multi-centre MRC stratified medicine programme in psoriasis outcomes to biologic therapy (PSORT) and heads its genetics working group. Professor Barker has published over 200 peer-reviewed papers, authored and edited several books including the new edition of the 'Rook Book'. Highly cited publications include those in Nature Genetics, American Journal of Human Genetics and New England Journal of Medicine. He sits on the editorials boards of several dermatology journals. He is past President of the European Dermatology Forum. Currently he is board member and chair scientific committee of IPC and President of the European Society for Dermatological Research.

**LECTURESHIP HISTORY**

The Eugene M. Farber endowment was established by the family of Eugene M. Farber, MD, who devoted his scientific career to understanding the pathogenesis of psoriasis. In 2007, the SID Board of Directors voted to create the Eugene M. Farber Endowed Lecture. It is presented at the Society's Annual Meeting by an investigator whose work is relevant to expanding our insights into the pathophysiology and treatment of psoriasis.

NAOMI M. KANOF LECTURE*Targeting the Epigenome in Cutaneous and Disseminated Malignancies***Thursday, April 27, 2017****9:30 am – 10:00 am****Oregon Ballroom 201-202**

Introduction by: Paul Nghiem, MD/PhD

**James Bradner, MD**

Novartis Institutes of BioMedical Research
Cambridge, Massachusetts

James (Jay) E. Bradner, MD is President of the Novartis Institutes for BioMedical Research (NIBR) and a member of the Executive Committee of Novartis. Prior to joining Novartis Dr. Bradner served on the research faculty of Harvard Medical School and as an attending physician in stem cell transplantation within the Department of Medical Oncology at the Dana-Farber Cancer Institute. The research focus of the Bradner laboratory has been the study of BET bromodomain proteins and their function in gene control, innovating chemical probes and investigational drugs to study and treat cancer. Dr. Bradner is a co-founder of five biotechnology companies and has co-authored more than 130 scientific publications and 30 United States patent applications. Dr. Bradner is a graduate of Harvard College and the University of Chicago Medical School. He completed residency in Medicine at Brigham & Women's Hospital, fellowship in Medical Oncology and Hematology at the Dana-Farber Cancer Institute and postdoctoral training in chemistry and chemical biology at Harvard University (Prof. Stuart Schreiber). He is the recipient of many honorific awards and was elected into the American Society of Clinical Investigation in 2011 and the Alpha Omega Alpha Honor Medical Society in 2013.

LECTURESHIP HISTORY

Established in 1988, this award was established to honor the memory of Naomi Kanof, MD. The Naomi M. Kanof Lectureship honors an individual making significant contributions to the improvement of health through clinical research. Clinical research is broadly defined as any scientific endeavor with a direct application to improving the prevention, diagnosis or treatment of clinical disease. This investigative work can be based in the laboratory and should be implemented or just ready to be implemented in clinical practice.

Come See My Poster I

Thursday, April 27, 2017

10:00 am – 10:15 am

Oregon Ballroom 201-202

Presider: Ethan Lerner, MD/PhD

The Come See My Poster sessions give opportunities to select presenting authors of highly scored abstracts to give a brief one-minute (and one slide) introduction to their submitted abstract. This rapid paced session leads right into one of the SID's Poster Sessions, providing both an excellent starting point into the Poster Hall and the generation of excitement for all attendees.

1. **Dynamic regulatory network controlling Tr1 cell development in epithelial tissue inflammation.**
A. Ho, A. Madi, N. Chihara, A. Regev and V. Kuchroo. Boston, MA and Cambridge, MA. 10:01 am, Abstract #046
2. **Type I interferon signaling suppresses the development of vitiligo as well as the response to melanoma immunotherapy.**
RL. Riding, K. Fukuda, JM. Richmond and JE. Harris. Worcester, MA. 10:02 am, Abstract #072
3. **Modulation of eIF4F complex assembly in Merkel cell carcinoma cells: Translational regulation of oncogenes and new therapeutic implications.**
J. Wu, H. Doan, R. Simonette, Q. He, P. Rady and S. Tying. Houston, TX. 10:03 am, Abstract #096
4. **Hedgehog signaling inhibitors fail to reduce merkel cell carcinoma viability.**
N. Hill, T. Carroll, J. Williams, K. Daily, T. Gelb, A. Coxon and I. Brownell. Bethesda, MD. 10:04 am, Abstract #106
5. **Combined activation of MAP kinase and beta-catenin signaling define deep penetrating nevi.**
M. Tee, U. Lang, E. Durieux, A. Jorapur, A. Shain, V. Haddad, D. Pissaloux, X. Chen, L. Cerroni, R. Judson, P. LeBoit, T. McCalmont, B. Bastian and A. de la Fouchardiere. San Francisco, CA; Lyon, France and Graz, Austria. 10:05 am, Abstract #148
6. **Skin microbiome and psoriasis: Staphylococcus induces robust biofilm formation by Aspergillus.**
PK. Mukherjee, J. Chandra, R. Sherif, M. Retuerto, MA. Ghannoum and T. McCormick. Cleveland, OH. 10:06 am, Abstract #647
7. **Characterization of the skin microbiota in rosacea.**
B. Rainer, E. Mongodin, J. Bui, AH. Fischer, H. Pasieka, LA. Garza, S. Kang and A. Chien. Graz, Austria and Baltimore, MD. 10:07 am, Abstract #661
8. **Characterization of the *in vivo* pharmacology of Oxymetazoline and Brimonidine using a mouse model of UV-induced erythema.**
E. Hsia, M. Tian and D. Gil. Irvine, CA. 10:08 am, Abstract #671
9. **Pro-apoptotic protein BIM influences PD-L1 expression in melanoma.**
N. Mukherjee, K. Lambert, M. Fujita, D. Norris and Y. Shellman. Aurora, CO. 10:09 am, Abstract #777
10. **Melanoma and chronic low dose ethinyl estradiol contraceptives in young women: A large midwestern U.S. patient population retrospective study.**
KA. Mueller, AE. Verzi, KA. Orrell, EL. Hagstrom, KS. Flood, BJ. Schlosser, K. Bhatt, B. Nardone and DP. West. Chicago, IL. 10:10 am, Abstract #813
11. **TSLP and SDF-1a/CXCR4 axis in skin fibrosis.**
J. Shin, S. Kim, H. Kim, W. Lee, J. Lee and K. Lee. New York, NY and Seoul, Republic of Korea. 10:11 pm, Abstract #901
12. **Laminin alpha 5 stimulates keratinocyte attachment and migration and wound repair.**
D. Castillo, S. Davis and J. Li. Miami, FL. 10:12 pm, Abstract #921

CLINICAL SCHOLARS PROGRAM SESSION I

Base Pairs to Bedside-Personalized Medicine

Thursday, April 27, 2017

10:15 am - 12:00 pm

Oregon Ballroom 201-202

10:15 am



Introduction

Doug Grossman, MD/PhD

Dr. Grossman is a Professor of Dermatology and an Investigator at the Huntsman Cancer Institute at the University of Utah. He received his undergraduate degree from Duke University and completed the Medical Scientist Training Program at Baylor College of Medicine in 1994. He completed his dermatology residency and postdoctoral research training at Yale University. Dr. Grossman's research focuses on tumor suppressors in melanoma and chemoprevention.

10:20 am

Mutations in KLHL24 add to the molecular heterogeneity of epidermolysis bullosa simplex

JY. W. Lee, L. Liu, C. Hsu, S. Aristodemou, L. Ozoemena, M. Ogboli, C. Moss, AE. Martinez, JE. Mellerio and J. McGrath. *Abstract # 515*.

10:35 am



Anthony Oro, MD/PhD

Cells as Drugs: Genetically modified Cell-based Therapies for Skin Diseases

As a practicing Dermatologist, Anthony Oro, MD/PhD has focused for the last 18 years on determinants of epithelial development, morphogenesis, and tumorigenesis using the skin as a model system. He has studied early embryonic development in *Drosophila*, focusing on the function of orphan nuclear receptors in pattern formation. As a post doc and now PI, he has studied the role of the hedgehog signaling pathway in skin and hair stem cell biology, hair stem cell regulation and patterning, and epithelial-mesenchymal regulation.

11:05 am



Keith Choate, MD/PhD

Genetic investigation of rare skin disorders reveals novel pathways for disease pathogenesis

Dr. Choate grew up in Connecticut and California and attended Caterbury School and Stanford University where he graduated in 3 years with honors in biological sciences in 1995. As a researcher in Paul Khavari's laboratory, he performed the first successful ex vivo gene therapy for the genetic skin disorder lamellar ichthyosis and came to Yale in 1996 to begin the Medical Scientist Training Program. He received the M.Phil ('00), PhD (Cell Biology, '01), and MD ('04, cum laude) before an internship at Yale-New Haven Hospital in Internal Medicine and residency in Dermatology. He pursued post-doctoral training in human genetics. Dr. Choate has published over 30 peer-reviewed articles in *Science*, *Nature*, *Human Molecular Genetics*, *The American Journal of Human Genetics*, *The Journal of Clinical Investigation*, *Nature Medicine*, and the *Journal of the American Academy of Dermatology*. He serves on committees for the Society for Pediatric Dermatology, the Pediatric Dermatology Research Alliance, the Society for Investigative Dermatology, the Yale Medical Scientist Training Program, and the American Board of Dermatology. His research is funded by the National Institutes of Health and the Foundation for Ichthyosis and Related Skin Types. Dr. Choate's laboratory is dedicated to understanding fundamental genetic and biologic pathways relevant to human disease.

11:35 am

The genomic landscape of sebaceous cell carcinoma

RJ. Cho, K. McMullen, D. Solomon, S. Benz, J. Golovato, B. Goode and JP. North. *Abstract # 114*.

11:50 am

Q & A



Selected ePoster Discussions I

Thursday, April 27, 2017 10:45 am – 11:45 am Exhibit Hall A Foyer

New to the 2017 SID Annual Meeting is “Selected ePoster Discussions.” In an effort to further increase participation and visibility of abstracts submitted to the Annual Meeting, the SID is pleased to add this new feature to the meeting.

Selected ePoster Discussions will take place during Poster Sessions that will occur on Thursday, Friday, and Saturday of the Annual Meeting at five (5) iPad terminals located outside of the Poster/Exhibit Hall. The discussions will be thematic tours of selected electronic posters accompanied by a presenting author. Each poster presenter will be asked to briefly describe their work (3 min), followed by a short group discussion (3 min), that will be held with the help of a moderator. If your poster has been selected for ePoster Discussions, please join the appropriate group at the relevant ePoster kiosk.

Topic	Poster Numbers
Clinical Research: Patient Outcomes Research <i>Moderator: Jonathan Silverberg, MD/MPH/PhD</i>	400, 371, 360, 382, 337, 342, 343, 350, 363, 379
Genetic Disease, Gene Regulation and Gene Therapy <i>Moderator: John McGrath, MD</i>	515, 487, 500, 518, 524, 529, 490, 496, 530, 532
Innate Immunity, Microbiology, Inflammation <i>Moderator: Delphine Lee, MD/PhD</i>	632, 635, 599, 628, 589, 608, 611, 564, 586, 616
Photobiology <i>Moderator: Richard Wang, MD/PhD</i>	792, 733, 725, 749, 486, 727, 744, 754, 751
Tissue Regeneration & Wound Healing <i>Moderator: Rivkah Isseroff, MD</i>	893, 906, 576, 894, 915, 920, 929, 914, 896



Aclaris Sponsored Symposium

You Don't Know JAK: Development of JAK inhibitors in Dermatology



Thursday April 27, 2017 12:00 pm - 1:45 pm Oregon Ballroom 201-202

12:00 pm **Welcome and Introduction**
John Harris, MD/PhD

12:05 pm **Paul Changelian, PhD**
Getting to know JAKs



Paul completed his undergraduate studies at the University of Michigan, received his PhD in Immunology at Harvard in 1979, and his postdoctoral fellowship at Washington University. He joined Pfizer 1989, in Groton, Connecticut with a focus on the identification of molecular targets that would lead to drugs for preventing renal transplant rejection and therapy for autoimmune disease. His lab developed a program to find JAK3 inhibitors, which led in 2000 to the discovery of CP-690,550 – a nanomolar inhibitor of JAK3. In 2003 they published work demonstrating efficacy of this compound in a rigorous model of renal transplantation in non-human primates. Expanding these studies to focus on autoimmune disease, CP-690,550 was renamed to facitininib, and approved in 2012 as Xeljanz – the first oral JAK kinase inhibitor for rheumatoid arthritis. Xeljanz is currently in clinical trials for psoriasis, ulcerative colitis, Crohn's disease and ankylosing spondylitis. After leaving Pfizer in 2007, Paul has worked as a consultant for several companies and is currently the head of biology at Confluence Life Science, a company focused on autoimmune disease and oncology.

12:15 pm **Jon Jacobsen, PhD**
JAKs be nimble: Building a Better Inhibitor



Dr. Jacobsen joined Confluence Life Sciences as Director of Chemistry in 2011. He is a trained organic chemist completing his undergraduate studies at Harvey Mudd College and PhD with Larry Overman at the University of California, Irvine. After post-doctoral studies with Wolfgang Oppolzer at the University of Geneva he joined the Upjohn Company in 1985. During his 25-year career in the pharmaceutical industry working with Upjohn, Pharmacia and Pfizer he successfully led drug discovery project teams that advanced multiple compounds from discovery into clinical development. Over his career, he worked on multiple projects within CNS, cancer, cardiovascular and inflammation disease areas. During the last ten years at Pfizer and Confluence his research has focused on the inhibition of multiple kinase targets involved in cancer and inflammation pathways.

12:35 pm **John Harris, MD/PhD**
See Spots Disappear: JAK Inhibitors in Vitiligo and Beyond



John E. Harris, MD/PhD, is an Associate Professor of Dermatology at the University of Massachusetts Medical School (UMMS) in Worcester, MA. He serves as Director of the Vitiligo Clinic and Research Center at UMMS, focusing both on the clinical management of vitiligo patients as well as research into new therapeutic strategies. His approach includes basic, translational, and clinical studies that incorporate the use of mouse models, human tissues, and small clinical trials that determine disease mechanisms of vitiligo, identify quantifiable markers of disease activity, and test new treatments. Previous work from his research team revealed that the IFN- γ signaling pathway is central to both the progression and maintenance of vitiligo, and recent studies in both mice and humans have demonstrated efficacy of new immunotherapies that target this pathway. Ongoing research seeks to better characterize the mechanism of action of these new treatments and to identify new targets in order to design an optimal therapeutic strategy for vitiligo patients, who currently have no FDA-approved treatment options. Long-term goals are to bring new treatments with better safety and efficacy into the clinic, to develop more durable, long-lasting treatments, and ultimately to find a cure for this psychologically devastating disease.

12:45 pm **Brian S. Kim, MD/MTR**
Scratch that Itch: JAK Inhibitors in Pruritus



Dr. Brian Kim is Assistant Professor of Dermatology, Anesthesiology, Pathology and Immunology, and Co-Director of the Center for the Study of Itch at Washington University School of Medicine in St. Louis. His laboratory focuses on innate immune mechanisms that underlie skin inflammation and the sensation of itch. Specifically, the Kim Lab identified previously unrecognized contributions of group 2 innate lymphoid cells (ILC2s) and basophils to the pathogenesis of atopic dermatitis (AD). These cells have emerged as critical sources of the type 2 cytokines IL-4, IL-5 and IL-13, which are now among the most important targets for biologic therapy in AD and other allergic disorders. Current studies in the Kim Lab are aimed at better understanding how innate immune cells and pro-inflammatory mediators specifically regulate the sensation of itch. These studies have broad therapeutic implications for numerous medical disorders that manifest as chronic itch. His research on the immune regulation of AD has led to awards and funding from the National Institutes of Health, Doris Duke Charitable Foundation, American Skin Association, American Academy of Dermatology and the American Society for Clinical Investigation.

CONTINUED ON NEXT PAGE

Continued

Aclaris Sponsored Symposium

You Don't Know JAK: Development of JAK inhibitors in Dermatology



Thursday April 27, 2017 12:00 pm - 1:45 pm Oregon Ballroom 201-202

12:55 pm

**Julian Mackay-Wiggan, MD/MPH*****Hair Raising Experiences: JAK Inhibitors in Alopecia***

Dr. Mackay-Wiggan is an Associate Professor of Dermatology, Director of the Clinical Research Unit, and the Dermatology Resident Clinic, in the Department of Dermatology at Columbia University, College of Physicians & Surgeons. She has primary responsibility for the development of protocols in clinical trials, compliance with regulatory requirements, and direct patient contact, including recruitment, evaluation, retention and safety of study subjects at Columbia University. Dr. Mackay-Wiggan completed a Master of Science in Biostatistics/Patient Oriented Research at the Columbia's Mailman School of Public Health. Over the past 15 years, Dr. Mackay-Wiggan has successfully designed and/or conducted over 50 clinical trials of all phases (phase 0-IV), ranging from topical applications of products to chemoprevention trials for multiple dermatologic indications. Dr. Mackay-Wiggan has an active focus on research into treatment options for alopecia areata (AA), including pilot trials to evaluate the efficacy of Intralesional steroids, abatacept, ruxolitinib and tofacitinib in the treatment of alopecia areata. Dr. Mackay-Wiggan has 2 FDA INDs related to AA trials. Many of the other trials Dr. Mackay has conducted are focused on diseases in which the immune system is known, or believed, to play a primary role and include studies funded by the NIH, investigator initiated studies and studies involving pharmaceutical companies. She also regularly evaluates and treats patients, and teaches residents the nuances of evaluation and treatment of a variety of hair disorders as well as general dermatologic conditions.

1:05 pm

**Vijendra Nalamothu, PhD*****JAK hammers: Topical Delivery for JAK Inhibitors***

Dr. Vijendra Nalamothu is CEO and Co-Founder of Tergus Pharma, the industry leader in topical formulation and development services, analysis, testing and cGMP clinical supply manufacturing. Dr. Nalamothu has been a leader in topical pharmaceutical development for more than two decades and holds several patents. His efforts have led to a number of successful commercial products. His passion is to develop products that speak for themselves. After earning his PhD in Pharmaceutics from the University of the Science's Philadelphia College of Pharmacy, he worked at Sanofi-aventis Worldwide Dermatology (Dermik) as the Head of the Early Compound Assessment and Preclinical Group. He has also served as Global Head of Dermatology R&D at Promius Pharma, a wholly-owned subsidiary of Dr. Reddy's Laboratories, where he spearheaded the development of specialty branded dermatological products from concept to commercialization. Dr. Nalamothu's interests include novel dosage form design and development of topical drug products. His commitment to quality and excellence led him to create the first Quality by Design (QbD) program for topicals, numerous articles and accolades. He is a sought-after speaker at conferences worldwide.

1:18 pm

Come to My Poster, JAK**Clinical investigation of JAK inhibitor Tofacitinib in scarring alopecias.**

Lindsey Bordone, MD, Columbia University, New York, NY *Abstract #075*

1:22 pm

Treatment of vitiligo with topical janus kinase inhibitor ruxolitinib.

Brooke Rothstein, Tufts Medical Center, Boston, MA *Abstract #770*

1:26 pm

Predictive modeling of drug response and mechanism of action in alopecia areata clinical trials.

James Chen, PhD Columbia University, New York, NY *Abstract #397*

1:30 pm

Panel Discussion and Q&A with Presenters**Stuart Shanler, MD**

Stuart D. Shanler, MD co-founded Aclaris Therapeutics, Inc. and has served as their Chief Scientific Officer since their inception in July 2012. Between July 2011 and July 2012, Dr. Shanler co-invented a topical rosacea drug for, and co-founded and served as Chief Scientific Officer of Vicept Therapeutics, Inc. from 2009 until its acquisition by Allergan, Inc. in July 2011. Previously, Dr. Shanler was a dermatologic surgeon in private practice. Dr. Shanler is a board-certified dermatologist and received his MD degree from Albany Medical College of Union University and received BS degrees in Biology and the Biological Basis of Behavior from the University of Pennsylvania.

**Neal Walker, DO**

Dr. Walker is a board certified dermatologist and serial entrepreneur with over 18 years of experience in the pharmaceutical industry. He served as a consultant to a number of pharmaceutical companies, co-founded and served as President and Chief Executive Officer and a member of the board of directors of Vicept Therapeutics, a dermatology-focused specialty pharmaceutical company, from 2009 until its acquisition by Allergan. Previously, Dr. Walker co-founded and led a number of life science companies including Octagon Research Solutions, Trigenesis Therapeutics, and Cutix.

debra of America's EB Symposium



Thursday, April 27, 2017

12:00 pm – 2:00 pm

B117-119

*Lunch will be served
Agenda is subject to change*

- 12:00 pm** **Welcome, Opening Remarks**
Jouni Uitto, MD/PhD
- 12:15 pm** **Keynote Lecture, What's new in EB Research: Clinical & Basic Science Advances**
John McGrath, MD
- 12:45 pm** **Development of New Technologies for EB Diagnosis & Treatment**
Moderator: Jouni Uitto, MD/PhD
Abstracts presented by:
Mahla Zahabiyon, *Abstract #521*
Ignacia Fuentes, *Abstract #512*
Amir Saeidian, *Abstract #509*
Jonathan O'Keeffe Ahern, *Abstract #532*
- 1:05 pm** **Gene Editing & CRISPr Based Approaches for EB**
Moderator: Katsuto Tamai, MD/PhD
Abstracts presented by:
Sean McGrath, *Abstract #527*
Joanna Jackow, *Abstract #858*
Shota Takashima, *Abstract #480*
Julie Reichelt, *Abstract #535*
- 1:25 pm** **Advances in Skin Cancer Research in EB**
Moderator: John McGrath, MD
Abstracts presented by:
Tran Nguyen, *Abstract #097*
Andrew South, *Abstract #122*
- 1:45 pm** **Perspectives & Closing Remarks**
Brett Kopelan, MA
Executive Director, debra of America

This symposium was supported in part by:
Amicus Therapeutics and Castle Creek Pharma



CONCURRENT MINI-SYMPOSIUM 1

Adaptive and Autoimmunity

Studies of adaptive immune responses involving T and B lymphocytes, dendritic cells, other antigen presenting cells, and antigen processing and presentation; Basic and pre-clinical experimental studies focused on autoimmunity.

Thursday, April 27, 2017

2:00 pm - 4:30 pm

Oregon Ballroom 204

Presiders: Niroshana Anandasabapathy, MD/PhD and Amanda MacLeod, MD

1. **Tissue resident memory T cell survival requires exogenous lipid uptake and metabolism.** Y. Pan, T. Tian, C. Park, SY. Lofftus, S. Mei, X. Liu, C. Luo, JT. O'Malley, A. Gehad, J. Teague, S. Divito, R. Fuhlbrigge, P. Puigserver, J. Krueger, G. Hotamisligil, R. Clark and T. Kupper. Boston, MA and New York, NY. 2:00 pm, Abstract #055
2. **Human melanoma TILs share phenotypic and transcriptional properties with tissue resident memory T cells.** K. Devi, M. Melssen, I. Tirosh, B. Izar, W. Olson, V. Engelhard, C. Slingluff, A. Regev, L. Garraway, T. Kupper, C. Yoon, M. Suarez-Farinas and N. Anandasabapathy. Boston, MA; Charlottesville, VA; Cambridge, MA and New York, NY. 2:12 pm, Abstract #062
3. **Vitiligo is maintained by antigen-specific resident memory t cells, which can be targeted to create a durable treatment response.** JM. Richmond, L. Zapata, M. Garg, J. Strassner, M. Rashighi, RL. Riding, M. Ahmed, K. Essien, L. Pell, P. Agarwal, N. Tsurushita and J. Tso. Worcester, MA and Mountain View, CA. 2:24 pm, Abstract # 047
4. **Alopecia areata is reversed by IL-7R α blockade via upregulation of the PD-1 signaling pathway.** Z. Dai, J. Cerise, J. Chen, L. Petukhova, A. de Jong, R. Clynes and AM. Christiano. New York, NY. 2:36 pm, Abstract #050
5. **Regulatory natural killer cells are protective in alopecia areata.** R. Clynes, Z. Dai, J. Cerise and AM. Christiano. New York, NY. 2:48 pm, Abstract #054
6. **Expression of α v β 8 by Langerhans cells is required for Th17 differentiation and tethering of LC in the epidermis.** S. Kashem, J. Mohammed and D. Kaplan. Minneapolis, MN and Pittsburgh, PA. 3:00 pm, Abstract #069
7. **Regulatory T cells drive stem cell differentiation during skin barrier repair.** A. Mathur, B. Zirak, M. Lowe, A. Abbas and M. Rosenblum. San Francisco, CA. 3:12 pm, Abstract #041
8. **IL-17RA and not IL-17RE is required for IL-17C-mediated psoriasiform inflammation.** SL. Sigurdardottir, Y. Fritz, P. Klenotic, X. Zhang, D. Diaconu, L. Zhang and NL. Ward. Cleveland, OH. 3:24 pm, Abstract #021
9. **Interferon kappa is required for regulation of baseline type I interferon responses in keratinocytes and is dysregulated in cutaneous lupus.** MK. Sarkar, X. Xing, A. Tsoi, Y. Liang, CC. Berthier, LW. Roberts, MT. Patrick, G. Hile, MA. Beamer, P. Tsou, PW. Harms, JT. Elder, JJ. Voorhees, A. Johnston, JM. Kahlenberg and JE. Gudjonsson. Ann Arbor, MI. 3:36 pm, Abstract #043
10. **Lupus Ro60 autoantigen cross-reactivity with commensal Ro60 orthologs.** T. Greiling, C. Dehner, X. Chen, K. Hughes, S. Vieira, W. Ruff, S. Sim, S. Wolin and M. Kriegel. Portland, OR and New Haven, CT. 3:48 pm, Abstract #068
11. **Fc γ RIIb is important for clonal ignorance and prevents pemphigus phenotype in pathogenic anti-desmoglein 3 antibody knock-in mice.** H. Nomura, Y. Kase, J. Yamagami, N. Wada, S. Koyasu, H. Takahashi and M. Amagai. Tokyo, Japan. 4:00 pm, Abstract #010
12. **Fli1-deficient B cells induce scleroderma-like vascular disorganization via activating pro-angiogenic gene program in dermal microvascular endothelial cells - A possible role in scleroderma vasculopathy.** R. Saigusa, Y. Asano, A. Yoshizaki, M. Trojanowska and S. Sato. Tokyo, Japan and Boston, MA. 4:12 pm, Abstract #005

Immediately following this session, a 30 minute mixer will be held. Presenters, moderators and attendees will be able to interact as they enjoy light refreshments and snacks. These mixers are designed to encourage informal discussion, mingling and networking among SID meeting attendees.



CONCURRENT MINI-SYMPOSIUM 2

Clinical Research: Pathophysiology and Therapeutics

Including studies involving human tissue and human cells that furthers our understanding of skin disease.

Thursday, April 27, 2017

2:00 pm – 4:30 pm

Oregon Ballroom 203

Presiders: Shawn Demehri, MD/PhD and Jean Tang, MD/PhD

1. **PD-1 blockade and T cell responses in merkel cell carcinoma.** NJ. Miller, C. Church, S. Fling, R. Kulikauskas, N. Ramchurren, M. Shinohara, M. Cheever, SL. Topalian and P. Nghiem. Seattle, WA and Baltimore, MD. 2:00 pm, Abstract #266
2. **PD-L1 expression is a positive prognostic factor in cutaneous angiosarcoma.** A. Otsuka, Y. Honda, S. Ono and K. Kabashima. Kyoto, Japan. 2:12 pm, Abstract #289
3. **Subcutaneous transplantation of allogenic mesenchymal stromal cells ameliorates intractable ulcers in recessive dystrophic epidermolysis bullosa patients.** K. Tamai, Y. Kikuchi, L. Zhang, Y. Komurasaki, T. Yamaoka and Y. Kaneda. Osaka, Japan. 2:24 pm, Abstract #329
4. **A randomized, double-blind, placebo-controlled crossover trial of levocarnitine for vis modegib-associated muscle spasms (NCT1893892).** JG. D Cannon, DC. Tran, S. Li and AL. S Chang. Palo Alto, CA; Redwood City, CA and Stanford, CA. 2:36 pm, Abstract #302
5. **An open label clinical trial of the JAK inhibitor tofacitinib for alopecia areata.** A. Jabbari, J. Cerise, JC. Chen, F. Sansaricq, R. Clynes, AM. Christiano and J. Mackay-Wiggan. New York, NY. 2:48 pm, Abstract #331
6. **An open label clinical trial of Abatacept (CTLA4-Ig) for alopecia areata.** F. Sansaricq, J. Mackay-Wiggan, A. Jabbari, AM. Christiano and R. Clynes. New York, NY. 3:00 pm, Abstract #320
7. **Preferential expression of PD-1 on malignant T cells of CTCL may underlie disease worsening in patients undergoing anti-PD1 therapy.** JT. O'Malley, A. Gehad, E. Lowry, J. Teague, N. LeBoeuf, T. Kupper and R. Clark. Boston, MA. 3:12 pm, Abstract #314
8. **Oral vitamin D3 5000IU as an adjuvant in the treatment of atopic dermatitis: A randomized controlled trial.** K. Sanchez Armendariz, A. Garcia Gil, J. Contreras Ruiz, M. Karam Orante and J. Dominguez Chérit. Mexico City, Mexico. 3:24 pm, Abstract #275
9. **The use of autologous cultured bone marrow-derived mesenchymal stem cells to treat venous ulcers: A pilot study.** A. Grada, M. Otero-Viñas, X. Lin, T. Yufit, P. Carson and V. Falanga. Boston, MA. 3:36 pm, Abstract #321
10. **Skin surface temperature detection with thermal imaging camera aids in cellulitis diagnosis.** A. Raff, L. Ko, A. Garza-Mayers, A. Dobry, R. Anderson and D. Kroshinsky. Boston, MA. 3:48 pm, Abstract #319
11. **Novel injectable coolant for treatment of pain.** L. Garibyan, E. Javorsky, Y. Wang, M. Purschke, W. Farinelli, T. Hequn, C. Evans and R. Anderson. Boston, MA. 4:00 pm, Abstract #253
12. **Multiphoton study of the impact on upper dermis of a 1 year daily solar exposure.** B. Ngo, E. Raynaud, S. Victorin, S. Brizion, T. Baldeweck, A. Pena, E. Tancrede and L. Aguilar. Paris, France and Aulnay, France. 4:12 pm, Abstract #264

Immediately following this session, a 30 minute mixer will be held. Presenters, moderators and attendees will be able to interact as they enjoy light refreshments and snacks. These mixers are designed to encourage informal discussion, mingling and networking among SID meeting attendees.



CONCURRENT MINI-SYMPOSIUM 3

Interdisciplinary Spotlight: Frontiers in Atopic Dermatitis

This session has been organized around a theme rather than a category and includes a full range of bench to bedside approaches.

Thursday, April 27, 2017

2:00 pm – 4:30 pm

B113-116

Presiders: Emma Guttman-Yassky, MD/PhD and Eric Simpson, MD

1. **Enhancement of Th2 polarization by Trim32 deficiency.** Y. Liu, Z. Wang, R. De La Torre, A. Barling, N. Hornick, J. Hanifin, E. Simpson and M. Kulesz-Martin. Portland, OR. 2:00 pm, Abstract #640
2. **PSM α as a key virulence in Staphylococcus aureus-induced skin inflammation through IL-36 and IL-1 release from keratinocytes.** S. Nakagawa, Y. Nakamura, G. Nunez and H. Matsue. Chiba, Japan and Ann Arbor, MI. 2:12 pm, Abstract #624
3. **Microbiome controls mast cell differentiation in the skin.** Z. Wang, N. Mascarenhas, L. Eckmann, Y. Miyamoto, X. Sun, T. Kawakami and A. Di Nardo. La Jolla, CA. 2:24 pm, Abstract #557
4. **Mutations in the epidermal fatty acid and ceramide metabolic pathway reveal functions of the Corneocyte-Bound Lipid Envelope (CLE).** PM. Elias, M. Man and D. Crumrine. San Francisco, CA. 2:36 pm, Abstract #439
5. **Regulation of lipid-specific T cell activation in human skin.** D. Lee, H. Jiang, W. Zeng, F. Kirscht, T. Kolster, S. Cremers and A. de Jong. New York, NY. 2:48 pm, Abstract #057
6. **Neuronal IL-4R α and JAK1 signaling mediate chronic itch.** L. Oetjen, M. Mack, T. Whelan, C. Guo, L. Yang, S. Hamilton, P. Wang, H. Niu, J. Feng, A. Xu, S. Tripathi, J. Luo, J. Brestoff, A. Shaffer, C. Hsieh, R. Gereau, M. Miller, H. Hu, S. Davidson, Q. Liu and B. Kim. St. Louis, MO and Cincinnati, OH. 3:00 pm, Abstract #580
7. **Targeted sequencing of filaggrin identifies novel loss-of-function mutations in pediatric African American patients with severe atopic dermatitis.** M. Mathyer, A. Quiggle, S. Bayliss, C. Wong, S. Denil, J. Common and C. de Guzman Strong. St. Louis, MO and Singapore, Singapore. 3:12 pm, Abstract #526
8. **Differential diversity of staphylococcal strains shapes cutaneous response in atopic dermatitis.** A. Byrd, C. Deming, S. Cassidy, O. Harrison, W. Ng, S. Conlan, Y. Belkaid, J. Segre and H. Kong. Bethesda, MD. 3:24 pm, Abstract #625
9. **A pathogenic role for Th22/IL-22 in atopic dermatitis is established by a placebo-controlled trial with an anti IL-22/ILV-094 mAb.** E. Guttman-Yassky, S. Khattri, PM. Brunner, A. Neumann, K. Malik, J. Fuentes-Duculan, S. Garcet, M. Suarez-Farinas, M. Lebwohl and JG. Krueger. New York, NY and Augsburg, Germany. 3:36 pm, Abstract #313
10. **Nitric oxide-releasing topical therapeutic agent for atopic dermatitis.** K. McHale, J. Gil, S. Davis, S. Hollenbach and N. Stasko. Morrisville, NC and Miami, FL. 3:48 pm, Abstract #709
11. **Tryptophan photoproduct 6-formylindolo[3,2-b]carbazole, FICZ, inhibits atopic dermatitis – A clue for photo-effectiveness to aryl hydrocarbon receptor.** M. Oda, H. Uchi, S. Morino-Koga and M. Furue. Fukuoka, Japan. 4:00 pm, Abstract #748
12. **Air pollution and incidence of eczema in elderly women.** W. Schnass, A. Hüls, A. Vierkötter, J. Xia, U. Krämer, J. Krutmann and T. Schikowski. Düsseldorf, Germany. 4:12 pm, Abstract #155

Immediately following this session, a 30 minute mixer will be held. Presenters, moderators and attendees will be able to interact as they enjoy light refreshments and snacks. These mixers are designed to encourage informal discussion, mingling and networking among SID meeting attendees.



CONCURRENT MINI-SYMPOSIUM 4

Pigmentation and Melanoma

Studies on all aspects of cutaneous and extracutaneous pigmentation; molecular cellular and biological facets of melanoma.

Thursday, April 27, 2017

2:00 pm – 4:30 pm

A105-106

Presiders: Marta Bertolini, PhD and Akinori Kawakami, MD/PhD

1. **LRP1 is a tumor promotor by inhibiting apoptosis in human melanoma.** Z. Zhai, W. Liu, Y. Shellman, D. Norris, C. Dinarello, R. Spritz and M. Fujita. Aurora, CO. 2:00 pm, Abstract #807
2. **SRCAP complex subunit YL1 as a novel epigenetic target in melanoma.** J. Dong, C. Vardabasso and E. Bernstein. New York, NY. 2:12 pm, Abstract #776
3. **Attenuated netrin-1 receptor mediated regulation of tiam1 is required for rac1 mutant melanoma progression.** MCG. Winge, J. Kovalski, NT. Nguyen, D. Wu, A. Zehnder, PA. Khavari and M. Marinkovich. Stanford, CA. 2:24 pm, Abstract #811
4. **Alpha-1 antitrypsin suppresses melanoma progression through immunological effects in the tumor microenvironment.** J. Samson, Y. Li, D. Pearson, Y. Luo, Z. Zhai, C. Dinarello and M. Fujita. Aurora, CO. 2:36 pm, Abstract #809
5. **Ablation of β -catenin signaling in stromal fibroblasts inhibits dynamic tumor-stromal interactions.** K. Yang, L. Zhou, A. Kadekaro and Y. Zhang. Cincinnati, OH. 2:48 pm, Abstract #833
6. **Coordinated changes in mitochondrial biogenesis, dynamics and metabolic tumor suppressor by cryptolepine, an alkaloid, leads to inhibition of melanoma cells growth.** HC. Pal, R. Prasad and SK. Katiyar. Birmingham, AL. 3:00 pm, Abstract #778
7. **Sestrin2 regulates metabolism reprogramming to protect melanoma cells from anoikis.** G. Zhu, P. Xu, T. Gao, G. Wang and C. Li. Xi'an, China. 3:12 pm, Abstract #818
8. **Myeloid derived suppressor cells are critical in increased melanoma progression in mice lacking BP180/collagen XVII function.** B. Hwang, Y. Zhang, B. Peng, N. Li, S. Williams, NE. Thomas, M. Su, L. Diaz and Z. Liu. Chapel Hill, NC. 3:24 pm, Abstract #805
9. **Loss of keratinocyte desmoglein 1 occurs during melanoma development and alters crosstalk between keratinocytes and melanocytes.** C. Arnette, JL. Johnson, JL. Koetsier and KJ. Green. Chicago, IL. 3:36 pm, Abstract #806
10. **Inhibition of isoprenylation synergizes with MAPK blockade to prevent growth in treatment-resistant melanoma.** N. Theodosakis, C. Langdon, G. Micevic, D. Stern and M. Bosenberg. New Haven, CT and Memphis, TN. 3:48 pm, Abstract #789
11. **CXCL5 and neutrophils determine metastatic routes in cutaneous melanoma.** A. Forsthuber, K. Lipp and R. Loewe. Wien, Austria. 4:00 pm, Abstract #783
12. **UVB and Poly(I:C) induce PAR-2 and enhance melanosome uptake by normal human epidermal keratinocytes through TLR3 signaling pathway.** S. Koike, K. Yamasaki, T. Yamauchi and S. Aiba. Sendai, Japan. 4:12 pm, Abstract #780

Immediately following this session, a 30 minute mixer will be held. Presenters, moderators and attendees will be able to interact as they enjoy light refreshments and snacks. These mixers are designed to encourage informal discussion, mingling and networking among SID meeting attendees.

CONCURRENT MINI-SYMPOSIUM 5

Skin and Hair Developmental Biology

Studies on the hair follicle, sebaceous gland, and other skin appendages; developmental biology of skin and hair; roles of stem cells in pre and post-natal growth and development.

Thursday, April 27, 2017

2:00 pm – 4:30 pm

C123-124

Presiders: Mayumi Ito, PhD and Maksim Plikus, PhD

1. **Spatiotemporal antagonism in mesenchymal-epithelial signaling in sweat versus hair fate decision.** CP. Lu, L. Polak, B. Keyes and E. Fuchs. New York, NY and South San Francisco, CA. 2:00 pm, Abstract #839
2. **BRAF activation induces sweat gland neogenesis in a WNT signaling dependent manner.** JY. Jin, T. Lechler and JY. Zhang. Durham, NC. 2:12 pm, Abstract #868
3. **After skin wounding, noncoding dsRNA coordinates prostaglandins and WNT7b to promote regeneration.** A. Zhu, A. Li, D. Kim, T. Ratliff, M. Melsom and LA. Garza. Houston, TX; Baltimore, MD and Cleveland, OH. 2:24 pm, Abstract #850
4. **Chromatin architectural protein CTCF controls epidermal barrier formation, hair follicle fate maintenance and suppresses inflammatory responses in the skin epithelium.** I. Malashchuk, J. Rudold, T. Vafaei, K. Poterliwicz, A. Sharov, M. Fessing, A. Mardaryev and V. Botchkarev. Bradford, United Kingdom and Boston, MA. 2:36 pm, Abstract #874
5. **Catalytic-dependent and -independent activities of Polycomb repressive complex 1 differentially regulate skin stem cell specification.** I. Cohen, J. Valdes, K. Dauber, C. Bar, D. Zhao, D. Zheng, W. Bickmore, H. Koseki and E. Ezhkova. New York, NY; Edinburgh, United Kingdom and Yokohama, Japan. 2:48 pm, Abstract #864
6. **WNT10A/ β catenin signaling is required for maintenance of Merkel cells in adult life.** M. Xu, Y. Choi, EE. Morrissey and SE. Millar. Philadelphia, PA and Boston, MA. 3:00 pm, Abstract #866
7. **Conditional ablation of JAK-STAT5 signaling induces anagen hair growth.** E. Wang and AM. Christiano. New York, NY. 3:12 pm, Abstract #865
8. **Early and late matrix progenitors form the terminally differentiated cell layers of the hair follicle.** A. Mesler, N. Veniaminova, M. Lull and S. Wong. Ann Arbor, MI. 3:24 pm, Abstract #840
9. **Ionizing radiation triggers dedifferentiation of outer root sheath cells into stem cell-like progenitors for hair follicle regeneration.** W. Huang, S. Lai, H. Chiu, M. Plikus and S. Lin. Taipei, Taiwan and Irvine, CA. 3:36 pm, Abstract #881
10. **Hair progenitor cells dictate hair pigmentation through non-cell autonomous KIT signaling.** C. Liao, RC. Booker, SJ. Morrison and LQ. Le. Dallas, TX. 3:48 pm, Abstract #853
11. **YBX1 mediated translational control of the senescence secretome in epidermal progenitors.** E. Kwon, K. Todorova, J. Wang, M. Hentze and A. Mandinova. Charlestown, MA and Heidelberg, Germany. 4:00 pm, Abstract #871
12. **Human hair follicle regeneration with trichogenic human dermal papilla precursor cells derived from induced pluripotent stem cells.** J. Kim, B. Kang, Y. Zheng, S. Jo, K. Kim, G. Cotsarelis and O. Kwon. Seoul, Republic of Korea and Philadelphia, PA. 4:12 pm, Abstract #857

Immediately following this session, a 30 minute mixer will be held. Presenters, moderators and attendees will be able to interact as they enjoy light refreshments and snacks. These mixers are designed to encourage informal discussion, mingling and networking among SID meeting attendees.



Friday Sessions

PAGE TITLE

57	Meeting-At-A-Glance
58	Pediatric Dermatology Research Alliance/ Society for Pediatric Dermatology Session
59	Plenary Session II
60	Stephen Rothman Memorial Award
61	Julius Stone Lecture
62	State-of-the-Art Plenary Lecture III & IV
63	Come See My Poster II
64	Business Meeting for Members
65	Selected ePoster Discussions II
66	International Eczema Council
67	International Psoriasis Council
68	American Dermato-Epidemiology Network (ADEN)
69	Medical Dermatology Society
70	International Society for Cutaneous Lymphomas/ Cutaneous T-Cell Lymphoma Symposium (ISCL/CTCL)
71	Research in Cutaneous Surgery Mini-Symposium
72	Concurrent Mini-Symposium 6 Clinical Research: Patient Outcomes Research
73	Concurrent Mini-Symposium 7 Genetic Disease, Gene Regulation and Gene Therapy
74	Concurrent Mini-Symposium 8 Innate Immunity, Microbiology, Inflammation
75	Concurrent Mini-Symposium 9 Photobiology
76	Concurrent Mini-Symposium 10 Tissue Regeneration and Wound Healing
77	Pfizer Symposium
78	National Eczema Association
79	North American Hair Research Society (NAHRS)
81	National Psoriasis Foundation Reception
82	SATO Japan Scientific Forum

Looking for a fun activity for the evening?

The city has many different neighborhoods with their own unique flare:

NORTHWEST PORTLAND/NOB HILL
Sophisticated shopping and dining destinations line these leafy avenues, accessible via the Portland Streetcar.



MISSISSIPPI/WILLIAMS

These vibrant North Portland avenue bustle with trend-setting shops, eateries, music spots and watering holes.



PEARL DISTRICT

This stylish neighborhood is filled with chic boutiques, galleries and eateries.



DOWNTOWN

The walkable city center is an energetic hub of eats, sightseeing, shopping and culture.



CENTRAL EASTSIDE

Find global flavors, local fashions and family fun in this dynamic industrial hub.

LLOYD DISTRICT

This transit-connected civic hub is home to many hotels, the Oregon Convention Center, Moda Center and the state's largest mall.

For more information about Portland please visit www.travelportland.com

Meeting-At-A-Glance

FRIDAY, APRIL 28, 2017

Women's Dermatologic Society

Networking & Breakfast 6:30 am – 7:15 am
Panel Discussion 7:15 am – 8:00 am
B117-119

Pediatric Dermatology Research Alliance/ Society for Pediatric Dermatology Session

7:00 am – 8:00 am
A105-106

Registration

7:30 am – 4:30 pm
Pre-Function A Foyer

Plenary Session II

8:00 am – 9:00 am
Oregon Ballroom 201-202

Stephen Rothman Memorial Award

9:00 am – 9:15 am
Presented to Oregon Ballroom 201-202
Amy Paller, MS/MD

Julius Stone Lecture

9:15 am – 9:45 am
Oregon Ballroom 201-202
Automated Discovery of Genetic Diseases by Saturation Mutagenesis in Mice
Bruce Beutler, MD

State-of-the-Art Plenary Lecture III

9:45 am – 10:15 am
Border Patrol and Melanoma: Keeping the Peace at a Cost?
Oregon Ballroom 201-202
Niroshana Anandasabapathy, MD/PhD

State-of-the-Art Plenary Lecture IV

10:15 am – 10:45 am
Oregon Ballroom 201-202
3D Bioprinting-An Emerging Paradigm in Tissue Engineering
Pankaj Karande, PhD

Come See My Poster II

10:45 am – 11:00 am
Poster #'s 033, 091, 107, Oregon Ballroom 201-202
127, 233, 279, 287, 348, 370, 424, 478, 512

Business Meeting for Members

11:00 am – 11:30 am
Oregon Ballroom 201-202

Poster Session II/Coffee Break

11:30 am – 1:30 pm
Odd Poster #'s 001-311 Exhibit Hall A
Even Poster #'s 314-624
Odd Late-Breaking Poster #'s 937-959
Even Late-Breaking Poster #'s 962-984

Selected ePoster Discussions II

See Page #65 12:00 pm – 1:00 pm
Exhibit Hall A Foyer

International Eczema Council

12:00 pm – 1:30 pm
Oregon Ballroom 204

International Psoriasis Council

12:00 pm – 1:30 pm
B113-116

American Dermato-Epidemiology Network (ADEN) Symposium

12:00 pm – 1:30 pm
B117-119

Medical Dermatology Society

12:00 pm – 1:45 pm
A105-106

International Society for Cutaneous Lymphomas / Cutaneous T-Cell Lymphoma Symposium (ISCL/CTCL)

12:00 pm – 1:30 pm
C123-124

Research in Cutaneous Surgery Mini-Symposium

12:00 pm – 1:30 pm
B112

Satellite Symposium

12:00 pm – 2:00 pm
Academic-Industry Partnership C120
Project (AIPP)
Individual Meetings (set up in advance by the SID)

Concurrent Mini-Symposia

2:00 pm – 4:30 pm
6. Clinical Research: Patient Outcomes Research Oregon Ballroom 204
7. Genetic Disease, Gene Regulation, Gene Therapy B113-116
8. Innate Immunity, Microbiology, Inflammation Oregon Ballroom 203
9. Photobiology C123-124
10. Tissue Regeneration and Wound Healing A105-106

Mini-Symposia Mixers

4:30 pm – 5:00 pm
Individual Concurrent Meeting Rooms

Pfizer Symposium

5:00 pm – 5:45 pm
Oregon Ballroom 201-202

National Eczema Association

6:00 pm – 7:00 pm
A105-106

North American Hair Research Society (NAHRS)

6:00 pm – 8:30 pm
Oregon Ballroom 203

National Psoriasis Foundation Reception

6:00 pm – 7:30 pm
B117-119

SATO Japan Scientific Forum

6:30 pm – 9:30 pm
C123-124

ASSOCIATE
GROUPS ARE
LISTED IN GREEN

Pediatric Dermatology at the SID Meeting

Friday, April 28, 2017

7:00 am - 8:00 am

A105-106

Coffee will be served

7:00 am

Introduction and Welcome

Amy Paller, MS/MD

Northwestern University

7:05 am

Association between pediatric psoriasis and cardiovascular risk in US children.

Jonathan Silverberg, MD/PhD/MPH, et al.; Northwestern University. *Abstract #238.*

7:15 am

Autoinflammation in Psoriasis

Johann Gudjonsson, MD/PhD

Professor of Dermatology, University of Michigan



7:40 am

Th17 and Th22 polarization in ichthyosis blood correlates with disease severity and highlights its systemic nature.

Tali Czarnowicki, MD/MSc, et al; Icahn School of Medicine at Mt. Sinai. *Abstract #073.*

7:50 am

Discussion and Concluding Remarks

Special thanks to the Pediatric Dermatology Research Alliance (PeDRA) and the Society for Pediatric Dermatology (SPD) for supporting this session.

PLENARY SESSION II

Presiders: Nicole Ward, PhD and Victoria Werth, MD

Friday, April 28, 2017

8:00 am – 9:00 am

Oregon Ballroom 201-202

1. **Completed suicide in patients with hidradenitis suppurativa: A population analysis in the United States.** A. Garg, H. Pomerantz, M. Midura, V. Papgermanos, A. Strunk, J. Merson and A. Alloo. New Hyde Park, NY. *8:00 am, Abstract #222*
2. **Biased CXCR3 ligands differentially alter allergic contact hypersensitivity and chemotaxis.** JS. Smith, L. Nicholson, J. Suwanpradid, R. Glenn, J. Gundry, P. Alagesan, N. Knape, AR. Atwater, MD. Gunn, AS. MacLeod, RJ. Lefkowitz and S. Rajagopal. Durham, NC. *8:12 am, Abstract #678*
3. **Analysis of molecular etiology and bacterial triggers of cutaneous T cell lymphoma.** M. Fanok, A. Sun, L. Fogli, V. Narendran, W. Sause, K. Kannan, I. Dolgalev, A. Heguy, Y. Fulmer, M. Sundrud, J. Kutok, N. Odum, S. Goel, J. Latkowski, V. Torres, K. Hymes, B. Shopsin and S. Koralov. New York, NY; Jupiter, FL; Boston, MA and Copenhagen, Denmark. *8:24 am, Abstract #149*
4. **Influence of FLG mutations and TSLP polymorphisms on atopic dermatitis onset age.** J. Wan, N. Mitra, OJ. Hoffstad and DJ. Margolis. Philadelphia, PA. *8:36 am, Abstract #197*
5. **Brentuximab vedotin demonstrates superior activity to standard therapy in CD30-expressing (CD30+) cutaneous T-cell lymphoma (CTCL) in the randomized phase 3 ALCANZA study.** YH. Kim, S. Whittaker, SM. Horwitz, M. Duvic, R. Dummer, J. Scarisbrick, P. Quaglino, P. Zinzani, P. Wolter, Y. Wang, M. Palanca-Wessels, E. Zagadailov, WL. Trepicchio, H. Lin, M. Little and H. Prince. Stanford, CA; London, United Kingdom; New York, NY; Houston, TX; Zürich, Switzerland; Birmingham, United Kingdom; Turin, Italy; Bologna, Italy; Leuven, Belgium; Bothell, WA; Cambridge, MA and Melbourne, Australia. *8:48 am, Abstract #262*

STEPHEN ROTHMAN MEMORIAL AWARD


Friday, April 28, 2017**9:00 am – 9:15 am****Oregon Ballroom 201-202**

Introduction by: Angela Christiano, PhD

**Amy Paller, MS/MD**

Northwestern University Feinberg School of Medicine
Chicago, IL

Amy Paller, MS/MD is the Walter J. Hamlin Professor and Chair, Professor of Pediatrics, and Director of the Skin Disease Research Center at Northwestern University's Feinberg School of Medicine. She received her undergraduate and graduate degrees from Brown University and her medical degree from Stanford University. Dr. Paller completed residency training in both Pediatrics and Dermatology at Northwestern University and her postdoctoral research fellowship at the University of North Carolina. She served as Chief of Dermatology at the Lurie Children's Hospital of Chicago prior to becoming Chair of Northwestern's Dept of Dermatology. An author of more than 350 peer-reviewed publications, Dr. Paller currently serves on Council for the National Institute for Arthritis, Musculoskeletal and Skin Diseases. Her NIH-funded laboratory focuses on the use of nanotechnology for topically applied gene regulation in treating skin disorders and on the role of glycosphingolipids in regulating signaling. Dr. Paller also directs the Pediatric Dermatology Clinical Trials Unit at Northwestern, has been a pioneer in discovery related to diagnosis and therapy of genetic skin disorders, and has been the lead investigator on several landmark papers related to inflammatory skin disease. Dr. Paller has served on the Board of the American Academy of Dermatology and American Dermatological Association, as inaugural co-Chair of the Pediatric Dermatology Research Alliance, and as President and Board of Directors of the Society for Investigative Dermatology, Society for Pediatric Dermatology, Women's Dermatologic Society, International Eczema Council, and Chicago Dermatological Society. She is co-author of Hurwitz's Clinical Pediatric Dermatology and an Associate Editor of the Journal of Investigative Dermatology. Among recently received honors are the Clarence S. Livingood, MD Memorial Award from the American Academy of Dermatology, the Mentor of the Year Award and Rose Hirschler Award from the Women's Dermatological Society, and the Founder's Award from the Chicago Dermatological Society.

**AWARD HISTORY**

The Stephen Rothman Memorial Award is presented annually for distinguished service to investigative cutaneous medicine. The recipient of this award has made major scientific achievements and excelled as a teacher and recruiter of outstanding dermatologists. The recipient is an individual who has distinctly altered the course and image of dermatology or its allied fields. It is the Society's highest award.

JULIUS STONE LECTURE*Automated Discovery of Genetic Diseases by Saturation Mutagenesis in Mice***Friday, April 28, 2017****9:15 am – 9:45 am****Oregon Ballroom 201-202**

Introduction by Ponciano Cruz, MD

**Bruce Beutler, MD**

UT Southwestern Medical Center
Dallas, TX

Bruce A. Beutler, MD, who shared the 2011 Nobel Prize in Physiology or Medicine, is an internationally recognized leader in immunology and the Director of the Center for the Genetics of Host Defense at UT Southwestern Medical Center. Drs. Beutler and Jules A. Hoffmann of Strasbourg University in France shared the Nobel Prize “for their discoveries concerning the activation of innate immunity,” the first step in the body’s immune response. The late Dr. Ralph M. Steinman of Rockefeller University in New York was also honored in 2011. Dr. Beutler is known for his work in unlocking the secret of how the body detects infection and launches an inflammatory response. His current endeavors involve an attempt to identify every gene involved in the response to potentially infectious agents like bacteria or viruses. At UT Southwestern, Dr. Beutler runs one of the largest mouse mutagenesis programs in the world. He and his group have tracked down several hundred mutations that cause abnormalities in mice. Many of these mutations have important implications in infectious diseases or autoimmune conditions in which the body turns on itself, such as lupus and rheumatoid arthritis. Dr. Beutler’s team also has identified many thousands of other genetic mutations that form the nucleus of a mutation archive that eventually will encompass all mouse genes. Dr. Beutler, a Regental Professor at UT Southwestern who holds the Raymond and Ellen Willie Distinguished Chair in Cancer Research, in Honor of Laverne and Raymond Willie Sr., earned his medical degree from the University of Chicago after graduating from the University of California, San Diego. His postgraduate career at UT Southwestern includes an internal medicine internship and neurology residency. During a brief fellowship and faculty appointment at Rockefeller University, Dr. Beutler isolated tumor necrosis factor, one of the most important mediators of inflammation. He then returned to UT Southwestern as a faculty member and Howard Hughes Medical Institute Investigator from 1986 to 2000. His seminal work during this period was broadly relevant to host responses to viral infection, cancer, and autoimmunity, and ultimately led to the Nobel Prize. Between 2000 and 2011, Dr. Beutler was at The Scripps Research Institute in La Jolla, Calif.

**LECTURESHIP HISTORY**

The Julius Stone Lectureship is intended to promote the advancement of knowledge in immunology as it relates to the skin and skin disease. The Lectureship is intended to honor Dr. Julius Stone, whose great commitment to the application of new principles of immunology to the benefit of patients with skin disorders is recognized by this award.



STATE-OF-THE-ART PLENARY LECTURES

LECTURE III

Border Patrol and Melanoma: Keeping the Peace at a Cost?

Friday, April 28, 2017

9:45 am - 10:15 am

Oregon Ballroom 201-202

Introduction by: Peggy Myung, MD/PhD



Niroshana Anandasabapathy, MD/PhD
Brigham and Women's Hospital
Boston, MA

Dr. Niroshana Anandasabapathy is an investigative physician scientist-formally trained in clinical translation, cancer biology, immunology and Dermatology. She attended medical school at Stanford University and completed her residency at NYU Medical Center. Her research program broadly investigates how mechanisms of tissue homeostasis in peripheral tissues such as skin lead to tumor immune escape of skin cancers. She is a faculty member of the BWH Department of Dermatology post-doctoral scholarship oversight committee, the Harvard Stem Cell Institute, and Harvard Program in Immunology.

LECTURE IV

3D Bioprinting- An Emerging Paradigm in Tissue Engineering

Friday, April 28, 2017

10:15 am - 10:45 am

Oregon Ballroom 201-202

Introduction by: Spiro Getsios, PhD



Pankaj Karande, PhD
Rensselaer Polytechnic Institute
Troy, NY

Dr. Karande joined Rensselaer Polytechnic Institute in 2008 as an Assistant Professor in the Chemical and Biological Engineering Department. Before coming to Rensselaer, Dr. Karande was the Anna Fuller Postdoctoral Fellow in Molecular Oncology (2006-2008) at the Center for Cancer Research at Massachusetts Institute of Technology. He received his PhD at University of California, Santa Barbara (2006) in the area of transdermal drug delivery. His doctoral work at Santa Barbara focused on rational and combinatorial design of permeation enhancers for the delivery of proteins and polypeptides across the skin. Dr. Karande holds several patents in the area of transdermal formulation design, drug delivery formulations, development of high throughput screening platforms, and novel drug delivery systems. His current research interests include 3D Biofabrication of organs and tissues, and novel drug delivery formulations.

Come See My Poster II

Friday, April 28, 2017

10:45am – 11:00 am

Oregon Ballroom 201-202

Presider: Victoria Werth, MD

The Come See My Poster sessions give opportunities to select presenting authors of highly scored abstracts to give a brief one-minute (and one slide) introduction to their submitted abstract. This rapid paced session leads right into one of the SID's Poster Sessions, providing both an excellent starting point into the Poster Hall and the generation of excitement for all attendees.

1. **Semaphorin 4D enhances antibody production in bullous pemphigoid.**
S. Shen, Y. Ke, E. Dang, H. Fang and G. Wang. Xi'an, China. 10:46 am, Abstract #033
2. **Vemurafenib impairs the repair of UV radiation induced DNA damage.**
S. Kimeswenger, D. Foedinger and C. Jantschitsch. Vienna, Austria. 10:47 am, Abstract #091
3. **Inherited cancer susceptibility mutations in individuals who develop high frequency of basal cell carcinomas.**
H.G. Cho, KY. Kuo, E. Epstein, JY. Tang and KY. Sarin. Stanford, CA and Oakland, CA. 10:48 am, Abstract #107
4. **UV-signature mutations in the nuclear pore complex are elevated in squamous cell carcinoma in situ and adjacent epidermis.**
S. Prouty, Q. Zheng, V. Anagnos, A. Chen, P. Barriera, H. Bashir, M. Pack, M. Capelson, E. Grice and J. Seykora. Philadelphia, PA. 10:49 am, Abstract #127
5. **Medicare Part D payments for topical steroids: Rising costs and potential savings.**
H. Song, A. Adamson and A. Mostaghimi. Boston, MA and Chapel Hill, NC. 10:50 am, Abstract #233
6. **Phase I study of the nivolumab combined with IFN-B in patients with advanced melanoma.**
T. Fujimura, Y. Kambayashi, S. Furudate, T. Hidaka and S. Aiba. Sendai, Japan. 10:51 am, Abstract #279
7. **MicroRNA based classifiers in diagnosis and prognosis of cutaneous T cell lymphoma.**
B. Wang, X. Shen and J. Zheng. Shanghai, China. 10:52 am, Abstract #287
8. **Histopathologic review of negative sentinel lymph node biopsies in thin melanomas: An argument for the routine use of immunohistochemistry and serial sectioning.**
A. Hickman, A. Stowman, A. Gru and C. Slingluff. Charlottesville, VA. 10:53 am, Abstract #348
9. **Infiltration of PD-1+ cells is a poor prognostic factor in invasive extramammary Paget disease.**
N. Iga, A. Otsuka and K. Kabashima. Kyoto, Japan. 10:54 am, Abstract #370
10. **Sensitive skin is highly frequent in atopic dermatitis and correlates with disease severity markers but not necessarily with skin barrier assessments.**
T. Yatagai, T. Shimauchi, H. Yamaguchi, J. Sakabe, M. Aoshima, S. Ikeya, K. Tatsuno, T. Fujiyama, T. Ito and Y. Tokura. Hamamatsu, Japan. 10:55 am, Abstract #424
11. **Mutation-specific siRNA Knockdown of GJB2 - Potential gene therapy for Keratitis-ichthyosis-deafness Syndrome.**
M. Lee, VA. Kinsler, SL. Hart and W. Di. London, United Kingdom. 10:56 am, Abstract #478
12. **Determining the genetic basis of epidermolysis bullosa symptoms through genotype-phenotype associations and NGS.**
I. Fuentes, M. Yubero, C. Fuentes, M. Mc Nab, S. Krämer, A. Kantor, F. Mellado, A. Klaussegger, J. Bauer, R. Cornwall and F. Palisson. Santiago, Chile; Salzburg, Austria and Cincinnati, OH. 10:57am, Abstract #512



Business Meeting For Members

Friday, April 28, 2017**11:00 am – 11:30 am****Oregon Ballroom 201-202**

Honory Membership is one of the highest honors the Society for Investigative Dermatology (SID) bestows. Each of the following SID Members has made sustained and important contributions to the research base in cutaneous biology and has contributed to the organizational success of the SID. Each has also excelled in their role as a mentor to numerous individuals over the course of their academic career.

Congratulations to Drs. Irene Leigh and Douglas Lowy on their appointment to SID Honorary Membership!

**Irene Leigh, MD**

University of Dundee
Dundee, Scotland

Dr. Leigh is a Professor at the University of Dundee, and her research has centered around all aspects of keratinocyte biology from studying basic epithelial differentiation into disease applications, particularly the molecular mechanisms of skin cancer, genetic disease and tissue engineering and she is widely recognized as an international leader in those fields. Her group has made major contributions to the understanding and treatment of human disease, including Recessive Dystrophic Epidermolysis Bullosa, Non-Melanoma Skin Cancers, and Wound Healing. She was also the Local Chair for the 2013 International Investigative Dermatology meeting in Edinburgh.

**Douglas Lowy, MD**

National Cancer Institute
Bethesda, MD

Dr. Lowy served as NCI Deputy Director from 2010 to 2015. In addition to serving as Acting NCI Director, Dr. Lowy is chief of the Laboratory of Cellular Oncology in NCI's Center for Cancer Research. He is a member of the National Academy of Sciences (NAS) and a member of the Institute of Medicine of the NAS. Dr. Lowy received the Federal Employee of the Year Service to America Medal from the Partnership for Public Service in 2007, and the Sabin Gold Medal Award from the Sabin Vaccine Institute in 2011. In November 2014, he was honored by President Obama with the National Medal of Technology and Innovation.

Selected ePoster Discussions II

Friday, April 28, 2017

12:00 pm – 1:00 pm Exhibit Hall A Foyer

New to the 2017 SID Annual Meeting is “Selected ePoster Discussions.” In an effort to further increase participation and visibility of abstracts submitted to the Annual Meeting, the SID is pleased to add this new feature to the meeting.

Selected ePoster Discussions will take place during Poster Sessions that will occur on Thursday, Friday, and Saturday of the Annual Meeting at five (5) iPad terminals located outside of the Poster/Exhibit Hall. The discussions will be thematic tours of selected electronic posters accompanied by a presenting author. Each poster presenter will be asked to briefly describe their work (3 min), followed by a short group discussion (3 min), that will be held with the help of a moderator. If your poster has been selected for ePoster Discussions, please join the appropriate group at the relevant ePoster kiosk.

Topic	Poster Numbers
Carcinogenesis and Cancer Genetics <i>Moderator: Masaaki Kawasumi, MD/PhD</i>	105, 114, 137, 143, 123, 120, 122, 140, 097, 095
Clinical Research: Epidemiology of skin diseases <i>Moderator: Robert Dellavalle, MD/PhD</i>	181, 190, 193, 159, 165, 174, 209, 217, 220, 227
Epidermal Structure and Barrier Function <i>Moderator: Theodora Mauro, MD</i>	636, 602, 410, 414, 456, 451, 438, 428, 403
Growth Factors, Cell Adhesion and Matrix Biology <i>Moderator: James Elder, MD/PhD</i>	551, 563, 543, 553, 552, 550, 555, 560, 561, 627
Pharmacology and Drug Development <i>Moderator: Michael Girardi, MD</i>	666, 675, 689, 704, 712, 722, 669, 694, 696, 701





International Eczema Council at the SID Meeting

Friday, April 28, 2017

12:00 pm – 1:30 pm

Oregon Ballroom 204

LUNCH WILL BE SERVED

12:00 pm

Welcome/Overview of the IEC and Roadmap of AD at the SID

Amy Paller

IEC President, Northwestern University, Chicago, IL, USA

12:10 pm

Abstract Presentations

Increased interleukin-19 expression in cutaneous T-cell lymphoma as well as atopic dermatitis. *Oka Tomonori et al. Univ. of Tokyo, Tokyo, Japan #256*

Cutaneous acquisition of *Staphylococcus quorum-sensing agr* mutations protects against atopic dermatitis development. *Yuumi Nakamura et al., Chiba Univ., Chiba, Japan. #623*

The serum proteomic signature of pediatric AD suggests early Th2/Th17 skewing and an inverse correlation of disease severity with Th1 markers. *Patrick Brunner et al. Rockefeller Univ., New York, NY, USA #642*

12:45 pm

Special Presentation:

The precise control of skin barrier homeostasis

Masayuki Amagai, Keio University, Tokyo, Japan



1:10 pm

Abstract Presentations

Bleach baths promote early induction of inflammatory pathway genes with no effect on skin bacterial dysbiosis in AD subjects. *Sara Knowlden et al., Univ. of Rochester, Rochester, NY, USA #296*

Treatment interruption did not impact efficacy or long-term safety of dupilumab: A phase 3 open-label trial. *Lisa Beck et al. Univ. of Rochester, Rochester, NY, USA #251*

Special thanks to the International Eczema Council for supporting this session.



International Psoriasis Council Symposium: Scientific and Clinical Advances in Psoriasis: 2017 and Beyond



Advancing Knowledge
Enhancing Care

Friday, April 28, 2017

12:00 pm – 1:30 pm

B113-116

This symposium will explore recent advances in the understanding of both the innate and adaptive immune pathways leading to the psoriasis phenotype. Global experts will present evidence describing the functional roles of novel cellular (neutrophils and Tregs) and molecular (Act1) drivers and their contribution to the inflammatory response. In addition, this symposium will highlight new epidemiological evidence demonstrating increased risk of comorbid development in children with psoriasis and premature death in adult patients with severe psoriasis.

PROGRAM CO-CHAIRS

Andrew Blauvelt, MD, MBA – Portland, Oregon

Oregon Medical Research Center

Johann Gudjonsson, MD, PhD – Ann Arbor, Michigan

University of Michigan

CONTRIBUTING CHAIR

Hervé Bachelez, MD, PhD – Paris, France

Hôpital Saint-Louis & Sorbonne Paris Cité Université

To view the full program agenda, please visit www.psoriasisCouncil.org/sid2017.

About the International Psoriasis Council (IPC)

Founded in 2004, the International Psoriasis Council (IPC) is a dermatology-led, voluntary, global nonprofit organization dedicated to innovation across the full spectrum of psoriasis through research, education and patient care.

Mission

IPC's mission is to advance the care of people with psoriasis world-wide, through education, research and advocacy.



American Dermato-Epidemiology Network (ADEN) Symposium



Friday, April 28, 2017

12:00 pm - 1:30 pm

B117-119

12:00 pm	Welcome and introductions
12:05 pm	Founders Award Presentation
12:25 pm	Trainee awards
12:30 pm	Natural history of basal cell carcinoma: A longitudinal study of clinically suspicious lesions in Ikaria, Greece #185
12:40 pm	Disparities in the incidence and survival of eccrine malignancies in the United States #167
12:50 pm	Global skin disease morbidity and mortality: An update from the Global Burden of Disease Study 2013 #181
1:00 pm	Real world systemic corticosteroid (SCS) utilization patterns and costs in adult patients with atopic dermatitis (AD) #243
1:10 pm	Influence of market competition on Tetracycline pricing and impact of price increases on clinician prescribing behavior #165
1:20 pm	ADEN business meeting

Medical Dermatology Society at the Society For Investigative Dermatology



Friday, April 28, 2017

12:00 pm - 1:45 pm


A105-106



DANIELA KROSHINSKY, MD/MPH
MDS President
Massachusetts General Hospital



JANET FAIRLEY, MD
MDS Immediate Past-President
University of Iowa Hospitals
and Clinics



ADELA RAMBÍ CARDONES, MD
MDS Board of Directors
Duke University

12:00 pm Introduction and Welcome

12:05 pm Psoriasis age of onset: Effect on treatment outcomes in the PSOLAR registry. Sanminder Singh, University of California, Davis. *Abstract #189*

12:17 pm The balance between the malignant clone and reactive T-cells in skin reliably predicts progression in CTCL. Adèle de Masson, MD, Brigham and Women's Hospital. *Abstract #400*

12:29 pm Changes of lesional and non-lesional skin microbiome in the treatment course of atopic dermatitis. Jung-Im Na, PhD, Seoul National University Bundang Hospital. *Abstract #656*

12:41 pm Skin surface temperature detection with thermal imaging camera aids in cellulitis diagnosis. Adam Raff, MD/PhD, Massachusetts General Hospital. *Abstract #319*

12:52 pm Molecular basis of hair follicle donor dominance in androgenetic alopecia and sexual dimorphism of the skin. Yanne Doucet, PhD, Columbia University. *Abstract #863*

1:04 pm Systematic review of treatments for keratinocyte carcinoma. Aaron Drucker, MD, The Warren Alpert Medical School of Brown University. *Abstract #402*

1:16 pm Bone marrow/cord blood transplantation (BMCBT) ameliorates symptoms in some, but not all, subtypes of severe generalized junctional epiderm. Jakub Tolar, MD/PhD, University of Minnesota/Pediatric BMT. *Abstract #308*

1:28 pm The cost of acne/rosacea prescriptions in Medicare patients varies by prescriber specialty. Myron Zhang, The Ohio State University College of Medicine. *Abstract #159*

1:40 pm Discussion and Concluding Remarks

Members of the Medical Dermatology Society (MDS) represent the heart and soul of our specialty: Medical Dermatology. The MDS is made up of the thought leaders of clinical dermatology and the teachers of the next generation of practicing dermatologists. Our members include academicians, private practitioners, and resident physicians. We specialize in the care of patients with serious dermatologic diseases. Our mission is to improve the care of patients with these conditions.

Dermatologists are encouraged to pursue a career in medical dermatology by:

- Encouraging resident presentations at our Annual Meeting
- Developing Advanced Medical Dermatology Rotations for residents to work with experts in our field across the country
- Encouraging dermatology programs to sponsor 5-year combined Internal Medicine/Dermatology training programs
- Coordinating and providing lectures and sessions on medical dermatology topics at major dermatology meetings
- Providing lectures, discussions and case presentations at the annual Medical Dermatology Society Meeting



International Society for Cutaneous Lymphomas Cutaneous T Cell Lymphoma Symposium



Friday, April 28, 2017

12:00 pm – 1:30 pm

C123-124

Presiders: Joan Guitart, MD, Larisa Geskin, MD, Sam Hwang, MD/PhD,
and Gary Wood, MD

12:00 pm **ISCL Announcements**

8 minutes for presentation + 2 minutes for Q&A and change of speaker

1. 12:10 pm **Cutaneous Lymphoma Foundation's Young Investigator's Award**
2. 12:20 pm **Anti-PD-L1 mAb reduces tumor growth in a mouse model of cutaneous T cell lymphoma.** Xuesong Wu, K. Wang and S. Hwang. *Abstract #273*
3. 12:30 pm **Epigenetically-enhanced PDT (ePDT) induces significantly higher levels of multiple extrinsic pathway apoptotic factors than conventional PDT, resulting in greater extrinsic and overall apoptosis of CTCL.** Gary Wood, K. Salva and Y. Kim. *Abstract #312*
4. 12:40 pm **SATB1 overexpression defines a subtype of cutaneous CD30+ lymphoproliferative disorders associated with Th17 cytokine profile.** Yang Wang, J. Sun, S. Yi, P. Tu and M. Kadin. *Abstract #115*
5. 12:50 pm **p38γ and its complementary pathway in cutaneous T cell lymphoma.** Xu Hannah Zhang, S. Nam, J. Wu, C. Chen, Y. Chen, C. Querfeld, D. Horne and S. Rosen. *Abstract #309*
6. 1:00 pm **MicroRNA based classifiers in diagnosis and prognosis of cutaneous T cell lymphoma.** Bo Wang, X. Shen and J. Zheng. *Abstract #287*
7. 1:10 pm **Th2-dominant microenvironment by IL-25 in cutaneous T-cell lymphoma.** Chu-Tomomitsu Miyagaki, R. Nakajima, T. Oka, N. Takahasi, M. Hirakawa, H. Suga, H. Fujita, M. Sugaya and S. Sato. *Abstract #259*
8. 1:20 pm **Combination Bcl-2 and HDAC inhibition in the treatment of cutaneous T-cell lymphoma.** Benoit Cyrenne, J. Lewis, J. Weed, F. Mirza, K. Carlson and M. Girardi. *Abstract #694*

Visit www.cutaneouslymphoma.org for more information
about the ISCL and membership!

Research in Cutaneous Surgery Mini-Symposium

Friday, April 28, 2017

12:00 pm – 1:30 pm

B112

The Research in Cutaneous Surgery Mini-Symposium is a forum for clinically relevant, patient-directed research in dermatologic surgery, including cancer surgery, laser surgery, and cosmetic surgery. With a primary emphasis on clinical research, the symposium aims to highlight clinical trials on procedure safety and effectiveness, as well as epidemiologic investigations. As research in cutaneous surgery is a growing field, the symposium also serves to bring together investigators to facilitate future collaborations. Pilot studies and early work are appropriate for submission. Those interested in directing an abstract to this session next year are encouraged to contact any of the co-moderators for more information.

Moderator: Murad Alam, MD**Co-Moderators:** Kachiu Lee, MD & Stephanie Rangel, PhD

1. 12:00 pm **Acne Core Outcomes Research Network (ACORN) reaches consensus on outcomes to measure.** Diane Thiboutot. *Abstract #338*
2. 12:07 pm **Patient Centered Outcomes for Skin Cancer Management; a single-day skin cancer patient Delphi process to assess the importance of treatment themes.** Ian Maher and Amanda Maisel
3. 12:14 pm **Potential adverse psychosocial impacts of skin biopsies in the context of melanoma screening.** Natalie Matthews. *Abstract #161*
4. 12:21 pm **Surveillance adherence of patients after treatment of primary cutaneous melanoma.** Jeave Reserva. *Abstract #177*
5. 12:28 pm **Melanoma and chronic low dose ethinyl estradiol contraceptives in young women: A large midwestern U.S. patient population retrospective study.** Kelly Mueller. *Abstract #813*
6. 12:35 pm **Risk factors of high frequency basal cell carcinoma: Gender, histologic subtypes, anatomic distribution, and associated immunosuppression**
Grace Cho. *Abstract #174*
7. 12:42 pm **A systematic review on the use of cryotherapy versus other treatments for basal cell carcinoma.** Catherine Tchanque-Fossuo. *Abstract #372*
8. 12:49 pm **Pentoxifylline for the prevention of post-surgical keloid recurrence: A retrospective pilot study.** Andrea Tan. *Abstract #353*
9. 12:56 pm **Predictors of wound healing in lower extremity wounds status post Mohs micrographic surgery.** Jeremy Honaker. *Abstract #907*
10. 1:03 pm **Factors associated with skin dehiscence in a large single center, U.S. population.** Beatrice Nardone.
11. 1:10 pm **Impact of topical 5-fluorouracil cream on photodamage using four validated photonumeric scales.** Kaveri Korgavkar. *Abstract #171*
12. 1:17 pm **Laser treatment in ffa.** Jacob Subash. *Abstract #340*



CONCURRENT MINI-SYMPOSIUM 6

Clinical Research: Patient Outcomes Research

Includes meta-analysis of interventional trials, and patient outcomes research.

Friday, April 28, 2017

2:00 pm – 4:30 pm

Oregon Ballroom 204

Presiders: Benjamin Chong, MD and Mary-Margaret Chren, MD

1. **Serious infections among a large cohort of subjects with systemically-treated psoriasis.** A. Dobry. Boston, MA. 2:00 pm, Abstract #399
2. **A longitudinal study of cutaneous dermatomyositis.** PB. Chansky, JM. Olazagasti, R. Feng and V. Werth. Philadelphia, PA. 2:12 pm, Abstract #341
3. **Predictors of clinical response in cutaneous lupus: A longitudinal study from the University of Texas Southwestern Cutaneous Lupus Registry.** B. Nanes and B. Chong. Dallas, TX. 2:24 pm, Abstract #364
4. **Cancer risk in clinically amyopathic dermatomyositis: A retrospective cohort study at four tertiary care centers.** J. Pinard, M. Roman, D. Kurtzman, A. Ho, A. Femia and R. Vleugels. Boston, MA and New York, NY. 2:36 pm, Abstract #401
5. **Direct-access online care for the management of atopic dermatitis: A randomized controlled clinical trial examining patient quality of life.** H. Kornmehl, S. Singh, M. Johnson and A. Armstrong. Los Angeles, CA; Sacramento, CA and El Dorado Hills, CA. 2:48 pm, Abstract #334
6. **Establishing severity strata for 5 different patient-reported outcomes in adults with atopic dermatitis.** R. Sacotte, P. Vakharia, R. Chopra, N. Patel, S. Immaneni, T. White, R. Kantor, D. Hsu, E. Simpson and J. Silverberg. Chicago, IL and Portland, OR. 3:00 pm, Abstract #383
7. **The relevance of PROMIS in dermatology.** J. Ryan Wolf, F. Essa, LB. Dolohanty and AP. Pentland. Rochester, NY. 3:12 pm, Abstract #355
8. **Type VII collagen (C7) expression and chimerism after bone marrow/cord blood transplantation (BMCBT) for severe generalized recessive dystrophic epidermolysis bullosa (RDEB).** J. Tolar, J. McGrath, M. Osborn, D. Keene, M. Riddle, K. Hook, M. Hordinsky, M. Marinkovich, D. Woodley, M. Chen, R. Tryon, T. DeFor, C. Ebens, K. Tamai, A. Hovnanian, B. Blazar and J. Wagner. Minneapolis, MN; London, United Kingdom; Portland, OR; Stanford, CA; Los Angeles, CA; Osaka, Japan and Paris, France. 3:24 pm, Abstract #377
9. **Determination of molecular remission in patients with mycosis fungoides (MF) and Sezary Syndrome (SS) following allogeneic transplant using high throughput sequencing (HTS).** T. Almazan, R. Armstrong, YH. Kim and W. Weng. Stanford, CA. 3:36 pm, Abstract #380
10. **Toward data-driven guidelines for Merkel cell carcinoma surveillance: Stage-specific recurrence risk from 535 patients.** A. McEvoy, K. Lachance, D. Hippe, C. Lewis, N. Singh, Z. Thuesmann and P. Nghiem. Seattle, WA. 3:48 pm, Abstract #373
11. **Outcomes among Merkel cell carcinoma patients with chronic immunosuppression.** M. Cook, K. Lachance, M. Nguyen, M. Redman, K. Baker, Y. Tseng and P. Nghiem. Seattle, WA. 4:00 pm, Abstract #365
12. **Effect of a single course of topical 5-fluorouracil (5FU) on basal cell carcinoma (BCC) chemoprevention in older veterans.** AD. Means, NF. Leader and MA. Weinstock. Boston, MA and Providence, RI. 4:12 pm, Abstract #362

Immediately following this session, a 30 minute mixer will be held. Presenters, moderators and attendees will be able to interact as they enjoy light refreshments and snacks. These mixers are designed to encourage informal discussion, mingling and networking among SID meeting attendees.



CONCURRENT MINI-SYMPOSIUM 7***Genetic Disease, Gene Regulation and Gene Therapy***

Studies on cutaneous gene expression and genetic diseases including gene therapy.

Friday, April 28, 2017**2:00 pm - 4:30 pm****B113-116**

Presiders: Keith Choate, MD/PhD and Alain Hovnanian, MD/PhD

1. **Phase I/IIa clinical trial for recessive dystrophic epidermolysis bullosa using genetically corrected autologous keratinocytes.** Z. Siprashvili, N. Nguyen, E. Gorell, K. Loutit, Y. Dutt-Singh, J. Nazarov, P. Khuu, L. Furukawa, H. Lorenz, T. Leung, D. Keene, K. Rieger, PA. Khavari, A. Lane, JY. Tang and M. Marinkovich. Stanford, CA; Philadelphia, PA and Portland, OR. 2:00 pm, Abstract #519
2. **Identification of a novel causative gene responsible for autosomal recessive congenital ichthyosis.** Y. Shigehara, S. Okuda, R. Hayashi, H. Nakai, R. Abe, A. Ghani Kibbi, M. Kurban and Y. Shimomura. Niigata, Japan and Beirut, Lebanon. 2:12 pm, Abstract #493
3. **Ichthyosis molecular fingerprinting shows profound Th17-skewing and a unique barrier gene expression pattern.** H. He, T. Huynh, E. Ibler, K. Malik, G. Tran, H. Esaki, JG. Krueger, AS. Paller and E. Guttman-Yassky. New York, NY and Chicago, IL. 2:24 pm, Abstract #495
4. **Stabilizing mutations of KLHL24 ubiquitin ligase cause loss of keratin 14 and human skin fragility.** C. Feng, Z. Lin, S. Li, H. Wang, Y. Yang and X. Tan. Beijing, China. 2:36 pm, Abstract #474
5. **Somatic mutations in nevus comedonicus identify nek9 as a determinant of follicular keratinocyte cell fate.** J. Levinsohn, J. Sugarman, J. McNiff, I. Freiden, R. Antaya and K. Choate. New Haven, CT and San Francisco, CA. 2:48 pm, Abstract #514
6. **GNA14 somatic mutation causes congenital and sporadic vascular tumors by MAPK activation.** Y. Lim, A. Bacchiocchi, J. Qiu, A. Bruckner, L. Bercovitch, D. Narayan, J. McNiff, C. Ko, L. Robinson-Bostom, R. Antaya, R. Halaban and K. Choate. New Haven, CT; Aurora, CO and Providence, RI. 3:00 pm, Abstract #513
7. **Determinants of intra-individual transcriptional homogeneity in inflammatory responses at anatomically separate sites.** LC. Tsoi, J. Yang, Y. Liang, MK. Sarkar, X. Xing, MA. Beamer, A. Aphale, K. Raja, J. Kozlow, S. Getsios, JJ. Voorhees, JM. Kahlenberg, JT. Elder and JE. Gudjonsson. Ann Arbor, MI and Chicago, IL. 3:12 pm, Abstract #525
8. **Genetic signature to assess risk of psoriasis subtypes through machine learning approach.** MT. Patrick, PE. Stuart, K. Raja, JE. Gudjonsson, T. Tejasvi, JJ. Voorhees, DD. Gladman, RP. Nair, JT. Elder and LC. Tsoi. Ann Arbor, MI. and Toronto, Canada. 3:24 pm, Abstract #485
9. **Sex bias in response to an NRF2 inducer in a pachyonychia congenita model.** ML. Kerns, J. Hakim, A. Ziemann and PA. Coulombe. Baltimore, MD. 3:36 pm, Abstract #502
10. **SNPs within the MHC associated with atopic dermatitis are located within miRNA sequences.** P. Clark, N. Chitnis, M. Kamoun, B. Johnson, DJ. Margolis and D. Monos. Philadelphia, PA. 3:48 pm, Abstract #492
11. **Integrative analysis of gene expression data and rare copy number variants in alopecia areata.** L. Petukhova, AV. Patel, R. Severin, L. Bian, M. Verbitsky, S. Sanna-Cherchi, J. Cerise, A. Jabbari and AM. Christiano. New York, NY. 4:00 pm, Abstract #522
12. **Plasma PPI is the major, but not exclusive, cause of ectopic mineralization in pseudoxanthoma elasticum.** J. Zhao, J. Kingman, J. Uitto and Q. Li. Philadelphia, PA. 4:12 pm, Abstract #501

Immediately following this session, a 30 minute mixer will be held. Presenters, moderators and attendees will be able to interact as they enjoy light refreshments and snacks. These mixers are designed to encourage informal discussion, mingling and networking among SID meeting attendees.



CONCURRENT MINI-SYMPOSIUM 8

Innate Immunity, Microbiology, Inflammation

Studies of cells, receptors and effector molecules of the innate immune response; studies on skin microbes and infectious processes of the skin.

Friday, April 28, 2017

2:00 pm – 4:30 pm

Oregon Ballroom 203

Presiders: Anna Di Nardo, MD/PhD and Heidi Kong, MD

1. **Spatial heterogeneity and functional diversity of innate lymphoid cells in the skin.** T. Kobayashi, A. Truong, H. Shih, T. Doebel, B. Voisin, T. Woodring, S. Sohn, E. Kennedy, J. Jo, K. Moro, W. Leonard, H. Kong and K. Nagao. Bethesda, MD and Yokohama, Japan. 2:00 pm, Abstract #604
2. **Plasmacytoid dendritic cell-derived type I interferon drives flares of rosacea.** A. Mylonas, O. Demaria, S. Meller, H. Friedrich, B. Homey, J. Di Domizio, M. Gilliet and C. Conrad. Lausanne, Switzerland; Marseille, France and Dusseldorf, Germany. 2:12 pm, Abstract #584
3. **Resistin-like molecule α (relm α) is a skin antimicrobial protein that is regulated by vitamin A.** T. Harris, S. Gattu, D. Propher and L. Hooper. Dallas, TX. 2:24 pm, Abstract #568
4. **Microbiome-induced S1P released from keratinocytes promotes antimicrobial activity in mast cells.** Y. Chang, Z. Wang, N. Mascarenhas and A. Di Nardo. La Jolla, CA. 2:36 pm, Abstract #637
5. **Specific strains of *S. epidermidis* suppress UV-induced skin tumor formation by production of 6-N-hydroxyaminopurine, a DNA synthesis inhibitor.** T. Nakatsuji, T. Chen and R.L. Gallo. San Diego, CA. 2:48 pm, Abstract #612
6. **Arginase1/Nos2 imbalance in macrophages mediates cutaneous contact hypersensitivity responses.** J. Suwanpradit, M. Shih, B. Yang, A. Birukova, E. Guttman-Yassky, L. Que, R. Tighe and A.S. MacLeod. Durham, NC and New York, NY. 3:00 pm, Abstract #573
7. **An atopic dermatitis-like flare is mediated by dysbiosis and release of nuclear IL 1 α from keratinocytes.** N. Archer, S. Lee, R. Ortines, Y. Wang, H. Liu, R. Miller, C. Dillen, M. Marchitto, A. Ashbaugh, A. Uppal, S. Cai, N. Malhotra, M. Oyoshi, R. Geha and L. Miller. Baltimore, MD and Boston, MA. 3:12 pm, Abstract #643
8. **Neutrophil extracellular traps exacerbate the inflammation in psoriasis by inducing CXCL1/CXCL10 secretion in keratinocytes.** J. Lei, S. Shao, H. Fang, E. Dang and G. Wang. Xi'an, China. 3:24 pm, Abstract #590
9. **Imiquimod has strain-dependent effects in mice and does not uniquely model human psoriasis.** W.R. Swindell, K. Michaels, A. Sutter, D. Diaconu, Y. Fritz, X. Xing, M.K. Sarkar, Y. Liang, L.C. Tsoi, J.E. Gudjonsson and N.L. Ward. Athens, OH; Cleveland, OH and Ann Arbor, MI. 3:36 pm, Abstract #645
10. **Microbial-sensing liver V γ 6+ $\gamma\delta$ T-cells modulate cutaneous inflammation.** E. Merrill, M. Constantinides, S. Nakajima and Y. Belkaid. Bethesda, MD. 3:48 pm, Abstract #600
11. **TLR2/MyD88 signaling on T cells mediates a compensatory protective immune response to IL-1 β /MyD88 signaling against secondary *S. aureus* skin challenge.** C. Dillen, B. Pinsker, H. Liu, Y. Wang, R. Ortines, N. Archer and L. Miller. Baltimore, MD. 4:00 pm, Abstract #631
12. **Staphylococcal lipopeptide induces beta-catenin to suppress TLR3-mediated skin inflammation in diabetes.** D. Li and Y. Lai. Shanghai, China. 4:12 pm, Abstract #571

Immediately following this session, a 30 minute mixer will be held. Presenters, moderators and attendees will be able to interact as they enjoy light refreshments and snacks. These mixers are designed to encourage informal discussion, mingling and networking among SID meeting attendees.



CONCURRENT MINI-SYMPOSIUM 9

Photobiology

Studies on biological, biochemical, and molecular responses to ultraviolet radiation in cells, animals and humans.

Friday, April 28, 2017

2:00 pm – 4:30 pm

C123-124

Presiders: Sewon Kang, MD and Thomas Ruenger, MD/PhD

1. **Phosphorylation of XPC regulates XPC's function in UV-induced DNA damage repair.** P. Shah, B. Zhao, L. Qiang and Y. He. Chicago, IL. 2:00 pm, Abstract #752
2. **Enhanced skin tumor development in CHOP knockout mice after UVB exposure involves modulation of multiple survival and apoptotic signaling pathways.** S. Anand and EV. Maytin. Cleveland, OH. 2:12 pm, Abstract #746
3. **In-vivo evidence that mitochondrial (mt) DNA mutagenesis drives skin aging.** K. Sondenheimer, K. Aufenvenne, M. Majora, M. Knechten, F. Larcher and J. Krutmann. Düsseldorf, Germany and Madrid, Spain. 2:24 pm, Abstract #742
4. **A novel strategy for topical photochemoprevention: Pharmacological TLR4 antagonism blocks non-melanoma skin cancer.** S. Dickinson, K. Blohm-Mangone, N. Burkett, S. Tahsin, P. Myrdal, A. Aodah, J. Janda, K. Saboda, Z. Dong, A. Bode, E. Petricoin, V. Calvert, C. Curiel-Lewandrowski and G. Wondrak. Tucson, AZ; Austin, MN and Manassas, VA. 2:36 pm, Abstract #764
5. **The role of p62-dependent regulation of COX-2 in UVA response and skin tumor progression.** A. Sample, L. Qiang, B. Zhao and Y. He. Chicago, IL. 2:48 pm, Abstract #753
6. **The aryl hydrocarbon receptor (AHR) protects keratinocytes (KC) against the UVA phototoxicity of 6-formylindolo[3,2-b]carbazole (FICZ), an AHR ligand formed after UVB irradiation.** K. Rolfes, M. Nakamura, S. Meller, B. Homey, J. Krutmann and T. Haarmann-Stemann. Düsseldorf, Germany and Nagoya, Japan. 3:00 pm, Abstract #737
7. **ALA-PDT induced immunogenic apoptotic cells enhanced DC vaccine for skin squamous cell carcinoma.** J. Ji, Z. Fan, X. Wang, L. Shi, H. Zhang, P. Wang, D. Yang, L. Zhang and X. Wang. Shanghai, China. 3:12 pm, Abstract #731
8. **REDD1 and AKT signaling in UVB-induced apoptosis.** RP. Feehan and LM. Shantz. Hershey, PA. 3:24 pm, Abstract #745
9. **Pollution and sunlight synergistically contribute to skin photodamage.** L. Marrot, A. Dimitrov and J. Soeur. Aulnay sous Bois, France. 3:36 pm, Abstract #729
10. **Chemoprevention of ultraviolet-B radiation mediated skin carcinogenesis by dietary grape powder in SKH-1 hairless mice.** CK. Singh, MA. Ndiaye, CA. Mintie, G. Chhabra and N. Ahmad. Madison, WI. 3:48 pm, Abstract #755
11. **Gasdermin C is induced by ultraviolet and contributes to MMP-1 expression via activation of ERK and JNK pathways.** N. Kusumaningrum. Seoul, Republic of Korea. 4:00 pm, Abstract #760
12. **Protective effects of ROCK inhibition on Neutrophil NETosis in UVB induced-skin inflammation.** M. Liu, M. Sharma and V. Werth. Philadelphia, PA. 4:12 pm, Poster #758

Immediately following this session, a 30 minute mixer will be held. Presenters, moderators and attendees will be able to interact as they enjoy light refreshments and snacks. These mixers are designed to encourage informal discussion, mingling and networking among SID meeting attendees.



CONCURRENT MINI-SYMPOSIUM 10

Tissue Regeneration and Wound Healing

Wound healing and regeneration studies; processes/signaling that regulate vascular development and angiogenesis; interactions between different skin components (epithelial cells, dermal cells, nerves, vasculature, melanocytes, fat) in homeostasis and regeneration.

Friday, April 28, 2017

2:00 pm – 4:30 pm

A105-106

Presiders: Christian Posch, MD and Marjana Tomic-Canic, PhD

1. **MicroRNA-132 with therapeutic potential in chronic wound.** X. Li, D. Li, A. Wang, T. Chu, W. Lohcharoenkal, E. Herter, M. Ehrström, L. Eidsmo, A. Pivarcsi, E. Sonkoly, S. Catrina, M. Ståhle and N. Xu Landén. Stockholm, Sweden and Dalian, China. 2:00 pm, Abstract #933
2. **CD44 and p38 participate in regulating the pro-fibrotic capability of dermal fibroblasts during skin wound healing.** Y. Wang, J. Mack and EV. Maytin. Shaker Heights, OH and Cleveland, OH. 2:12 pm, Abstract #917
3. **Oral vitamin D rapidly attenuates inflammation from sunburn: An interventional study.** K. Lu, J. Scott, L. Das, S. Ahsanuddin, K. Cooper, S. Debanne, and R. Boxer. Cleveland, OH and Denver, CO. 2:24 pm, Abstract #927
4. **Autophagy reprogramming by vitamin D promotes suppression of UV-induced inflammation via macrophage polarization.** L. Das, Z. Traylor, A. Binko and K. Lu. Cleveland, OH. 2:36 pm, Abstract #922
5. **Tissue engineered human hair follicles from genetically, environmentally and extrinsically reprogrammed dermal papilla cells.** A. Coffman, H. Abaci, JC. Chen, E. Wang, Y. Doucet, Z. Guo and AM. Christiano. New York, NY. 2:48 pm, Abstract #918
6. **Suppression of DNA repair and lack of cellular migration are major contributors of diabetic foot ulcer pathophysiology.** H. Ramirez, I. Pastar, R. Stone, T. Cao Wikramanayake, I. Jozic, O. Stojadinovic, N. Ojeh, RS. Kirsner and M. Tomic-Canic. Miami, FL and Bridgetown, Barbados. 3:00 pm, Abstract #905
7. **Cellular versus acellular matrix devices in treatment of diabetic foot ulcers: Preliminary results of a comparative efficacy randomized controlled trial.** C. Tchanque-Fossuo, S. Dahle, H. Lev-Tov, C. Li and R. Isseroff. Sacramento, CA; Mather, CA; Miami, FL and Davis, CA. 3:12 pm, Abstract #910
8. **Ipsc reprogramming rescues epigenetic signature and cellular functions of diabetic foot ulcer fibroblasts to promote healing.** L. Liang, R. Stone, I. Pastar, I. Jozic, O. Stojadinovic, H. Ramirez, O. Kashpur, B. Gerami-Naini, A. Maione, A. Smith, V. Yanez, RS. Kirsner, A. Veves, J. Garlick and M. Tomic-Canic. Miami, FL and Boston, MA. 3:24 pm, Abstract #903
9. **Developing a 3D microfluidic model of immune-competent human skin using autologous cells.** H. Abaci, H. Wobma, Y. Doucet, JU. Shin, J. Jackow, Z. Guo, K. Yeager, G. Vunjak-Novakovic and AM. Christiano. New York, NY. 3:36 pm, Abstract #909
10. **Fat cells regenerate from myofibroblasts during wound healing.** C. Guerrero-Juarez, M. Ito, Y. Zheng, G. Cotsarelis and M. Plikus. Irvine, CA; New York, NY and Philadelphia, PA. 3:48 pm, Abstract #931
11. **Adipose multilineage-differentiating stress enduring (Muse) cell maintain pluripotency regardless of donors' age.** T. Yamauchi, K. Yamasaki, K. Tsutiyama, S. Koike and S. Aiba. Sendai, Japan. 4:00 pm, Abstract #904
12. **Keratinocytes and fibroblasts facilitate maturation of sensory neurons differentiated from human induced pluripotent stem cells.** Z. Guo, C. Tong, Y. Doucet, H. Abaci, J. Jackow, E. Lumpkin and AM. Christiano. New York, NY. 4:12 pm, Abstract #908

Immediately following this session, a 30 minute mixer will be held. Presenters, moderators and attendees will be able to interact as they enjoy light refreshments and snacks. These mixers are designed to encourage informal discussion, mingling and networking among SID meeting attendees.



Introducing a New Topical Prescription Treatment Option for Atopic Dermatitis



Friday, April 28, 2017

5:00 pm – 5:45 pm

Oregon Ballroom 201-202

Come learn about a new nonsteroidal treatment option for patients with mild-to-moderate atopic dermatitis.

Please join us for a non-CME program presented by:



Lawrence Eichenfield, MD

Professor of Dermatology and Pediatrics
Chief of Pediatric and Adolescent Dermatology
University of California, San Diego
Rady Children's Hospital-San Diego
San Diego, California

Refreshments will be provided.

Notice: This event is conducted in accordance with the PhRMA Code on Interactions with Healthcare Professionals and is limited to healthcare professionals (HCPs). Attendance by guests or spouses is not appropriate. Government employees are subject to state and federal laws and ethics rules that may limit their ability to receive any gifts, including meals, from pharmaceutical companies. If you are a state or federal employee, it is your responsibility to seek guidance and prior approval from your employer or site ethics counselor to attend this or any Pfizer event. Your attendance will be considered confirmation to Pfizer that you have obtained any necessary approvals to attend this event.

State Laws and Pfizer Disclosures: The cost of meals and refreshments provided to US licensed Healthcare Professionals attending this Pfizer-sponsored program will be subject to public disclosure on www.pfizer.com as part of Pfizer's Healthcare Professional Disclosure policies, and may also be subject to disclosure by state governmental authorities pursuant to your state law and applicable federal law such as the National Physician Payment Transparency Program (otherwise known as "Sunshine"). Pfizer's disclosure will allocate the cost of meals and refreshments equally across all attendees regardless of actual consumption. **If you are licensed to practice in Minnesota or Vermont, we are prohibited from providing you any meals and/or refreshments due to your state limitation on meals, gifts or other items of value to HCPs and ask that you do not partake in the hospitality provided.**



National Eczema Association



Friday, April 28, 2017

6:00 pm – 7:00 pm

A105-106

**The National Eczema Association invites you to join us
at our cocktail reception at the 2017 Annual SID Meeting.**

Raise a glass to celebrate advancements in eczema!

It's been a great year for advancements in eczema care and treatment. Clinical research is moving at a rapid rate and life-changing medications are entering the market for the first time in decades.

We have much to celebrate, so join us and toast the health of the millions of people with eczema who can see the future – and it's clear.

Thank you to our presenting sponsor



North American Hair Research Society Scientific Meeting and Annual General Meeting



Friday, April 28, 2017

6:00 pm – 8:30 pm

Oregon Ballroom 203

Presiders: John T. Seykora, MD/PhD, Chair, Scientific Program Committee, and Maria K. Hordinsky, MD, President

6:00 pm Poster Viewing & Reception

1. **Dermal Wnt/ β -catenin signaling controls hair follicle dermal condensate size during development.** Peggy Myung, D. Chen, T. Sun and K. Gupta. *Abstract #872*.
2. **The role of astrotactin2 in regulating mammalian skin polarity.** Hao Chang. *Abstract #851*
3. **Human scalp-derived fibroblasts alter FGF expression profile upon WNT activation: implication of their role to provide folliculogenetic microenvironment.** Misaki Kinoshita-Ise, A. Tsukashima, T. Kinoshita, Y. Yamazaki and M. Ohyama. *Abstract #846*
4. **Congenital generalized hypertrichosis with a copy number variation on chromosome 17q24.** Hayashi Ryota, K. Yoshida, R. Abe, N. Yoshida and Y. Yoshida. *Abstract #494*
5. **Comorbid diseases and risk of alopecia areata amongst US women.** J. Thompson, MK. Park, K. Huang, M. Mirza, A. Qureshi and Eunyoung Cho. *Abstract #230*
6. **Endoplasmic reticulum stress upregulates NKG2D ligands in the hair follicle.** Alexa Abdelaziz, S. Erjavec, L. Petukhova, Z. Dai and AM. Christiano. *Abstract #616*
7. **Identification of pathogenic T cell subsets in human alopecia areata.** Annemieke du Jong, A. Jabbari, Z. Dai, L. Xing, D. Lee, V. Price, M. Duvic, D. Norris, M. Hordinsky, J. Mackay-Wiggan, R. Clynes and AM. Christiano. *Abstract #052*
8. **A small molecule modulator of the wnt pathway (SM04554) as a potential topical treatment for androgenetic alopecia (AGA).** Vishal Deshmukh, M. Pedraza, C. Barroga, J. Seykora and Y. Yazici. *Abstract #712*
9. **Analysis of the paired TCR alpha- and beta-chains of single, intralesional CD8+T-cells in alopecia areata patients.** Marta Bertolini, S. Altendorf, Y. Uchida, D. Below, R. Kelsch, Q. Zhou, A. Rossi, K. Dornmair and R. Paus. *Abstract #081*
10. **Predictive modeling of drug response and mechanism of action in alopecia areata clinical trials.** James Chen, A. Jabbari, R. Clynes, J. Mackay-Wiggan and AM. Christiano. *Abstract #397*
11. **Treatment of severe alopecia areata with the oral Janus kinase inhibitor, tofacitinib: A retrospective chart review.** Omer Ibrahim, S. Hogan, M. Piliang and W. Bergfeld. *Abstract #378*
12. **Molecular basis of hair follicle donor dominance in androgenetic alopecia and sexual dimorphism of the skin.** Yanne Doucet, HE. Abaci, C. Jahoda, J. Chen and AM. Christiano. *Abstract #863*

CONTINUED

CONTINUED:

North American Hair Research Society Scientific Meeting and Annual General Meeting



Friday, April 28, 2017

6:00 pm – 8:30 pm

Oregon Ballroom 203

6:45 pm Keynote Speaker

Immune regulation mediated by the hair follicles

Keisuke (Chris) Nagao, MD/PhD

Earl Stadtman Investigator, Dermatology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health

7:15 pm Oral Presentations

12 minutes for presentation + 3 minutes for Q&A and change of speaker

1. **Small T antigen from a folliculotropic polyomavirus activates canonical Wnt/ β -catenin signaling in vivo.** L.J. Syu, M. Verhaegen, M. Grachtchouk, D. Mangelberger, H. Zabawa and A. Dlugosz. 7:15 pm, *Abstract #877*
2. **Dermal lymphatic vessels promote hair follicle growth via the BMP inhibitor Sostdc1.** Sun-Young Yoon, LC. Dieterich, S. Karaman, ST. Proulx, S. Bachmann, C. Sciaroni and M. Detmar. 7:30 pm, *Abstract #845*
3. **Large-scale screening for T cell epitopes in human alopecia areata.** Eddy Hsi Chun Wang, T. Gordon, A. de Jong, P. Sinu, P. Lindestam, A. Sette and AM. Christiano. 7:45 pm, *Abstract #028*

8:00 pm NAHRS Business Meeting

Visit www.nahrs.org for more information
about the NAHRS and membership!

SATO JAPAN Scientific Forum at SID 2017



Friday, April 28, 2017

6:30 pm – 9:30 pm

C123-124

Please join us for a contemporary scientific lecture and social gathering.

Chair: **Kenshi Yamasaki, MD/PhD**

Associate Professor, Vice-Chair, Department of Dermatology
Tohoku University Graduate School of Medicine Tohoku University School of Medicine
Tohoku University Hospital, Sendai Japan



Acne – Now and the Future: Figuring Out Puzzles of Pathogenesis and Translating Insights into Therapy

Lawrence F. Eichenfield, MD

Chief, Pediatric and Adolescent Dermatology
Professor of Dermatology and Pediatrics
Vice Chair, Department of Dermatology
University of California, San Diego School of Medicine and Rady
Children's Hospital, San Diego, CA

Dr. Lawrence F. Eichenfield is Chief of Pediatric and Adolescent Dermatology at Rady Children's Hospital-San Diego, Vice Chair of the Department of Dermatology, and Professor of Dermatology and Pediatrics at the University of California, San Diego (UCSD) School of Medicine. He received his medical degree from Mount Sinai School of Medicine in New York, was a pediatric resident and Chief Resident at Children's Hospital of Philadelphia, and completed his dermatology residency at the Hospital of the University of Pennsylvania. Dr. Eichenfield's clinical interests include atopic dermatitis, acne, psoriasis, vascular lesions including port wine stains and hemangiomas, neonatal dermatology, laser surgery, nevi, and skin signs of systemic disease. He has authored more than 300 journal articles, chapters, abstracts, and books on these topics and has served as the senior editor of Neonatal and Infant Dermatology, published by Elsevier, as well as The Eczemas, published by Summit Communications. He is also Editor-in-Chief of Pediatric Dermatology and serves on the editorial boards of multiple journals and periodicals. In addition, Dr. Eichenfield has been honored as a member of the Alpha Omega Alpha Medical Honor Society during medical school, as a recipient of the Benjamin Ritter Award at Children's Hospital of Philadelphia, and as a recipient of excellence in teaching awards from UCSD Pediatrics, UCSD Dermatology, and Rady Children's Hospital-San Diego. He has been named one of the "Best Doctors in America" since 1994. Dr. Eichenfield is past president of the Society for Pediatric Dermatology, past Board member of the American Academy of Dermatology as well as Chair for the 69th Annual Meeting of the American Academy of Dermatology. Dr. Eichenfield is also a founding board member of the American Acne and Rosacea Society. He is a founder and Co-Chair of the Pediatric Dermatology Research Alliance (PeDRA).





Saturday Sessions

PAGE TITLE

85	Meeting-At-A-Glance
86	Plenary Session III
87	William Montagna Lecture
88	Herman Beerman Lecture
89	Come See My Poster III
90	Clinical Scholars Program Session III
91	Selected ePoster Discussions III
92	Concurrent Mini-Symposium 11 Carcinogenesis and Cancer Genetics
93	Concurrent Mini-Symposium 12 Clinical Research: Epidemiology of Skin Diseases
94	Concurrent Mini-Symposium 13 Epidermal Structure and Barrier Function
95	Concurrent Mini-Symposium 14 GrowthFactors, Cell Adhesion and Matrix Biology
96	Concurrent Mini-Symposium 15 Pharmacology and Drug Development

Stay in touch with the SID throughout the year!



@SocietyforInvestigativeDermatology



@SocInvestDerm



Society for Investigative Dermatology



socinvestderm

Claim your CME Credits

In order to receive CME credit, participants must sign-in, review the CME information (accreditation, learning objectives, faculty disclosure, etc.) and attend the CME activity. To access the program evaluation, claim CME Credits, or print your certificate, go to www.cme.urmc.edu or use the QR Code.



Meeting-At-A-Glance



SATURDAY, APRIL 29, 2017

Registration 7:30 am – 12:00 pm
Pre-Function A Foyer

Plenary Session III 8:00 am – 9:00 am
Oregon Ballroom 201-202

William Montagna Lecture 9:00 am – 9:30 am
From Morphogenesis to Disease: A Wnt's Tale
Sarah Millar, PhD
Oregon Ballroom 201-202

Herman Beerman Lecture 9:30 am – 10:00 am
How to Make Antibodies for Tumor Immunotherapy
Alan J. Korman, PhD
Oregon Ballroom 201-202

Come See My Poster III 10:00 am – 10:15 am
Poster #'s 325, 357, 421, 427, 535, 623, 714, 812, 884
Oregon Ballroom 201-202

Clinical Scholars Program Session II 10:15 am – 12:00 pm
Emerging Immunotherapies
Oregon Ballroom 203

Poster Session III/Coffee Break 10:15 am – 12:15 pm
Odd Poster #'s 313-623 Exhibit Hall A
Even Poster #'s 626-934
Odd Late-Breaking Poster #'s 961-985
Even Late-Breaking Poster #'s 986-1008

Selected ePoster Discussions III 10:45 am – 11:45 am
See Page #91 Exhibit Hall A Foyer

Concurrent Mini-Symposia 12:30 pm – 3:00 pm

11. Carcinogenesis and Cancer Genetics B113-116
12. Clinical Research: Epidemiology of Skin Diseases Oregon Ballroom 203
13. Epidermal Structure and Barrier Function Oregon Ballroom 204
14. Growth Factors, Cell Adhesion and Matrix Biology C123-124
15. Pharmacology and Drug Development A105-106

PLENARY SESSION III

Presiders: Ponciano Cruz, MD and Paul Nghiem, MD/PhD

Saturday, April 29, 2017

8:00 am – 9:00 am


Oregon Ballroom 201-202

1. **Gentamicin therapy induced functional type VII collagen in recessive dystrophic epidermolysis bullosa patients harboring nonsense mutations.** M. Chen, J. Cogan, Y. Hou, D. Keene and D. Woodley. Los Angeles, CA and Portland, OR. *8:00 am, Abstract #299*
2. **Defining the molecular signature of the hair follicle dermal sheath and its functional requirement for hair cycle progression during catagen.** N. Heitman, R. Sennett, Z. Wang, A. Rezza, K. Mok, A. Ma'ayan and M. Rendl. New York, NY. *8:12 am, Abstract #862*
3. **Temporally controlled B cell depletion with universal chimeric antigen receptor (CAR) T cells for pemphigus vulgaris (PV) therapy.** CT. Ellebrecht, X. Mao, JJ. Melenhorst, S. Lacey, Y. Zhao, MC. Milone and AS. Payne. Philadelphia, PA. *8:24 am, Abstract #035*
4. **Staphylococcus aureus drives atopic dermatitis-like skin inflammation via IL-36-induced IL-17 responses.** H. Liu, N. Archer, C. Dillen, Y. Wang, A. Ashbaugh, R. Ortines, S. Lee, R. Miller, M. Marchitto, G. Nunez and L. Miller. Baltimore, MD and Ann Arbor, MI. *8:36 am, Abstract #629*
5. **Aging and diet-induced obesity impair activation of adipocytes that protect against invasive Staphylococcus aureus skin infection.** L. Zhang, F. Li and RL. Gallo. San Diego, CA. *8:48 am, Abstract #634*

WILLIAM MONTAGNA LECTURE*From Morphogenesis to Disease: A Wnt'ers Tale***Saturday, April 29, 2017****9:00 am – 9:30 am****Oregon Ballroom 201-202****Introduction by: Alice Pentland, MD****Sarah Millar, PhD**

University of Pennsylvania
Philadelphia, Pennsylvania

Sarah Millar, PhD is internationally recognized as a leading researcher in epithelial development, stem cells and regeneration and has over 60 publications in leading peer-reviewed journals. Her research group has made seminal discoveries on the roles of Wnt inter-cellular signaling in epithelial development and regeneration. They also identified key roles for miRNAs in epidermal development and regeneration, and essential requirements for histone deacetylases in epidermal stem cell proliferation and survival. Their current research directions include elucidating the functions of Wnt ligands and their receptors, and chromatin repressive complexes, in the development and regeneration of skin, hair follicles, mammary glands and teeth. They are also developing genetic mouse models for human ectodermal dysplasias to delineate disease mechanisms and test potential therapeutic approaches. NIH has continuously supported Dr. Millar's laboratory's research since 2001. In addition, Dr. Millar is the Director and PI of a new NIH P30-supported UPenn Skin Biology and Diseases Resource-based Center. She has mentored, or is currently mentoring, 14 graduate students and ten post-doctoral fellows in her laboratory, four of whom now have faculty positions at Texas A & M University, Vanderbilt University, the University of Pennsylvania, and the University of Cincinnati. She is PI of the UPenn Dermatology T32 training grant which supports research training for medical students, graduate students, post-doctoral fellows and research track dermatology residents, 10 of whom are now on the faculty at academic institutions. She also served as Chair of the Developmental Stem Cell and Regenerative Biology (DSRB) graduate group at UPenn from 2009-12. In this capacity she was in charge of administration, admissions, advising, mentoring, and fund raising. Under her leadership the program grew from 43 applicants and 3 matriculating students in 2008 to 94 applicants and 11 matriculating students in 2011. She serves as an Editorial Board member for Developmental Cell and Experimental Dermatology, was a Standing Member of the NIH ACTS study section from 2006-10, and has served on numerous other national and international grantreview committees. She is regularly invited to speak at research conferences and institutions worldwide and has received several awards in recognition of her research contributions, including an NIH MERIT Award for her research on Wnt signals in skin and hair development and hair growth, and the Albert Kligman Endowed Chair in Dermatology.

**LECTURESHIP HISTORY**

The William Montagna Lecture is given annually at the Society's Annual Meeting. This award is intended to honor and reward young active investigators. Primary emphasis is given to researchers in skin biology.



HERMAN BEERMAN LECTURE*How to Make Antibodies for Tumor Immunotherapy***Saturday, April 29, 2017****9:30 am – 10:00 am****Oregon Ballroom 201-202****Introduction by: Angela Christiano, PhD****Alan J. Korman, PhD**

Vice President of Immuno-Oncology Discovery
Bristol-Myers Squibb
Redwood City, California

Alan J. Korman received his PhD degree from Harvard University (Cambridge, Massachusetts, USA) in 1984 and was a Whitehead Fellow at the Whitehead Institute, Massachusetts Institute of Technology (Cambridge, Massachusetts, USA) from 1984 to 1989. He was also a Chargé de Recherche at the Institut Pasteur (Paris, France) from 1990 to 1993. He has worked in the biotechnology and pharmaceutical industry since 1993 and is currently Vice President of Immuno-Oncology Discovery at Bristol-Myers Squibb (Redwood City, California, USA). He led the preclinical development of the FDA approved checkpoint inhibitor antibodies, ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1), as well as their combination for the treatment of cancer.

**LECTURESHIP HISTORY**

This award is given in recognition of Dr. Herman Beerman's long and devoted service to the SID and his efforts to secure for it a position of respect in the scientific community. The Herman Beerman Lecture is given by a distinguished medical scholar at a scientific session of the Society's Annual Meeting. Traditionally, lecturers from fields other than dermatology are chosen in order to give meeting attendees the opportunity to learn about scientific advances in other fields.

Come See My Poster III

Saturday, April 29, 2017 10:00 am – 10:15 am Oregon Ballroom 201-202

Presider: Paul Nghiem, MD/PhD

The Come See My Poster sessions give opportunities to select presenting authors of highly scored abstracts to give a brief one-minute (and one slide) introduction to their submitted abstract. This rapid paced session leads right into one of the SID's Poster Sessions, providing both an excellent starting point into the Poster Hall and the generation of excitement for all attendees.

1. **Analysis of sirolimus treatment response in lymphatic malformations with and without PIK3CA mutation.**
MN. Pyles, JH. Tu, W. Donahue, E. Tafoya, Z. Zinn, A. Marqueling, MR. Jeng and J. Teng. Stanford, CA and Salt Lake City, UT. 10:01 am, Abstract #325
2. **Surgical delays in melanoma vary by insurance type.**
AS. Adamson, L. Zhou, C. Baggett, NE. Thomas and A. Meyer. Chapel Hill, NC. 10:02 am, Abstract #357
3. **Elevated serum IgE level, but not TARC and LDH, may reflect the impairment of stratum corneum barrier function in healthy individuals; Results of cross-sectional study of 1141 Japanese healthy individuals.**
E. Akasaka, K. Hara, M. Takahashi, T. Fukui, A. Korekawa, H. Nakano, I. Takahashi, S. Nakaji and D. Sawamura. Hirosaki-shi, Japan. 10:03 am, Abstract #421
4. **Three dimensional ultrastructural analysis of lamellar granules in stratum granulosum by focused ion beam scanning electron microscopy.**
H. Yamanishi, T. Soma, A. Ishida-Yamamoto and T. Hibino. Yokohama, Japan and Asahikawa, Japan. 10:04 am, Abstract #427
5. **Ex vivo COL7A1 editing via CRISPR/Cas9 in recessive dystrophic epidermolysis bullosa.**
S. Hainzl, P. Peking, T. Kocher, E. Muraier, F. Larcher, B. Duarte, M. Steiner, J. Bauer, J. Reichelt and U. Koller. Salzburg, Austria and Madrid, Spain. 10:05 am, Abstract #535
6. **Cutaneous acquisition of *Staphylococcus* quorum-sensing *agr* mutations protects against atopic dermatitis development.**
Y. Nakamura, H. Takahashi, A. Takaya, Y. Katayama, F. Yamade, Y. Kusuya, N. Shimojo, G. Nunez and H. Matsue. Chiba, Japan and Ann Arbor, MI. 10:06 am, Abstract #623
7. **Rhomomyltone suppresses TNF- α and IL-17A-induced keratinocyte inflammatory responses: A potential therapeutic for psoriasis.**
J. Chorachoo, S. Lambert, LW. Roberts, S. Voravuthikunchai and A. Johnston. Hay Yai, Thailand and Ann Arbor, MI. 10:07 am, Abstract #714
8. **An imbalance between IL-1 and IL-1Ra in human melanoma cells accounts for autoinflammation and contributes to tumor progression in metastatic melanoma.**
Y. Li, M. Okamoto, C. Dinarello and M. Fujita. Aurora, CO. 10:08 am, Abstract #812
9. **Olfactory receptor stimulation promotes human hair growth.**
J. Chéret, M. Bertolini, T. Tsai, M. Alam, H. Hatt and R. Paus. Muenster, Germany and Manchester, United Kingdom. 10:09 am, Abstract #884

CLINICAL SCHOLARS PROGRAM SESSION II

Emerging Immunotherapies

Saturday, April 29, 2017

10:15 am – 12:00 pm

Oregon Ballroom 203

10:15 am



Introduction

Heidi Kong, MD

Dr. Kong is an Investigator in the Dermatology Branch at the NIH. She received her undergraduate degree in biological sciences from Stanford University and earned her medical degree from the Baylor College of Medicine. She completed her dermatology residency at Duke University Medical Center and clinical research fellowship training in the Dermatology Branch, NCI and the Duke-NIH Master's Program in Clinical Research. Dr. Kong's research on the human microbiome focuses on understanding host-microbial relationships, particularly of human skin.

10:20 am




Paul Nghiem, MD/PhD

Merkel cell carcinoma & the immunogenic principles transforming the care of all UV-induced skin cancers

Dr. Paul Nghiem (pronounced NEE-em) is Head, Division of Dermatology, Department of Medicine and the George F. Odland Endowed Professor, Department of Medicine/ Dermatology. He is also Adjunct Professor in the Departments of Oral Health Sciences and Pathology and an Affiliate Investigator in the Clinical Research Division at Fred Hutchinson Cancer Research Center. He grew up in Olympia, Washington, and attended college at Harvard University. He then pursued MD and PhD degrees at Stanford University where he studied Cancer Biology and Immunology. He then completed a medicine internship at Brigham and Women's Hospital in Boston, a Dermatology residency at Massachusetts General Hospital in Boston and a Howard Hughes Post-Doctoral Fellowship with Stuart Schreiber in the Harvard Department of Chemistry and Chemical Biology. In 2003, he started his own lab at the Cutaneous Biology Research Center at Massachusetts General Hospital in Boston. In 2006, he and his wife moved 'home' to Seattle. He leads a multi-disciplinary team that follows a cohort of approximately 1200 patients with Merkel cell carcinoma. In April, 2015, he became Head of Dermatology in the Department of Medicine at the University of Washington. He has published over 90 papers that in aggregate have been cited over 3500 times. He currently has 4 grant awards from the NIH, including a K24 grant for mentoring young physicians and scientists.

10:50 am



Johann E. Gudjonsson, MD/PhD

Psoriasis – where are we and where are we heading

Dr. Johann E. Gudjonsson is an assistant Professor of Dermatology at the University of Michigan and Director of Inpatient Dermatology and Consultation. He is also the Frances and Kenneth Eisenberg Emerging Scholar of the Taubman Medical Research Institute. Dr. Gudjonsson is a graduate of the University of Iceland Medical School and completed his Internship and Dermatology Residency Training at the University of Michigan. Dr. Gudjonsson's laboratory is focused on the intersection between genetics and immunology, and he has published over 100 peer-reviewed publications in journals such as Nature Immunology, Nature Genetics, Journal of Clinical Investigation and Journal of Investigative Dermatology. He received the Young Investigator Award from the American Academy of Dermatology in 2007 and his work has earned several research awards, including awards from the American Skin Association, National Psoriasis Foundation, the Dermatology Foundation, Pfizer Aspire Award, Doris Duke Foundation and the NIH.

11:20 am

Q & A

11:25 am

SRF/MRTF drive basal cell carcinoma growth through hedgehog pathway activation

R. Whitson, A. Lee, N. Urman, A. Mirza, A. Brown, C. Yao, G. Shankar, KY. Sarin, E. Epstein, JY. Tang and A. Oro. *Abstract #137*

11:40 am

Modulation of eIF4F complex assembly in Merkel cell carcinoma cells: Translational regulation of oncogenes and new therapeutic implications

J. Wu, H. Doan, R. Simonette, Q. He, P. Rady and S. Tying. *Abstract #096*

11:55

Q & A

Selected ePoster Discussions III

Saturday, April 29, 2017

10:45 am – 11:45 am

Exhibit Hall A Foyer

New to the 2017 SID Annual Meeting is “Selected ePoster Discussions.” In an effort to further increase participation and visibility of abstracts submitted to the Annual Meeting, the SID is pleased to add this new feature to the meeting.

Selected ePoster Discussions will take place during Poster Sessions that will occur on Thursday, Friday, and Saturday of the Annual Meeting at five (5) iPad terminals located outside of the Poster/Exhibit Hall. The discussions will be thematic tours of selected electronic posters accompanied by a presenting author. Each poster presenter will be asked to briefly describe their work (3 min), followed by a short group discussion (3 min), that will be held with the help of a moderator. If your poster has been selected for ePoster Discussions, please join the appropriate group at the relevant ePoster kiosk.

Topic	Poster Numbers
Adaptive and Autoimmunity <i>Moderator: Masayuki Amagai, MD/PhD</i>	001, 007, 049, 059, 070, 002, 003, 022
Clinical Research: Pathophysiology and Therapeutics <i>Moderator: Shawn Demehri, MD/PhD</i>	322, 294, 272, 274, 291, 296, 301, 303, 308
Pigmentation and Melanoma <i>Moderator: Jennifer Zhang, PhD</i>	770, 795, 832, 835, 775, 788, 796, 799, 772, 765
Skin and Hair Developmental Biology <i>Moderator: Andrzej Dlugosz, MD</i>	859, 873, 870, 845, 846, 851, 877, 883, 885
Late-Breaking Abstracts <i>Moderator: Robert Swerlick, MD</i>	LB947, LB966, LB965, LB968, LB970, LB962, LB993, LB948, LB967, LB971



CONCURRENT MINI-SYMPOSIUM 11

Carcinogenesis and Cancer Genetics

Studies on the genetics and other causes of cancer as well as mechanisms relevant to metastasis.

Saturday, April 29, 2017

12:30 pm – 3:00 pm

B113-116

Presiders: Raymond Cho, MD/PhD and Brian Pollack, MD/PhD

1. **A cohort of miRNAs can be used as an early predictive biomarker of UV-driven cutaneous squamous cell carcinoma.** T. Nguyen, K. Rajapakshe, V. Chitsazzadeh, C. Nicholas, C. Coarfa and K. Tsai. Tampa, FL and Houston, TX. 12:30 pm, Abstract #098
2. **Complement C5a regulates squamous carcinogenesis.** TR. Medler and LM. Coussens. Portland, OR. 12:42 pm, Abstract #139
3. **Epigenetic enhancer disruption as a driver of squamous carcinogenesis.** B. Capell, G. Donahue, J. Seykora and S. Berger. Philadelphia, PA. 12:54 pm, Abstract #102
4. **Complement components C3 and complement factor B promote growth of cutaneous squamous cell carcinoma.** P. Riihilä, L. Nissinen, M. Farshchian, M. Kallajoki, A. Kivisaari, S. Meri, R. Grénman, S. Peltonen, J. Peltonen, T. Pihlajaniemi, R. Heljasvaara and V. Kähäri. Turku, Finland; Helsinki, Finland and Oulu, Finland. 1:06 pm, Abstract #118
5. **Defining cellular quiescence as a multi-drug resistance mechanism in squamous cell carcinoma.** M. Schober, J. Brown, Y. Yonekubo and A. Tsigos. New York, NY. 1:18 pm, Abstract #131
6. **RNA sequencing of squamous cell carcinoma in situ and epidermis identifies early drivers of carcinogenesis.** B. Capell, V. Parekh, C. O'Day, C. Attilasoy, E. Shim, Q. Zheng and J. Seykora. Philadelphia, PA. 1:30 pm, Abstract #125
7. **Breaking down barriers: Defining the role of EphA2 in building epidermal tight junctions in cancer.** C. Cable, S. Getsios and B. Perez White. Chicago, IL. 1:42 pm, Abstract #119
8. **Merging mass cytometry and flow-assisted cell sorting to simultaneously characterize a tumor and its microenvironment.** A. Crouch, B. Kubick and DR. Roop. Aurora, CO. 1:54pm, Abstract #128
9. **Eyes absent gene (EYA1) is a pathogenic driver and a therapeutic target for melanoma.** J. Zhou, R. Huang, X. Zhang, Y. Cheng and L. Tang. Vancouver, Canada; Xiamen, China and Burnaby, Canada. 2:06 pm, Abstract #132
10. **T cell anergy regulator Egr2 identifies a quiescent stem-like phenotype in malignant T cells.** H. Hamidullah, S. Roy, A. Anshu, W. Kittipongdaja and SM. Schieke. Madison, WI and Milwaukee, WI. 2:18 pm, Abstract #144
11. **K-RAS oncogene activation is regulated by a snoRNA/SNARE protein axis that controls its subcellular transport.** Y. Che, Z. Siprashvili, J. Kovalski and PA. Khavari. Stanford, CA. 2:30 pm, Abstract #117
12. **Identification of an atypical protein kinase C - histone deacetylase 1 axis as a therapeutic target in basal cell carcinoma.** A. Mirza, JY. Tang, KY. Sarin and A. Oro. Stanford, CA. 2:42 pm, Abstract #086

CONCURRENT MINI-SYMPOSIUM 12***Clinical Research: Epidemiology of Skin Diseases*****Saturday, April 29, 2017****12:30 pm – 3:00 pm****Oregon Ballroom 203****Presiders: Suephy Chen, MD and Joel Gelfand, MD**

1. **A new mortality prediction tool for Stevens-Johnson syndrome/toxic epidermal necrolysis.** RG. Micheletti and MH. Noe. Philadelphia, PA. 12:30 pm, Abstract #216
2. **Changes in the geographic distribution of atopic dermatitis on the body with age.** TT. Schwartz, DJ. Margolis and K. Abuabara. San Francisco, CA and Philadelphia, PA. 12:42 pm, Abstract #164
3. **Does atopic dermatitis remain a disease of the advantaged in adulthood? A national birth cohort study.** K. Abuabara, LL. Kohn and SM. Langan. San Francisco, CA and London, United Kingdom. 12:54 pm, Abstract #221
4. **Black children less likely to receive outpatient care for eczema than whites, but show signs of more severe disease: A cross-sectional analysis of the medical expenditure panel surveys.** DB. Shin, AH. Fischer, DJ. Margolis and J. Takeshita. Philadelphia, PA and Baltimore, MD. 1:06 pm, Abstract #198
5. **A real-world study evaluating adeQUacy of Existing Systemic Treatments for patients with moderate-to-severe Atopic Dermatitis (AD-QUEST): Baseline treatment patterns and unmet needs assessment.** W. Wei, E. Ghorayeb, ML. Andria, V. Walker, J. Chao, J. Schnitzer, M. Kennedy, Z. Chen, A. Belland, J. White and JI. Silverberg. Bridgewater, NJ; Tarrytown, NY; Eden Prairie, MN and Chicago, IL. 1:18 pm, Abstract #204
6. **Inpatient burden of dermatomyositis in United States adults.** M. Kwa, K. Ardalan, AE. Laumann and J. Silverberg. Chicago, IL. 1:30 pm, Abstract #176
7. **Comprehensive analysis of CTCL incidence and mortality in Canada identifies geographic clustering of cases in industrial areas and low incidence in Ottawa and other administrative cities.** F. Al-Ghazawi, E. Rahme, D. Sasseville and I. Litvinov. Montreal, Canada and Ottawa, Canada. 1:42 pm, Abstract #150
8. **Associations of phenotypic characteristics, MC1R variants, and prior amelanotic melanoma with incident amelanotic melanoma.** S. Vernali, PA. Kanetsky, I. Orlow, L. Luo, M. Berwick and NE. Thomas. Chapel Hill, NC; Tampa, FL; New York, NY and Albuquerque, NM. 1:54pm, Abstract #163
9. **Decreasing prevalence of tanning bed use in the US: Data from the 2010, 2013, and 2015 National Health Surveys.** AH. Fischer, S. Kang and A. Chien. Baltimore, MD. 2:06 pm, Abstract #194
10. **Seasonality of itch: A digital epidemiology time series analysis of real-time data from 2004 to 2016.** R. Grandhi, A. He, ER. Semenov and SG. Kwatra. Cincinnati, OH; Baltimore, MD and St. Louis, MO. 2:18 pm, Abstract #248
11. **Antihypertensive drugs and cutaneous squamous cell carcinoma in non-Hispanic whites.** K. Levandoski, L. Habel, N. Achacoso, G. Friedman and M. Asgari. Boston, MA and Oakland, CA. 2:30 pm, Abstract #154
12. **Initial explorations into genotype-phenotype correlations in psoriasis: The homozygous recessive model.** M. Milliken, B. Feng, K. Duffin and G. Krueger. Salt Lake City, UT. 2:42 pm, Abstract #213

CONCURRENT MINI-SYMPOSIUM 13***Epidermal Structure and Barrier Function***

Research on the components or regulation of keratinocyte proliferation, differentiation, including epidermal barrier function.

Saturday, April 29, 2017**12:30 pm – 3:00 pm****Oregon Ballroom 204****Presiders: Luis Garza, MD/PhD and Spiro Getsios, PhD**

1. **A role for nuclear-localized keratin 17 in the response of skin tumor keratinocytes to DNA damaging agents.** RP. Hobbs, J. Hsu, JT. Jacob and PA. Coulombe. Baltimore, MD. 12:30 pm, Abstract #449
2. **Dynamic and stable enhancer-promoter contacts regulate epidermal terminal differentiation.** V. Lopez-Pajares, A. Rubin, B. Barajas, M. Furlan-Magaril, M. Mumbach, W. Greenleaf, A. Kundaje, M. Snyder, H. Chang, P. Fraser and PA. Khavari. Stanford, CA. 12:42 pm, Abstract #464
3. **mTORC1 loss impairs epidermal adhesion and differentiation via ROCK activation downstream of TGF- β signaling.** K. Asrani, A. Sood, A. Fabiola, A. Dubin, C. Talbot, L. Elhelu, B. Xiao, P. Worley and T. Lotan. Baltimore, MD and Detroit, MI. 12:54 pm, Abstract #443
4. **PFKFB3 is a p63 target gene that is required for proliferation, and inhibits differentiation in epidermal keratinocytes.** RB. Hamanaka and GM. Mutlu. Chicago, IL. 1:06 pm, Abstract #467
5. **Epigenetic control of epithelial stem cell differentiation by Galpha-s and protein kinase A signaling.** J. Park and R. Iglesias-Bartolome. Bethesda, MD. 1:18 pm, Abstract #407
6. **The Vps33b-Vipar complex is required for epidermal homeostasis.** C. Rogerson and P. Gissen. London, United Kingdom. 1:30 pm, Abstract #404
7. **EphA2 transmembrane domain governs receptor membrane distribution and differentiation-associated signaling in keratinocytes.** R. Ventrella, N. Kaplan, P. Hoover, B. Perez White, RM. Lavker and S. Getsios. Chicago, IL. 1:42 pm, Abstract #453
8. **Transient elevation of cytoplasmic calcium ion precedes the cornification of epidermal keratinocytes.** T. Murata, T. Honda and K. Kabashima. Kyoto, Japan. 1:54pm, Abstract #426
9. **Real time 3D in vivo pH imaging reveals tightly-regulated pH layers with distinct properties in mouse stratum corneum.** Y. Furuichi, T. Matsui and M. Amagai. Yokohama, Japan and Tokyo, Japan. 2:06 pm, Abstract #450
10. **The autophagy receptor NIX drives injury-induced mitophagy in keratinocytes and promotes mitochondrial fragmentation during epidermal differentiation.** CL. Simpson, P. Rompolas and ELF. Holzbaur. Philadelphia, PA. 2:18 pm, Abstract #406
11. **Recent evolution for an involucrin/sperm mitochondria haplotype associated with epidermal function in modern humans.** Z. Goodwin, I. Oh, M. Mathyer, A. Quiggle and C. de Guzman Strong. St. Louis, MO. 2:30 pm, Abstract #461
12. **GJA1 mutations causing erythrokeratoderma variabilis et progressiva display increased connexin hemichannel activity.** HM. Khan, L. Boyden, S. Tomita and K. Choate. New Haven, CT. 2:42 pm, Abstract #463

CONCURRENT MINI-SYMPOSIUM 14

Growth Factors, Cell Adhesion and Matrix Biology

Studies on growth factors and the interactions of cells with their local cellular and extracellular environment that affect signaling, adhesion, migration and development.

Saturday, April 29, 2017

12:30 pm – 3:00 pm

C123-124

Presiders: Ryan Driskell, PhD and Alexa L. Mattheyses, PhD

1. **Proteomic evaluation of desmosomes reveals novel components essential for maintaining epidermal integrity.** KA. Badu-Nkansah, J. Underwood and T. Lechler. Durham, NC. 12:30 pm, Abstract #558
2. **Dynamic organization and order of desmoglein 3 in desmosomes determined by fluorescence polarization microscopy.** El. Bartle, TM. Urner and AL. Mattheyses. Atlanta, GA. 12:42 pm, Abstract #554
3. **A mutation in the desmoglein 1 transmembrane domain abrogates lipid raft targeting and causes severe dermatitis, multiple allergies, and metabolic wasting (SAM) syndrome.** J. Lewis, A. Caldara, N. Strong, JK. Wahl, AL. Mattheyses, M. Amagai, T. Sasaki, K. Nakabayashi, K. Hata, Y. Matsubara, A. Kubo, S. Stahley and A. Kowalczyk. Atlanta, GA; Lincoln, NE; Tokyo, Japan and Princeton, NJ. 12:54 pm, Abstract #544
4. **Palmitoylation of plakophilin-3 requires the carboxyl terminal domain.** NJ. Eurek and JK. Wahl. Lincoln, NE. 1:06 pm, Abstract #540
5. **Ganglioside GM3, which mediates insulin resistance, disrupts insulin/IGF-1 receptor heterodimerization by receptor membrane mobilization.** D. Dam, S. Jelsma and A. Paller. Chicago, IL. 1:18 pm, Abstract #541
6. **Hyaluronan synthase 3 induces epidermal hyaluronan production by hapten stimulation and modulate contact hypersensitivity response.** H. Terui, K. Yamasaki and S. Aiba. Sendai, Japan. 1:30 pm, Abstract #549
7. **Modeling tumor promoting extracellular matrix dynamics in 3-D suspension culture.** R. Russell, T. Webster, M. Prisco, D. Cagnetti, A. Luginbuhl, J. Curry, A. Fertala, J. Rosenbloom and A. South. Philadelphia, PA. 1:42 pm, Abstract #556
8. **The role of ECM in inducing complex human skin morphogenesis *in vitro*.** G. Imparato, F. Urciuolo, C. Casale and PA. Netti. Naples, Italy. 1:54pm, Abstract #562
9. **Evaluation of native and non-native bio-inks for 3D printing of human tissues.** C. Catarino, T. Baltazar, G. Dai, S. Maria-Engler and P. Karande. Troy, NY and Sao Paulo, Brazil. 2:06 pm, Abstract #542
10. **The influence of a novel mechanical loading regimen on the molecular response of human facial skin cells.** SM. Jones, DA. Hart, A. Blythe, JL. Ronsky, J. Namkoong and DG. Kern. Calgary, Canada and Provo, UT. 2:18 pm, Abstract #536
11. **Inhibitory regulation of MFG-E8 on fibrosis in systemic sclerosis.** C. Fujiwara, A. Sekiguchi, O. Ishikawa and S. Motegi. Gumma, Japan. 2:30 pm, Abstract #548
12. **Mechanistic insight into the extracellular ATP-induced IL-6 via purinergic receptor in systemic sclerosis dermal fibroblasts.** B. Perera, A. Uchiyama, A. Sekiguchi, C. Fujiwara, O. Ishikawa and S. Motegi. Gumma, Japan. 2:42 pm, Abstract #547

CONCURRENT MINI-SYMPOSIUM 15

Pharmacology and Drug Development

Basic and preclinical studies aimed at developing therapeutics, elucidating their mechanisms of action, and identifying biomarkers of drug activity.

Saturday, April 29, 2017

12:30 pm – 3:00 pm

A105-106

Presiders: Masaoki Kawasumi, MD/PhD and Georg Wondrak, PhD

1. **Viral status of Merkel cell carcinoma impacts responses to small molecule inhibitors.** T. Gelb, D. Urban, K. Daily, Y. Xiao, M. Shen, M. Hall and I. Brownell. Bethesda, MD and Rockville, MD. 12:30 pm, Abstract #673
2. **Efficacy of topical Vorinostat in the reversal of alopecia areata.** E. Wang, JC. Chen and AM. Christiano. New York, NY. 12:42 pm, Abstract #688
3. **Allergen-loaded microneedle patches efficiently induce Treg cells in atopic dermatitis.** C. Park, S. Kim, JU. Shin, J. Kim, Z. Sun and K. Lee. Seoul, Republic of Korea and New York, NY. 12:54 pm, Abstract #718
4. **Ultra-small nanoparticle-based platform for photodynamic skin cancer therapy.** D. Dam, L. Zhao, S. Jelsma, Y. Zhao and A. Paller. Chicago, IL and Singapore, Singapore. 1:06 pm, Abstract #687
5. **PI3-Kinase inhibitors represent a novel class of drug repurposing candidates to prevent/alleviate glucocorticoid-induced skin atrophy.** S. Agarwal, G. Baida, B. Readhead, J. Dudley and I. Budunova. Chicago, IL and New York, NY. 1:18 pm, Abstract #707
6. **Folic acid conjugated hollow mesoporous silica nanoparticles encapsulating dacarbazine for targeted melanoma drug delivery and therapy.** N. Xu, J. Li, J. Zhu and J. Tao. Wuhan, China. 1:30 pm, Abstract #679
7. **ITK and RLK inhibitor improves skin disease in a psoriatic mouse model.** JM. Fuhrman, MCG. Winge, H. Habersack-Debic, J. Oliver Funk, M. Bradshaw and M. Marinkovich. Stanford, CA and South San Francisco, CA. 1:42 pm, Abstract #700
8. **Building an improved humanized mouse model of psoriasis for drug discovery.** K. Lewandowski, R. Edelmayer, M. Guerrero-Zayas, P. Honore and AS. Paller. Chicago, IL and North Chicago, IL. 1:54pm, Abstract #681
9. **Fighting cancer with fat: Utilizing ceramide lipid to induce lethal mitophagy.** M. Dany and B. Ogretmen. Charleston, SC. 2:06 pm, Abstract #685
10. **Adenosine A_{2A} receptor (A_{2A}R) modulation attenuates innate and adaptive immune cell signaling during pathogenesis of psoriasis-like dermatitis in mice.** A. Welihinda, P. Ravikumar, M. Kaur, J. Mechanic and E. Amento. Sunnyvale, CA. 2:18 pm, Abstract #690
11. **Induced DNA repair in xeroderma pigmentosum group C cells by readthrough of premature termination codons.** R. Ono, S. Khan, C. Kuschal, D. Tamura, J. Chen, X. Luo, J. DiGiovanna and K. Kraemer. Kobe, Japan and Bethesda, MD. 2:30 pm, Abstract #683
12. **Small molecule inhibitor of the wnt pathway (SM04755) as a potential topical scleroderma treatment.** V. Deshmukh, A. Hood and Y. Yazici. San Diego, CA. 2:42 pm, Abstract #706

[illegible]

The 42nd Annual Meeting of the Japanese Society for Investigative Dermatology

42nd JSID



We've got science under your skin



Dates

December 15 (Fri.) - 17 (Sun.) 2017

Venue

KOCHI CITY CULTURE PLAZA CULPORT Kochi, Japan

President

Shigetoshi Sano, M.D., Ph.D. [Department of Dermatology,
Kochi Medical School, Kochi University]

Secretary-General: Kimiko Nakajima, M.D., Ph.D.

Secretariat: Department of Dermatology,
Kochi Medical School, Kochi University
Kohasu, Oki-cho, Nankoku, Kochi 783-8505, Japan



Secretariat Office: The Japanese Dermatological Association

1-4, Hongo 4-chome, Bunkyo-ku, Tokyo 113-0033, Japan
Fax: +81-3-3812-6790

E-mail: jsid42@dermatol.or.jp **URL:** <http://jsid42.jp/>



47th Annual ESDR Meeting

The Sound of Dermatology

27–30 September 2017
Salzburg, Austria

www.esdr2017.org



May 16-19, 2018

IID 20¹⁸

International Investigative Dermatology



Rosen Shingle Creek Resort
Orlando, Florida